Siglec ligand polymers, conjugates, and methods of use thereof

Siglec ligand extended structures and their conjugates address immune responses to therapeutic proteins by suppressing ADA formation, enhancing drug efficacy and safety through improved pharmacology.

WO2026241447A1PCT designated stage Publication Date: 2026-11-19ADAXION THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028072
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Therapeutic proteins and gene therapies face challenges due to patient immune responses that inhibit drug activity, accelerate drug clearance, compromise safety, and lead to the formation of neutralizing and non-neutralizing drug-specific antibodies (ADA), which compromises drug efficacy and safety.

Method used

Development of Siglec ligand extended structures (SigLEs) and their conjugates with biologically active substances, which suppress immunogenicity by covalently bonding to linkers, thereby reducing ADA responses.

Benefits of technology

SigLEs and their conjugates enhance drug exposure, improve efficacy durability, and reduce ADA-related toxicities, providing favorable pharmacology for otherwise undruggable modalities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028072_19112026_PF_FP_ABST
    Figure US2026028072_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides Siglec Ligand Extended structures (SigLE). The present disclosure also provides SigLE conjugates that include a biologically active substance that is covalently bonded to the SigLE via a linker. In addition, the present disclosure provides methods of use of such SigLE conjugates. Pharmaceutical compositions of such SigLE conjugates are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Atty Dkt No.: ADTH-007WOSIGLEC LIGAND POLYMERS, CONJUGATES, AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U. S. Provisional Application No. 63 / 807,311, filed May 16, 2025, the disclosure of which is incorporated by reference herein in its entirety.INTRODUCTION

[0002] Therapeutic proteins and gene therapies are novel and successful drug modalities for the treatment of disease. However, patient immune responses to such therapeutics often result in inhibition of drug activity, accelerated drug clearance, compromised drug safety, and loss of drug efficacy. Prevention of the formation of neutralizing and non-neutralizing drugspecific antibodies ("anti-drug antibodies" or " ADA") is a key unsolved problem in the field of biotherapeutics. Blocking ADA responses to biotherapeutics would improve drug exposure, improve durability of efficacy, reduce ADA-related toxicities, and enable favorable pharmacology for otherwise undruggable modalities (e.g., de novo designed drugs, drugs based on endogenous proteins). Biotherapeutic conjugates with polymers that incorporate optimized Siglec ligand structures could suppress immunogenicity.SUMMARY

[0003] The present disclosure provides Siglec ligands (SigLs) with linkers, hereafter called Siglec Ligand Extended structures, or SigLEs. Also provided are conjugates that include a biologically active substance that is covalently bonded to the linker of the SigLE (SigLE Conjugates). The SigLEs can have advantageous properties that improve the technical qualities of the corresponding SigLE Conjugates.BRIEF DESCRIPTION OF THE DRAWINGS

[0004] FIG. 1 depicts one aspect of the model for Siglec-2-engaging biotherapeutics with suppressed anti-drug antibody responses.

[0005] FIG. 2A and FIG. 2B depict a model for SigLE Conjugates compared to short linker SigL Conjugates for effecting drug-specific B cell suppression. SigLE suppresses all possible anti-drug B cell clones with a smaller number of protein linkage sites (e.g., lysine or cysteine) than are needed with a shorter SigL. FIG. 2A illustrates a test case where a given antigen / therapeutic is conjugated with shorter SigLs. Four different conjugates, each bearing one SigL group at aAtty Dkt No.: ADTH-007WO distinct conjugation site, are shown. Conjugation with 4 SigLs at the 4 different sites is required for full suppression across all possible B cell epitopes. FIG.2B illustrates a related test case where the same given antigen / therapeutic is conjugated with SigLEs instead of shorter SigLs. In contrast to the SigL, conjugation of fewer (2) SigLEs at only 2 sites is sufficient for full and effective B cell suppression across all possible B cell epitopes.

[0006] FIG.3 shows liquid chromatography and mass spectroscopy of CMP014 according to embodiments of the present disclosure.

[0007] FIG.4 shows liquid chromatography and mass spectroscopy of CMP016 according to embodiments of the present disclosure.

[0008] FIG.5 shows liquid chromatography and mass spectroscopy of CMP017 according to embodiments of the present disclosure.

[0009] FIG.6 shows liquid chromatography and mass spectroscopy of CMP018 according to embodiments of the present disclosure.

[0010] FIG.7 shows liquid chromatography and mass spectroscopy of CMP019 according to embodiments of the present disclosure.

[0011] FIG.8 shows liquid chromatography and mass spectroscopy of CMP021 according to embodiments of the present disclosure.

[0012] FIG.9 shows liquid chromatography and mass spectroscopy of CMP022 according to embodiments of the present disclosure.

[0013] FIG. 10 shows liquid chromatography and mass spectroscopy of CMP024 according to embodiments of the present disclosure.

[0014] FIG. 11 shows the site-specific cysteine locations on the anti-IgM antibody used for SigL or SigLE conjugation in B-cell stimulation assays.

[0015] FIG. 12, panels A-D, show B-cell stimulatory activities of anti-IgM and anti-lgM-Siglec-2 Ligand Conjugates in dose titration experiments with an activation readout of CD69 upregulation. Conjugates contained shorter SigLs or longer SigLEs. FIG.12, panel A shows the B cell activation assay with anti-IgM conjugated at the light chain K183C position. FIG.12, panel B shows the B cell activation assay with anti-IgM conjugated at the heavy chain A140C position. FIG.12, panel C shows the B cell activation assay with anti-IgM conjugated at theAtty Dkt No.: ADTH-007WO heavy chain K290C. FIG. 12, panel D shows the B cell activation assay with anti-IgM conjugated at the heavy chain L443C.

[0016] FIG.13 summarizes the B cell activation assay data.

[0017] FIG.14, panels A-D show the competitive binding analysis of SigL- or SigLE-conjugated anti-human IgM binding on human PBMCs when SigL / SigLE is conjugated at light chain K183C (FIG.14, panel A), heavy chain A140C (FIG.14, panel B), heavy chain K290C (FIG.14, panel C), or heavy chain L443C (FIG. 14, panel D).

[0018] FIG. 15, panels A-C characterize Adalimumab-SigL / SigLE Conjugate binding and in vivo pharmacology. FIG.15, panel A shows the SPR analysis of human TN Fa binding. FIG.15, panel B shows the anti-Adalimumab anti-drug antibody (ADA) titer time course. FIG.15, panel C shows the pharmacokinetic profile of the Adalimumab and SigL / SigLE Conjugates.DETAILED DESCRIPTION

[0019] Before the present invention is described in greater detail, it is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is forthe purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0020] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0021] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and exemplaryAtty Dkt No.: ADTH-007WO methods and materials may now be described. Any and all publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.

[0022] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any element, e.g., any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely", "only" and the like in connection with the recitation of claim elements, or the use of a "negative" limitation.

[0023] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. To the extent the definition or usage of any term herein conflicts with a definition or usage of a term in an application or reference incorporated by reference herein, the instant application shall control.

[0024] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.DEFINITIONSChemical Groups

[0025] " Alkyl" refers to a monoradical, branched or linear, non-cyclic, saturated hydrocarbon group. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, cyclopentyl, and cyclohexyl. In some cases, the alkyl group has 1 to 24 carbon atoms, e.g. 1 to 12, 1 to 6, or 1 to 3.

[0026] " Alkenyl" refers to a monoradical, branched or linear, non-cyclic hydrocarbonyl group that comprises a carbon-carbon double bond. Exemplary alkenyl groups include ethenyl, n-Atty Dkt No.: ADTH-007WO propenyl, isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, and tetracosenyl.

[0027] " Alkynyl" refers to a monoradical, branched or linear, non-cyclic hydrocarbonyl group that comprises a carbon-carbon triple bond. Exemplary alkynyl groups include ethynyl and n-propynyl.

[0028] " Cycloalkyl" refers to a monoradical, cyclic, saturated hydrocarbon group. Similarly, "cycloalkenyl" refers to a monoradical and cyclic group having carbon-carbon double bond whereas "cycloalkynyl" refers to a monoradical and cyclic group having carbon-carbon triple bond.

[0029] " Heterocyclyl" refers to a monoradical, cyclic group that contains a heteroatom (e.g. O, S, N) as a ring atom and that is not aromatic (i.e. distinguishing heterocyclyl groups from heteroaryl groups). Exemplary heterocyclyl groups include piperidinyl, tetrahydrofuranyl, dihydrofuranyl, and thiocanyl.

[0030] " Aryl" refers to an aromatic group containing at least one aromatic ring, wherein each of the atoms in the ring are carbon atoms, i.e. none of the ring atoms are heteroatoms (e.g. O, S, N). In some cases the aryl group has a second aromatic ring, e.g. that is fused to the first aromatic ring. Exemplary aryl groups are phenyl, naphthyl, biphenyl, diphenylether, diphenylamine, and benzophenone.

[0031] " Heteroaryl" refers to an aromatic group containing at least one aromatic ring, wherein at least one of the atoms in the aromatic ring is a heteroatom (e.g. O, S, N). Exemplary heteroaryl groups include those obtained from removing a hydrogen atom from pyridine, pyrimidine, furan, thiophene, or benzothiophene.

[0032] The term "substituted" refers the removal of one or more hydrogens from an atom (e.g. from a C or N atom) and their replacement with a different group. For instance, a hydrogen atom on a phenyl (-CeHs) group can be replaced with a methyl group to form a -C6H4CH3 group. Thus, the -C6H4CH3 group can be considered a substituted aryl group. As another example, two hydrogen atoms from the second carbon of a propyl (-CH2CH2CH3) group can be replaced with an oxygen atom to form a -CH2C(O)CH3 group, which can be considered a substituted alkyl group. However, replacement of a hydrogen atom on a propyl (-CH2CH2CH3) group with a methyl group (e.g. giving -CH2CH(CH3)CH3) is not considered a "substitution" as used herein since the starting group and the ending group are both alkyl groups. However, if the propylAtty Dkt No.: ADTH-007WO group was substituted with a methoxy group, thereby giving a -CH2CH(OCH3)CH3 group, the overall group can no long be considered "alkyl", and thus is "substituted alkyl". Thus, in order to be considered a substituent, the replacement group is a different type than the original group. In addition, groups are presumed to be unsubstituted unless described as substituted. For instance, the term "alkyl" and "unsubstituted alkyl" are used interchangeably herein.

[0033] Exemplary substituents include alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.

[0034] In some cases, the substitutions can themselves be further substituted with one or more groups. For example, the group -C6H4CH2CH3 can be considered as substituted aryl, i.e. an aryl group substituted with the ethyl, which is an alkyl group. Furthermore, the ethyl group can itself be substituted with a pyridyl group to form -C6H4CH2CH2C5H5N, wherein -C6H4CH2CH2C5H5N can also be considered as a substituted aryl group as the term is used herein. In some cases, the substituents are not substituted with any other groups.

[0035] Monoradical and multiradical groups are described herein. For example, the methyl group (-CH3) and the ethyl group (-CH2CH3) are monoradical groups. In contrast, exemplary diradical groups include diylmethane (-CH2-, which is also known as a methylene group) and 1,2-diylethane (-CH2CH2-). The term "arylene" refers to the diradical version of an aryl group, e.g. 1,4-diylbenzene refers to a CeF fragment wherein two hydrogens that are located para to one another are removed and replaced with single bonds to other groups. The terms "alkenylene", "alkynylene", "heteroarylene", and "heterocyclene" are also used herein. The term "diradical connector" is used interchangeably with the term "diradical group". Exemplary diradical groups include alkyl groups, substituted alkyl groups, polyethylene glycol groups, alkoxy groups, substituted alkoxy groups, arylalkyl groups, and substituted arylalkyl groups.

[0036] " Acyl" refers to a group of formula -C(O)R wherein R is alkyl, alkenyl, alkynyl, or substituted versions thereof. For example, the acetyl group has formula -C(O)CH3. " Carbonyl" refers to a diradical group of formula -C(O)-.

[0037] " Alkoxy" refers to a group of formula -O(alkyl). Similar groups can be derived from alkenyl, alkynyl, aryl, heteroaryl, and other groups.Atty Dkt No.: ADTH-007WO

[0038] " Amino" refers to the group -NRXRYwherein Rxand RYare each independently H or a non-hydrogen substituent. Exemplary non-hydrogen substituents include alkyl groups (e.g. methyl, ethyl, and isopropyl) and the carbonyl group.

[0039] " Amide" refers to the group -C(O)NRQRRwherein RQand RRare each independently H or a non-hydrogen substituent.

[0040] " Carbonyl" refers to a diradical group of formula -C(O)-.

[0041] " Carboxy" is used interchangeably with carboxyl and carboxylate to refer to the -CO2H group and salts thereof.

[0042] " Ether" refers to a diradical group of formula -O-. For instance, if the ether group is connected to an alkyl group, then the overall group is an alkoxy group (e.g. -OCH3 or methoxy). If the ether is connected to a carbonyl group, then the overall group is an ester group of formula -OC(O)-.

[0043] " Halo" and "halogen" refer to the chloro, bromo, fluoro, and iodo groups.

[0044] " Nitro" refers to the group of formula -NO2.

[0045] " Oxamide" refers to the group -RPN-C(O)C(O)-NRPR° wherein Rpand RQare each independently H or a non-hydrogen substituent. " Oxamide" can also be referred to as ethanediamide oroxalamide.

[0046] " Phosphoramide" refers to the group -HNP(O)(NH2)2- " Phosphoramide" can also be referred to as phosphoric triamide.

[0047] " Sulfonamide" refers to the group -RPN-S(O)2-NRPRQwherein Rpand RQare each independently H or a non-hydrogen substituent. " Sulfonamide" can also be referred to as Sulfuric diamide.

[0048] " Thioamide" refers to the group -RPS(O)NRPRQwherein Rp, RQand RRare each independently H or a non-hydrogen substituent. " Thioamide" can also be referred to as alkylsulfnamide.

[0049] " Ureido" refers to univalent radical of urea. In other words, "ureido" refers to the group -HNC(O)NHRR, wherein RRis H or a non-hydrogen substituent. " Ureido" can also be referred to as urea.

[0050] " Chemoselective functional group" refers to a functional group that can selectively react with another compatible functional group to form a covalent bond, in some cases, afterAtty Dkt No.: ADTH-007WO optional activation of one of the functional groups. Chemoselective functional groups of interest include, but are not limited to, thiols and maleimide or iodoacetamide, amines and carboxylic acids or active esters thereof, as well as groups that can react with one another via Click chemistry, e.g., azide and alkyne groups (e.g., cyclooctyne groups), tetrazine, transcyclooctene, dienes and dienophiles, and azide, sulfur(VI) fluoride exchange chemistry (SuFEX), sulfonyl fluoride, as well as hydroxyl, hydrazido, hydrazino, aldehyde, ketone, azido, alkyne, phosphine, epoxide, succinimide, pentafluorophenyl (PFP) ester, and carboxylic acid (e.g. on a lysine residue). Additional examples of chemoselective functional groups of use are esters (e.g. pentafluorophenyl ester, N-hydroxysuccinimide ester, 4-nitrophenyl ester, imidoester), isocyanates, isothiocyanates, sulfonyl chlorides, aldehydes, carbodiimides, acyl azides, anhydrides, fluorobenzenes, carbonates, epoxides, hydroxymethyl phosphines, maleimides, haloacetyls, pyridyl disulfides, thiosulfonates, vinyl sulfones, or squaramates (e.g. -amino(cyclobut-3-ene-l,2-dione)oxy-).

[0051] Unless otherwise specified, reference to an atom is meant to include all isotopes of that atom. For example, reference to H includes1H,2H (i.e. D or deuterium) and3H (i.e. tritium), and reference to C is includes both12C and all other isotopes of carbon (e.g.13C). Unless specified otherwise, groups include all possible stereoisomers.Treatment

[0052] The terms "individual," "host," "subject," and "patient" are used interchangeably herein, and referto an animal, including, but not limited to, human and non-human primates,O 0 0 0 0 including simians and humans rodents, including rats and mice bovines equines ovines felines’ canines’ and the like. " Mammal" means a member or members of any mammalian 0 0 O 0 0 species, and includes, by way of example, canines felines equines bovines ovines rodentia, etc. and primates, e.g., non-human primates, and humans. Non-human animal models, e.g., mammals, e.g. non-human primates, murines, lagomorpha, etc. may be used for experimental investigations.

[0053] As used herein, the terms "treatment," "treating," and the like, refer to obtaining a desired pharmacologic and / or physiologic effect, such as reduction of viral titer. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and / or may be therapeutic in terms of a partial or complete cure for a disease and / or adverse effect attributable to the disease. " Treatment," as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease or aAtty Dkt No.: ADTH-007WO symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease (as in liver fibrosis that can result in the context of chronic HCV infection)” (b) inhibiting the disease, i.e., arresting its development” and (c) relieving the disease, i.e., causing regression of the disease (e.g., reduction in viral titers).

[0054] A "therapeutically effective amount", a "therapeutically effective dose" or "therapeutic dose" is an amount sufficient to effect desired clinical results (i.e., achieve therapeutic efficacy, achieve a desired therapeutic response, etc.). A therapeutically effective dose can be administered in one or more administrations. For purposes of this disclosure, a therapeutically effective dose of a SigLE Conjugate or a pharmaceutical composition is an amount that is sufficient, when administered to the individual, to palliate, ameliorate, stabilize, reverse, prevent, slow or delay the progression of a disease state (e.g., cancer, etc.) present in the subject.

[0055] As used herein, the terms "determining," "measuring," "assessing," and "assaying" are used interchangeably and include both quantitative and qualitative determinations.

[0056] The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of a SigLE Conjugate calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable excipient. The specifications for unit dosage forms depend on the particular SigLE Conjugate employed and the effect to be achieved, and the pharmacodynamics associated with each SigLE Conjugate in the host.

[0057] A "pharmaceutically acceptable excipient," "pharmaceutically acceptable diluent," "pharmaceutically acceptable carrier," and "pharmaceutically acceptable adjuvant" means an excipient, diluent, carrier, and adjuvant that are useful in preparing a pharmaceutical composition that are generally safe, non-toxic and neither biologically nor otherwise undesirable, and include an excipient, diluent, carrier, and adjuvant that are acceptable for veterinary use as well as human pharmaceutical use. " A pharmaceutically acceptable excipient, diluent, carrier and adjuvant" as used herein includes both one and more than one such excipient, diluent, carrier, and adjuvant.

[0058] As used herein, a "pharmaceutical composition" is meant to encompass a composition suitable for administration to a subject, such as a mammal, especially a human. In general a "pharmaceutical composition" is sterile, and preferably free of contaminants that are capableAtty Dkt No.: ADTH-007WO of eliciting an undesirable response within the subject (e.g., the compound(s) in the pharmaceutical composition is pharmaceutical grade). Pharmaceutical compositions can be designed for administration to subjects or patients in need thereof via a number of different routes of administration including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intracheal, intramuscular, subcutaneous, and the like.SIGLEC LIGAND EXTENDED STRUCTURES (SIGLES) AND SIGLE CONJUGATES

[0059] The term " Siglec" as used herein refers to cell surface proteins that binds to a sialic acid group. Siglecs are commonly found on the surface of leukocytes.

[0060] There are 14 different mammalian Siglecs, which are expressed on different types of leukocytes and which may exert inhibitory or activating effects on the cells on which they are expressed depending on whether they comprise an inhibitory motif or activating motif. Siglecs show distinct binding preferences for different sialic acids, and the type of linkage and type of underlying sugar also affect recognition of sialic acids. (Varki, A. and Crocker, P. R. (2009) l-type lectins. In Essentials of Glycobiology (2nd edn) (Varki, A. et al., eds), pp. 459-474, Cold Spring Harbor Laboratory Press” Crocker, P. R. et al. (2007) Nat. Rev. Immunol. 7, 255-266). Together, this provides for an array of alternative Siglec ligands that may be deployed to modulate an immune response to a biotherapeutic.

[0061] Provided by the present disclosure are Sialic acid-binding immunoglobulin-type lectin ligands, which are also referred to herein as " Siglec ligand extended structures" or " SigLEs".Siglec Ligand Extended Structures (SigLEs)

[0062] In one aspect the invention provides a compound, such as a Siglec ligand extended structure, according to Formula (I) or (la):Z is a chemoselective functional group or Zl'-T-Z2, wherein Zl' is a diradical group, T is absent or a diradical group, and Z2 is a chemoselective functional group,— X1— E1— Y— X2— E2—D is wherein * represents covalent connection to M, and represents covalent connection to Z°b is an integer from 1 to 5°k is an integer from 1 to 5°Atty Dkt No.: ADTH-007WO j is an integer from 0 to 15when j is 0, each of the members of D1are not absent”when j is 0, and k is each of the members of D1are not absent and at least two of the members of D are not absent’M is a lysine residue, or a portion thereof’each D2is independently selectedwherein ^ represents. **covalent connection to Q, and represents covalent connection to M,AAeach D3iswherein5represents covalent connection to M, and* represents covalent connection to D1’each Q is independently H, substituted or unsubstituted C1-C10 alkyl,D1is independently selectedwherein?representscovalent connection to D3, and? represents covalent connection to Q1’Q1is H, substituted or unsubstituted C1-C10 alkyl,each A1is independently absent or alkylene’each A2is independently absent, alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof’each R2is independently -COOH, -P(O)(OH)z, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereof’each R3is independently H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof’each R4is independently hydroxy, alkoxy, amino, amide, or a substituted version thereof’Atty Dkt No.: ADTH-007WO each R5is independently H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene- 1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof’each R7is independently hydroxy or halo°each X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CFz-° each E1is independently absent, -(substituted or unsubstituted Ci-Cg alkyleneoxy)g-, - (substituted or unsubstituted Ci-Cg alkylene)g-, -(substituted or unsubstituted Ci-Cg alkyleneoxy ^(substituted or unsubstituted Ci-Cg alkylene)q-, -(substituted or unsubstituted Ci-Ce alkylene)gO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)g(substituted or unsubstituted Ci-C alkylene)qO-, -(substituted or unsubstituted Ci-C alkylene)gO(substituted or unsubstituted Ci-Cg alkylene)q-, benzyl, -(substituted or unsubstituted Ci-Cg alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted Ci-Cg alkyleneoxy )gbenzyloxy, cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C=C-, -CH2C C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methlyene)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)n-, -(substituted or unsubstituted Ci-Cg alkylene)n-, wherein n is an integer ranging from 1 to 10°each X2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m-, - (substituted or unsubstituted Ci-Cg alkylene)m-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)w-, -(substituted or unsubstituted Ci-Ce alkylene)mO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-Cg alkylene)w-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)NH-, - (substituted or unsubstituted Ci-Cg alkylene)mC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(0)-, -(substituted or unsubstituted Ci-CgAtty Dkt No.: ADTH-007WO alkylene)mC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)wC(O)-, -(substituted or unsubstituted Ci-C alkyleneoxy)mC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)O-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-C alkyleneoxy)mtriazole-, -(substituted or unsubstituted Ci-C alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wtriazole-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-triazole-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-Cg alkylene)w-triazole, -(substituted or unsubstituted Ci-Cg alkylene)m-triazole, -(substituted or unsubstituted Ci-Cg alkylene)mOtriazole-, triazole, -(methylene)triazole-, - (methylene)triazole(methylene)-, or a substituted version thereof, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36°each E2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h-, - (substituted or unsubstituted Ci-Cg alkylene)h-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-C alkylene)xO-, -(substituted or unsubstituted Ci-C alkylene)hO(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted Ci-CgAtty Dkt No.: ADTH-007WO alkylene)hC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-C alkylene)xC(O)NH-, -(substituted or unsubstituted Ci-C alkyleneoxy)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-C alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)-, -(substituted or unsubstituted Ci-C alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)(substituted or unsubstituted Ci-C alkylene)x-, -(substituted or unsubstituted Ci-C alkylene)hC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)(substituted or unsubstituted Ci-C alkylene)x-, -(substituted or unsubstituted Ci-C alkyleneoxy)hC(O)O-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(0)0(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hOC(O)(substituted or unsubstituted Ci-C alkylene)x-, -(substituted or unsubstituted Ci-C alkylene)hNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O-, -(substituted or unsubstituted Ci-C alkylene)hOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH(substituted or unsubstituted Ci-C a I kylene)x-, -(substituted or unsubstituted Ci-C alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xOC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-C alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-C alkylene)xNHC(O)NH(substituted or unsubstituted Ci-C alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-C alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, (substituted or unsubstituted Ci-Cgalkylene)C(O)N(substituted or unsubstituted Ci-Cgalkylene)2-, -C=C-, or -CH2C C-, or a substituted version thereof, wherein h is an integer ranging from 1 to 36, orAtty Dkt No.: ADTH-007WO from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36.

[0063] In an exemplary embodiment, the invention provides a compound, such as a SigLE, according to Formula (I) or (la), whereinZ is a chemoselective functional group or Zl'-T-Z2, wherein Zl' is a diradical group, T is absent or a diradical group, and Z2 is a chemoselective functional group,— X1— E1— Y— X2— E2— *<;D is wherein < represents covalent connection to M, and represents covalent connection to Z°b is an integer from 1 to 5°j is an integer from 0 to 15°k is an integer from 1 to 5°when j is 0, each of the members of D1are not absent’when j is 0, and k is 1, each of the members of D1are not absent and at least two of the members of D are not absent’M is a lysine residue, or a portion thereof’each D2is independently selectedwhereinrepresentscovalent connection to Q, and? represents covalent connection to M,AA AAeach D3iswhereinrepresents covalent connection to M, andAA2 represents covalent connection to D1’each Q is independently H, substituted or unsubstituted Ci-Cio alkyl,D1is independently selectedwherein representscovalent connection to D3, and? represents covalent connection to Q1’Q1is H, substituted or unsubstituted Ci-Cw alkyl,each A1is independently absent or alkylene’Atty Dkt No.: ADTH-007WO each A2is independently absent, alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereofeach R2is independently -COOH, -P(O)(OH)2, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereofeach R3is independently H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereofeach R4is independently hydroxy, alkoxy, amino, amide, or a substituted version thereof each R5is independently H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene- 1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereofeach R7is independently hydroxy or halo°each X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-° each E1is independently absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(OCH2CH2)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, - (CH2CH2O)g(CH2)qO(CH2)q-, -(OCH2CH2)g(CH2)qO(CH2)q-, -(CH2)q(OCH2CH2)gO(CH2)q-, - (CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCFhCl-hJgbenzyl-, benzyloxy, - (CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36°each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C C-, -CH2C C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(CFhCFhOjn-, -(Ch in-, wherein n is an integer ranging from 1 to 10°each X2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CFhCFhOJm-, -(CH2)m-, - (CH2CH2O)m(CH2)w-, -(OCH2CH2)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, - (OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)m(CH2)wO(CH2)w-, - (OCH2CH2)m(CH2)wO(CH2)w-, -(CH2)w(OCH2CH2)mO(CH2)w-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, - (OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, - (CH2)w(OCH2CH2)mNHC(O)-, -(CH2)mNHC(O)(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)(CH2)w-, -(CH2CH2O)mC(O)NH-, - (OCH2CH2)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -Atty Dkt No.: ADTH-007WO(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)NH(CH2)w-, - (OCH2CH2)mC(O)NH(CH2)w-, -(CH2)mC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wC(O)NH(CH2)w-, - (OCH2CH2)m(CH2)wC(O)NH(CH2)w- / -(CH2)w(OCH2CH2)mC(O)NH(CH2)w-, -(CH2CH2O)mC(O)-, - (CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, - (CH2CH2O)mC(O)O-, -(CH2)mC(O)(CH2)w-, -(CH2CH2O)m(CH2)wC(O)(CH2)w-, - (OCH2CH2)m(CH2)wC(O)(CH2)w-, -(CH2)w(OCH2CH2)mC(O)(CH2)w-, -(CH2CH2O)mC(O)O(CH2)w-, - (CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, - (CH2)w(OCH2CH2)mC(O)O-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, - (OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(OCH2CH2)mNHC(O)O-, - (CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, - (CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mNHC(O)O(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)O(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)O(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)O(CH2)w-, - (OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, - (OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wOC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wOC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mOC(O)NH(CH2)w- / -(OCH2CH2)mNHC(O)NH-, -(CH2)mNHC(O)NH-, - (CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, - (CH2)w(OCH2CH2)mNHC(O)NH-, -(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2)mNHC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wNHC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, - (OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, -(CH2CH2O)m(CH2)wO-triazole-, - (CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each E2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(OCH2CH2)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, - (CH2)x(OCH2CH2)hO-, -(CH2CH2O)h(CH2)xO(CH2)x-, -(OCH2CH2)h(CH2)xO(CH2)x-, - (CH2)x(OCH2CH2)hO(CH2)x-, -(CH2)hO(CH2)x-, -(CH2)hNHC(O)-, -(OCH2CH2)hNHC(O)-, - (CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, - (CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, - (CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(OCH2CH2)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, -Atty Dkt No.: ADTH-007WO(CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, - (CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, - (CH2)x(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)hC(O)-, (CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, - (OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2CH2O)hC(O)O-, -(CH2)hC(O)(CH2)x-, - (CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, - (CH2CH2O)hC(O)O(CH2)x-,-(CH2)hC(O)O- / -(CH2CH2O)h(CH2)xC(O)O-, -(OCH2CH2)h(CH2)xC(O)O-, -(CH2)x(OCH2CH2)hC(O)O-, -(CH2)hOC(O)-, -(CH2CH2O)h(CH2)xOC(O)-, -(OCH2CH2)h(CH2)xOC(O)-, -(CH2)x(OCH2CH2)hOC(O)-, -(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O-, - (CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, - (CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH-, - (CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-, - (CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, - (CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2)x(OCH2CH2)hNHC(O)NH-, - (OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or -(alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° or a pharmaceutically acceptable salt thereof.Siglec Ligand Extended Structure Conjugates (SigLE Conjugates)

[0064] In an exemplary embodiment, the invention provides a compound, such as a SigL conjugate, according to Formula (II) or (Ila):BAS is a biologically active substance”Atty Dkt No.: ADTH-007WO*** ** r?° wherein2represents covalent connection to E2, andrepresents covalent connection to BAS, and Q, Q1, D, D1, D2, D3, M, b, j, and k are as described herein.Further Embodiments:Molecular mass of Formula

[0065] In an exemplary embodiment, the molecular mass of the compound of Formula (I), (la),from 3,000 Da to 50,000 Da. In an exemplary embodiment, the molecular mass of the compound of Formula (I), (la),from 5,000 Da to 45,000 Da, from5,000 Da to 30,000 Da, from 5,000 Da to 15,000 Da, from 5,000 Da to 10,000 Da, 10,000 Da to 45,000 Da, from 10,000 Da to 30,000 Da, from 10,000 Da to 15,000 Da, from 7,500 Da to 12,500 Da, and from 12,500 Da to 25,000 Da.Length of E1, X2, and E2

[0066] In an exemplary embodiment, when E1is substituted or unsubstituted Ci-Ce alkyleneoxy, g is 24 or less. In an exemplary embodiment, when E1is CH2CH2O, g is 24 or less. In an exemplary embodiment, when X2is substituted or unsubstituted Ci-Ce alkyleneoxy, m is 24 or less. In an exemplary embodiment, when X2is CH2CH2O, m is 24 or less. In an exemplary embodiment, when E2is substituted or unsubstituted Ci-Cg alkyleneoxy, h is 24 or less. In an exemplary embodiment, when E2is CH2CH2O, h is 24 or less.Z

[0067] In an exemplary embodiment, Z is selected from esters (e.g. pentafluorophenyl ester,N-hydroxysuccinimide ester, 4-nitrophenyl ester, imidoester), isocyanates, isothiocyanates,Atty Dkt No.: ADTH-007WO sulfonyl chlorides, aldehydes, carbodiimides, acyl azides, anhydrides, fluorobenzenes, carbonates, epoxides, hydroxymethyl phosphines, maleimides, haloacetyls, pyridyl disulfides, thiosulfonates, vinyl sulfones, or squaramates (e.g. -amino(cyclobut-3-ene-l,2-dione)oxy-). In an exemplary embodiment, Z is a maleimide. In an exemplary embodiment, Z is a pentafluorophenyl ester.Z'

[0068] In an exemplary embodiment,exemplary embodiment, Z'isIn an exemplary embodiment, Z' is. In an exemplary** *** embodiment, Z' is. In an exemplary embodiment,BAS

[0069] In an exemplary embodiment, BAS is a protein (such as an enzyme or an antibody) or a nanoparticle.b

[0070] In an exemplary embodiment, b is 1, 2, 3, 4, or 5.j and k

[0071] In an exemplary embodiment, j is 0 and k is 1. In an exemplary embodiment, j is 0 and k is 2. In an exemplary embodiment, j is 0 and k is 3. In an exemplary embodiment, j is 0 and k is 4. In an exemplary embodiment, j is 0 and k is 5.

[0072] In an exemplary embodiment, j is 1 and k is 1.D, D1, D2, and D3

[0073] In an exemplary embodiment, each D, D2, D3, and D1has a molecular weight independently selected from 2,000 Da to 15,000 Da, or from 2,250 Da to 2,750 Da, or from 3,250 Da to 3,750 Da, or from 4,750 Da to 5,250 Da, or from 9,750 Da to 10,250 Da.Atty Dkt No.: ADTH-007WOQ& Q1—

[0074] In an exemplary embodiment, Q is H. In an exemplary embodiment, Q is methyl. In an exemplary embodiment, Q1is H. In an exemplary embodiment, Q1is methyl. In an exemplaryembodiment,exemplary embodiment, Q1is.,. In anexemplary embodiment,exemplary embodiment, R2is - COOH, R3is H, R4is hydroxy, R5is -NHC(O)R5awherein R5ais substituted or unsubstituted Ci-Cg alkyl, and R7is hydroxy. In an exemplary embodiment, Q and Q1are each independently selected from:

[0075] In an exemplary embodiment, Q1is H. In an exemplary embodiment, Q1is methyl. In anexemplary embodiment,M

[0076] In an exemplary embodiment, M a portion of a lysine residue. In an exemplaryrepresents covalent connection to D2, represents covalent connection to D3, and? represents covalent connection to D.Atty Dkt No.: ADTH-007WOA1

[0077] In an exemplary embodiment, A1is absent, or A1is unsubstituted alkylene, such as unsubstituted methylene, or A1is substituted alkylene, such as methylene substituted with two carbons joined together with the methylene carbon to form a 3 membered ring.A2

[0078] In an exemplary embodiment, A2is alkyl, for example, saturated, straight-chain, or branched C1-C15 alkyl. In an exemplary embodiment, A2is methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1,1-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethyl butyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-l-methylpropyl, l-ethyl-2-methylpropyl, heptyl, or octyl. In an exemplary embodiment, A2is an aryl, for example, Cg-Cu aryl, such as A2is phenyl, 1-naphthyl, 2-naphthyl, 1-biphenylene, or 2-biphenylene, or A2is substituted aryl, such as substituted with Ci-Cs alkyl, halogen, hydroxy, amino, Ci-Cs alkyloxy, Ci-Cg haloalkyl, cyano, nitro, aryl, heteroaryl, or C3-C8 cycloalkyl.

[0079] In an exemplary embodiment, A2is phenyl, substituted or unsubstituted biphenyl, halosubstituted phenyl, phenyl substituted with Ci-C alkyl, phenyl substituted with substituted Ci-Cg alkyl, phenyl substituted with substituted or unsubstituted cycloalkyl. In an exemplary embodiment, A2is phenyl, substituted or unsubstituted biphenyl, halosubstituted phenyl, phenyl substituted with Ci-Cg alkyl, phenyl substituted with substituted Ci-Cg alkyl, or phenyl substituted with substituted or unsubstituted C3-C7 cycloalkyl. In an exemplary embodiment, A2is chlorosubstituted phenyl, fluorosubstituted phenyl, phenyl substituted with halosubstituted Ci-Cg alkyl (such as halosubstituted C1-C3 alkyl), or phenyl substituted with substituted or unsubstituted cyclopropyl or substituted or unsubstituted cyclopropyl. In an exemplary embodiment, A2is 4-chlorophenyl, 3-chlorophenyl, l,l'-biphenyl, 4-(difluoromethyl)phenyl, 4-(cyclopropyl)phenyl, or phenyl. In an exemplary embodiment, A2is a heteroaryl for example, 5-10 membered heteroaryl containing one or more heteroatoms selected from S, N, O or SO2. In some cases, A2is furyl, thienyl, pyrrolyl, pyrazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or 4H-thieno[3,2-c]chromene. In some cases, A2is a substituted version of a heteroaryl, for example substituted with Ci-Cs alkyl, halogen, amino, Ci-Cs alkyloxy, cyano, nitro, aryl, heteroaryl, or C3-C8 cycloalkyl. In some embodiments, A2is a cycloalkyl, forAtty Dkt No.: ADTH-007WO example, C3-C8 cycloalkyl. In some cases, A2is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.

[0080] I n some cases, A1is absent, methylene, or methylene substituted with two carbons joined together with the methylene carbon to form a 3 membered ring, and A2is -CRXRYRZwherein Rxis H, F, -CF3, or -OH, RYis H, F, -OCH3, or -CH3, and Rzis selected from any one of the groups described below:Atty Dkt No.: ADTH-007WOR2

[0081] In an exemplary embodiment, R2is -COOH.R3

[0082] In an exemplary embodiment, R3is H.R4

[0083] In an exemplary embodiment, R4is hydroxy.R5

[0084] In an exemplary embodiment, R5is substituted or unsubstituted amide. In an exemplary embodiment, R5is -NHC(O)R5aor -C(O)NHR5awherein R5ais substituted or unsubstituted Ci-Cg alkyl. In an exemplary embodiment, R5is -NHC(O)R5a, wherein R5ais unsubstituted Ci-Cg alkyl, such as methyl. In an exemplary embodiment, R5is -NHC(O)R5awherein R5ais substituted Ci-Ce alkyl. In an exemplary embodiment, R5is -NHC(O)R5a, wherein R5ais Ci-Ce alkyl, substituted with -OR5bor -NR5bR5c, wherein R5band R5care each independently H or Ci-Cg alkyl. In an exemplary embodiment, R5is -NHC(O)CH3, -NHC(O)CH2OH or -NHC(O)CH2N(CH3)2.Atty Dkt No.: ADTH-007WOR7

[0085] In an exemplary embodiment, R7is hydroxy.X1

[0086] In an exemplary embodiment, X1is O. In an exemplary embodiment, X1is NH. In an exemplary embodiment, X1is S. In an exemplary embodiment, X1is absent.E1

[0087] In an exemplary embodiment, E1is -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, -(CH2CH2O)gbenzyloxy, or -(OCH2CH2)gbenzyloxy, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15. In an exemplary embodiment, E1is -(CH2)g-, -(CH2)gO-, or -(CH2)gO(CH2)q-, wherein g is an integer ranging from 1 to 15 and q is an integer ranging from 1 to 15, wherein g is 2, 3, 4, 5, 6, 7, 8 or 9, wherein g is 4, 5, 6, 7, 8 or 9, wherein g is 2, wherein g is 6, wherein q is 1, 2, or 3, wherein q is 1, wherein q is 2, or wherein g is 2 and q is 1. In an exemplary embodiment, g + q = 4, 5, 6, 7, 8, 9, or 10. In an exemplary embodiment, g + q = 5, 6, 7, or 8. In an exemplary embodiment, E1is as described herein, g is from 10 to 25, or from 10 to 20, or from 12 to 25, or from 12 to 23, or from 15 to 25, or from 15 to 23, or from 18 to 25 or from 18 to 23 or from 20 to 25 or from 20 to 23, or 22. In an exemplary embodiment, In an exemplary embodiment, E1is as described herein, q is from 1 to 10, or from 1 to 5, or from 1 to 8. In an exemplary embodiment, In an exemplary embodiment, E1is as described herein, g is from 10 to 25, and q is from 1 to 5, or g is from 15 to 25, and q is from 1 to 4. In an exemplary embodiment, E1is -(CH2CH2O)g(CH2)q- wherein g is 22 and q is 1 or 2. In an exemplary embodiment, E1is -(CH2CH2O)g(CH2)q- wherein g is 2 and q is 1.Y

[0088] In an exemplary embodiment, Y is -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, -NHC(O)O-, -NHC(O)NH-, -OC(O)O-, or triazole. In an exemplary embodiment, Y is triazole. In an exemplary embodiment, Y is -NH-(cyclobut-3-ene-l,2-dione)-NH-. In an exemplary embodiment, Y is absent. In an exemplary embodiment, Y is -NHC(O)-.X2

[0089] In an exemplary embodiment, X2is -(CH2CH2O)m-, -(CH2)m-, -(CH2CH2O)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2)mO(CH2)w-, -Atty Dkt No.: ADTH-007WO(CH2CH2O)mNHC(O)-, -(CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)-, -(CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, -(CH2)w(OCH2CH2)mC(O)O- / -(CH2CH2O)mOC(O)-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, -(OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O- / -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 25 and w is an integer ranging from 1 to 25. In an exemplary embodiment, X2is -(CH2CH2O)m-, -(CH2CH2O)m(CH2)w-, -(CH2CH2O)m(CH2)wO-, -(OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, -(CH2CH2O)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, -(CH2)w(OCH2CH2)mC(O)O-,-(CH2CH2O)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, -(OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 25 and w is an integer ranging from 1 to 25. In an exemplary embodiment, X2is -(CH2CH2O)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, -(CH2)m(OCH2CH2)wNHC(O)O-, -(CH2CH2O)m(CH2)wOC(O)NH-, -(OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -(CH2)w(OCH2CH2)mNHC(O)NH-, wherein m is an integer ranging from 1 to 25 and w is an integer ranging from 1 to 25. In an exemplary embodiment, X2is -(CH2CH2O)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -Atty Dkt No.: ADTH-007WO(CH2CH2O)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, wherein m is an integer ranging from 1 to 25 and w is an integer ranging from 1 to 25. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, -(CH2)w(OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wC(O)NH-, -(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, wherein m is 10 to 25 and w is 1, 2, 3,4, or 5, or wherein m is 22 and w is 1 or 2. In an exemplary embodiment, X2is as described herein, m is from 10 to 25, or from 10 to 20, or from 12 to 25, or from 12 to 23, or from 15 to 25, or from 15 to 23, or from 18 to 25 or from 18 to 23 or from 20 to 25 or from 20 to 23, or 22. In an exemplary embodiment, X2is as described herein, w is from 1 to 10, or from 1 to 5, or from 1 to 8. In an exemplary embodiment, X2is as described herein m is from 10 to 25, and w is from 1 to 5, or m is from 15 to 25, and m is from 1 to 4. In an exemplary embodiment, X2is -(CH2)w(OCH2CH2)mNHC(O)- w is 1, and m is 22. In an exemplary embodiment, X2is -(CH2)w(OCH2CH2)mNHC(O)- w is 2, and m is 22. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)w- w is 1, and m is 22. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)w-w is 2, and m is 22. In an exemplary embodiment, X2is -(CH2CH2O)m(CH2)wC(O)NH- wherein m is 22 & w is 1.E2

[0090] In an exemplary embodiment, E2is -(CH2)h-, wherein h is an integer ranging from 1 to 10, or wherein h is 1, 2, 3, 4, 5, or 6. In an exemplary embodiment, E2is -(CH2)hO(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10, wherein h is 1, 2, 3, 4, 5 and x is 1, 2, 3, 4, or 5, wherein h is 1 and x is 1, wherein h is 2 and x is 2, wherein h is 3 and x is 3, wherein h is 4 and x is 4, or wherein h is 5 and x is 5. In an exemplary embodiment, E2is -(CH2CH2O)h(CH2)x-, wherein h is an integer ranging from 1 to 10, and x is an integer ranging from 1 to 10, wherein h is 1, 2, 3, 4, 5 and x is 1, 2, or 3, wherein h is 1, 2, 3, 4,5, 6, 7, 8, 9, or 10 and x is 2. In an exemplary embodiment, E2is -(CH2CH2O)hNHC(O)-, -(CH2)hNHC(O)-, -(CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, -(CH2CH2O)hNHC(O)(CH2)x-, -(CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, -(CH2CH2O)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hC(O)NH(CH2)x-, wherein h is an integer ranging from 1 to 25, and x is an integer ranging from 1 to 25. In an exemplary embodiment, E2Atty Dkt No.: ADTH-007WO is -(CH2)hNHC(O)O-, -(CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, - (CH2)x(OCH2CH2)hNHC(O)O-, -(CH2)hOC(O)NH-, -(CH2CH2O)h(CH2)xOC(O)NH-, - (OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-,-(CH2)hNHC(O)O(CH2)x-, - (CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, - (CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, - (OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, - (CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-,-(CH2)x(OCH2CH2)hNHC(O)NH-, - (CH2CH2O)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, - (OCH2CH2)h(CH2)xNHC(O)NH(CH2)x- / -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, wherein h is an integer ranging from 1 to 25, and x is an integer ranging from 1 to 25. In an exemplary embodiment, E2is -(CH2)x(OCH2CH2)hC(O)NH-, wherein h is an integer ranging from 1 to 25, and x is an integer ranging from 1 to 25. In an exemplary embodiment, E2is -(CH2)x(OCH2CH2)hC(O)NH-, wherein h is 1, and x is 2. In an exemplary embodiment, E2is -(CH2CH2O)h(CH2)xC(O)NH- wherein m is 22 and w is 1. In an exemplary embodiment, E2is -(CH2)hC(O)NH-, wherein h is 1. In an exemplary embodiment, E2is absent. In an exemplary embodiment, E2is -(CH2)x(OCH2CH2)hC(O)NH-, wherein h is 1 and x is 2.

[0091] In an exemplary embodiment, the SigLE is selected fromAtty Dkt No.: ADTH-007WOAtty Dkt No.: ADTH-007WO

[0092] In an exemplary embodiment, the SigLE is selected fromAtty Dkt No.: ADTH-007WO

[0093] In an exemplary embodiment, the SigLE is selected fromAtty Dkt No.: ADTH-007WOAtty Dkt No.: ADTH-007WO

[0094] In an exemplary embodiment, the SigLE Conjugate is selected fromAtty Dkt No.: ADTH-007WOAtty Dkt No.: ADTH-007WO

[0095] In an exemplary embodiment, the SigLE Conjugate is selected fromAtty Dkt No.: ADTH-007WOAspects of SigLEs and SigLE Conjugates thereof

[0097] As discussed above, the SigLE Conjugates provided herein include a SigLE and biologically active substance (BAS). As used herein, the term "biologically active substance" refers to a substance that causes a change in a biological system when the biological system is contacted with the substance. In some cases, the biologically active substance is a protein. In some cases, the biologically active substance is a biotherapeutic. In some cases, the biologically active substance is an autoantigen.Atty Dkt No.: ADTH-007WOBiotherapeutic

[0098] The term "biotherapeutic" refers to a composition that is composed of sugars, amino acids, proteins, lipids or nucleic acids or complex combinations of these substances and that is therapeutic in an individual. Examples of biotherapeutics include protein therapeutics (e.g. antibodies, fusion proteins, and enzymes), viral therapeutics (e.g. viral particle), cell therapeutics, and nucleic acid therapeutics (e.g. polypeptides and nucleic acids).

[0099] Any protein or nucleic acid biotherapeutic may serve as the biotherapeutic that is engineered to become a hypoimmunogenic biotherapeutic according to the present disclosure, including, for example, a protein, e.g. an antibody, a fusion protein, an enzyme, a viral particle, a DNA molecule or an RNA molecule. The biotherapeutic may be naturally occurring, for example a naturally occurring protein that is delivered to a patient as a therapeutic, a naturally occurring capsid, etc. The biotherapeutic may be an engineered protein, for example, an antibody therapeutic, a fusion or "chimeric" protein, i.e. a protein comprising protein domains from two or more different proteins, or an entirely non-natural protein, i.e. having 30% identity or less with any naturally occurring protein across its functional domains (see e.g. Chen et al. (2020) De novo design of protein logic gates. Science 368 (6486): 78-84° and Polizzi et al.(2020) A defined structural unit enables de novo design of small-molecule-binding proteins Science 369 (6508): 1227-1233). In some embodiments, the biotherapeutic is a variant of a naturally occurring protein or a known engineered protein. By "variant" it is meant a mutant of a protein having less than 100% sequence identity with the protein from which it is derived. For example, a variant protein may be a protein having 60% sequence identity or more with a full length native protein, e.g. 65%, 70%, 75%, or 80% or more identity, such as 85%, 90%, or 95% or more identity, for example, 98% or 99% identity with the full length native protein. Variants also include fragments of naturally occurring proteins, particularly those having comparable or improved activity over the naturally occurring protein. The biotherapeutic may be derived from any source, e.g. human, non-human, or engineered.

[0100] Of particular interest is the suppression of an immune response to a biotherapeutic, and more particularly, of a B cell response to the biotherapeutic. Accordingly, in some embodiments, the Siglec ligand is a ligand for a Siglec that is expressed on B lymphocytes, for example Siglec-2 (also called CD22), Siglec-5 (CD170), Siglec-6, Siglec-9 (CD329), or Siglec-10 (Siglec-G). In some embodiments, the Siglec is Siglec-2. In some embodiments, the Siglec is Siglec-5. In some embodiments, the Siglec is Siglec-6. In some embodiments, the Siglec isAtty Dkt No.: ADTH-007WOSiglec-9. In some embodiments, the Siglec is Siglec-10. In some embodiments, the hypoimmunogenic biotherapeutic has been engineered to comprise the sialic acid ligands for one Siglec. In other embodiments, the hypoimmunogenic biotherapeutic has been engineered to comprise the Siglec ligands for two or more Siglecs, e.g. for 3 Siglecs or for 4 Siglecs, in certain cases, for 5 Siglecs. In some cases there are 5, 6, 7, 8, 9, 10, 11, 12, 13, or 15 Siglecs.

[0101] In some embodiments, the protein is an antibody or fragment thereof, for example a monoclonal antibody, a bispecific antibody, a trispecific antibody, an scFv, a Fab, a camelid nanobody, etc. Nonlimiting examples of antibodies for which the engineering contemplated herein finds particular use include adalimumab and infliximab (for the treatment of autoimmune or an inflammatory disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, or juvenile idiopathic arthritis), cetuximab (for the treatment of cancers, including for example metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer), natalizumab (for the treatment of multiple sclerosis), Lumoxiti / moxetumomab pasudotox (for the treatment of hairy cell leukemia), Tecentriq / atezolizumab (for the treatment of various cancers), Opdivo / Nivolumab (for the treatment of various cancers), Reopro / abciximab (anti-GPIIb / ll la, for the prevention of thrombosis during and after coronary artery procedures such as angioplasty), Brentuximab (for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL)), Certolizumab pegol (for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis), Elotuzumab (for the treatment of relapsed multiple myeloma), Benralizumab (for the treatment of asthma), Vedolizumab (for the treatment of ulcerative colitis and Crohn's disease), Galcanezumab (for the treatment of migraines and cluster headaches), Rituximab (for the treatment of autoimmune diseases and various cancer), Alemtuzumab (for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis), Dupilumab (for the treatment of allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps), Golimumab (for the treatment of inflammation), Obinutuzumab (for the treatment of lymphomas, e.g. chronic lymphocytic leukemia, follicular lymphoma), Tildrakizumab (for the treatment of immunologically mediated inflammatory disorders), Erenumab (for the prevention of migraine), Mepolizumab (for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES)), Ramucirumab (for the treatment of solid tumors), Ranibizumab (for the treatment of "wet" age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macularAtty Dkt No.: ADTH-007WO edema), Ustekinumab (for the treatment of psoriasis, Crohn's disease, and ulcerative colitis), Reslizumab (for the treatment of asthma), Ipilimumab (for the treatment of various cancers), Alirocumab (for the treatment of high cholesterol), Belimumab (for the treatment of systemic lupus erythematosus (SLE)), Panitumumab (for the treatment of various cancers), Avelumab (for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma), Necitumumab (for the treatment of metastatic squamous non-small-cell lung carcinoma (NSCLC)), Mogamulizumab (for the treatment of relapsed or refractory mycosis fungoides and Sezary disease, relapsed or refractory CCR4+ adult T-cell leukemia / lymphoma (ATCLL), and relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL)), Olaratumab (for the treatment of solid tumors), Brodalumab (for the treatment of inflammatory diseases), Eculizumab (for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica), Pertuzumab (for the treatment of metastatic HER2-positive breast cancer), Pembrolizumab (for the treatment of various cancers), and Tocilizumab (for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis).

[0102] In some embodiments, biotherapeutic is an antibody that is not an antibody that is specific for a receptor selected from a B cell receptor (BCR), a receptor for the Fc region of immunoglobulin E (FciRI), a Toll Like receptor (TLR), a T-cell receptor (TCR), or complexes thereof.

[0103] As used herein, an antibody that specifically binds to a target antigen refers to an antibody comprising a complementarity determining region (CDR) domain that specifically recognizes and binds to the target antigen. Thus, an antibody that specifically binds to a B cell receptor or complex thereof refers to an antibody comprising a CDR that specifically recognizes and binds to a B cell receptor or a complex comprising a B cell receptor, an antibody that specifically binds to a receptor for the Fc region of IgE refers to an antibody comprising a CDR that specifically recognizes and binds to a receptor for the Fc region of IgE or a complex comprising a receptor for the Fc region of IgE, an antibody that specifically binds to a Toll like receptor refers to an antibody comprising a CDR that specifically recognizes and binds to a Tolllike receptor or a complex comprising a Toll-like receptor, and an antibody that specifically binds to a T-cell receptor refers to an antibody comprising a CDR that specifically recognizes and binds to a T-cell receptor or a complex comprising a T-cell receptor.Atty Dkt No.: ADTH-007WO

[0104] In some embodiments, the protein is a native, or naturally occurring, protein. In other embodiments, the protein is an engineered protein. Examples of proteins for which the engineering contemplated herein finds particular use include erythropoietin (EPO, to stimulate the production of red blood cells), thrombopoietin (TPO, to stimulate the production of platelets), human growth hormone, tissue factor, IFNβ-1b (for the treatment of Multiple Sclerosis), IFNβ-1a (for the treatment of Multiple Sclerosis), IL-2 or the IL-2 mimetic aldesleukin (for the treatment of melanoma and renal cell carcinoma), exenatide (for the treatment of Type 2 Diabetes), albiglutide (for the treatment of Type 2 Diabetes), alefacept (to control inflammation in moderate to severe psoriasis with plaque formation, for the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma), palifermin (to stimulate the growth of cells that line the surface of the mouth and intestinal tract following chemotherapy), belatacept (to promote graft / transplant survival), and neutral and basic amino acid transport protein rBAT or b(0,+)-type amino acid transporter 1 (for the treatment of cystinuria).

[0105] In some embodiments, biotherapeutic is a protein that is not ovalbumin or immunoglobulin E (IgE).

[0106] In some embodiments, the protein is an enzyme, for example a metabolic enzyme, a lysosomal enzyme, a protease, a peptidase, etc. Nonlimiting examples of enzymes for which the engineering contemplated herein finds particular use include asparaginase from Erwinia chrysanthemi (for the treatment of leukemia), bacterial IdeS (for immunosuppression following tissue transplantation or in the administration of a therapy, e.g. a gene therapy, for which the patient had preexisting immunity0for treatment of IgG antibody-driven diseases, such as Systemic lupus erythematosus, Pemphigus vulgaris or IgA Nephropathy), bacterial mucinase (for the treatment of MUC+ cancers, e.g. MUC1+ cancers), Factor VIII (for the treatment of Hemophilia A), Factor IX (for the treatment of Hemophilia B), Factor Xa (to promote clotting), a complement degrading protease, e.g. from a pathogen such as a bacterial pathogen or fungal pathogen (e.g. Pseudomonas Elastase (PaE), Pseudomonas Alkaline protease (PaAP), Streptococcal pyrogenic Exotoxin B (SpeB), a gingipain from Porphyromonas gingivalis, Aspergillus Alkaline protease 1 (Alpl), C. albicans Secreted aspartyl proteinases 1 (Sapl), 2 (Sap2), and 3 (Sap3) for the treatment of complement-mediated disease, such as IgA nephropathy), phenylalanine ammonia-lyase or the mimetic pegvaliase (for the treatment of PKU), alpha-galactosidase A (for the treatment of Fabry Disease), acid a-glucosidase or the mimetic Alglucosidase alfa (GAA, for the treatment of Pompe Disease), glucocerebrosidaseAtty Dkt No.: ADTH-007WO(GCase, for the treatment of Gaucher), aspartylglucosaminidase (AGA, for the treatment of Aspartylglucosaminuria), asfotase (for treatment of hypophosphatasia (HPP)), alpha-L-iduronidase (for the treatment of MPS I), iduronate sulfatase or the iduronate sulfatase mimetic idursulfase (for the treatment of MPS II), sulfaminase (for the treatment of MPS Illa), a-N-acetylglucosaminidase (NAGLU, for the treatment of MPS 111 B), heparin acetyle CoA: a-glucosaminide N-acetyltransferase (HGSNAT, for the treatment of MPS 11 IC), N-acetylglucosamine 6-sulfatase (GNS, for the treatment of MPS HID), N-glucosamine 3-0-sulfatase (arylsulfatase G or ARSG, for the treatment of MPS HIE), N-acetylgalactosamine 6-sulfatase(for the treatment of MPS IVA), beta-galactosidase (for the treatment of MPS IVB), N-acetylgalactosamine 4-sulfatase (for the treatment of MPS VI), beta-glucuronidase (for the treatment of MPS VI), palmitoyl protein thioesterase (PPT1, for the treatment of Batten disease / CLNl), Tripeptidyl peptidase (TPP1, for the treatment of Batten Disease / CLN2), arginase-1 or pegzilarginase (for the treatment of arginase-1 deficiency), or cystathionine beta synthase or Aeglea product AGLE-177 (for the treatment of cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria).

[0107] In some embodiments, biotherapeutic is an enzyme that is not Factor VIII.

[0108] In some embodiments, the protein is a viral protein or a viral particle, for example, a recombinant viral particle. By a "recombinant" virus or viral particle it is meant a virus / viral particle that comprises a genome comprising a polynucleotide that is heterologous to the virus, i.e., not found in nature to be associated with the capsid / envelope of the virus, wherein the polynucleotide encodes a gene product (RNA or protein). Recombinant viral particles find use in the delivery of polynucleotides that encode a therapeutic gene product for the purpose of gene therapy or oncolytic virus therapy. Gene therapy is a well-established art. Also well-established is the fact that gene therapy is severely hampered by the inability to readminister the same viral therapeutic more than once or a few times, owing to the fact that the viral particle will induce an immune response in an individual. As such, the ordinarily skilled artisan will appreciate that any viral particle used in gene therapy would benefit from engineering as contemplated herein. Nonlimiting examples of viral particles that may serve as the biotherapeutic that is engineered to become a hypoimmunogenic biotherapeutic according to the present disclosure include recombinant adeno-associated virus (rAAV) particles, e.g. an rAAV particle comprising a capsid VP1 protein from the group consisting of an AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, AAV11, AAV12, or AAV13 VP1Atty Dkt No.: ADTH-007WO protein or a variant or pseudotyped virus thereof recombinant human adenovirus particles, e.g. an rHAdV particle comprising a capsid protein from rHAdV-A, rHAdV-B, rHAdV-C, rHAdV-D, rHAdV-E, rHAdV-F, or rHAdV-G or a variant thereof recombinant Herpes Simplex Virus (rHSV) particles, e.g. a rHSVl or rHSV2 or variant or pseudotyped virus thereof recombinant papillomavirus (PV) particles” recombinant polyomavirus particles” recombinant vaccinia virus particles” a recombinant cytomegalovirus (CMV) particle” a recombinant baculovirus particle” a recombinant human papillomavirus (HPV) particle” or a recombinant retrovirus particle, e.g. a recombinant lentivirus, recombinant human immunodeficiency virus (HIV) particle, Simian immunodeficiency virus (SIV) particle, Feline immunodeficiency virus (FIV) particle, Puma lentivirus (PLV) particle, Equine infectious anemia virus (EIAV) particle, Bovine immunodeficiency virus (BIV) particle, Caprine arthritis encephalitis virus particle, gammaretrovirus particle, and murine leukemia virus (MLV) particle, or variant or pseudotyped virus thereof.

[0109] In some embodiments, biotherapeutic is not a toxin. Generally, toxins are compounds that are harmful to cells in generally non-specific manner, i.e. a toxin will cause a similar amount of harm to different cells, even if such cells are from significantly different categories. In contrast, selectively damaging compounds will harm certain cells to a significantly greater degree than the harm inflicted on other types of cells. For instance, the selectively damaging compound can cause harm based on a biochemical process that is common in a lung cell but rare in a kidney cell, whereas a toxin can cause harm based on a biochemical process common to both lung and kidney cells. In some cases, the harm is cell death. In some cases, the toxin is Pseudomonas exotoxin A. In some embodiments, biotherapeutic is not a B cell modulator. Y does not increase or decrease the immune action of a B cell. Examples of modulation of the B cell include differentiation of the B cell into a biotherapeutic-specific mature B cell, e.g. plasma cells or memory cells, preventing B cells from producing antigen-specific antibodies, preventing the upregulation of activation markers such as CD69, promoting a decrease in viability of a biotherapeutic-specific B cell population. In some embodiments, B cell activation is inhibited only for those B cells with a B cell receptor that recognizes Y (in contrast to the entire B cell population recognizing X).Autoantigen

[0110] The term "autoantigen" (abbreviated as " AutoAg") refers to an endogenous molecule present in a subject which the subject's immune system does not recognize as an endogenousAtty Dkt No.: ADTH-007WO molecule (i.e., as a self-antigen) and thus mounts an immune response to the self-antigen. Such an immune response is referred to as an autoimmune response. The autoantigen is encoded by an endogenous gene present in a subject and may be a polypeptide, e.g., a soluble or membrane-localized polypeptide, a lipidated, glycosylated, or otherwise post-translationally modified polypeptide’ a nucleic acid (e.g., DNA, RNA)° or a complex thereof. In some embodiments, the autoantigen is any autoantigen that elicits a B-cell driven immune response in an individual, where the individual produces B cells that bind to the autoantigen via B-cell receptors (BCRs) and upon binding to the autoantigen differentiate into plasma cells that produce autoantibodies that bind to the autoantigen.

[0111] In contrast to a biotherapeutic, an autoantigen is a molecule that is endogenously produced by the subject, whereas a biotherapeutic is a molecule that the subject does not produce and is exogenously supplied to the person, e.g., as a polypeptide or a gene encoding the polypeptide. Thus, an immune response to a biotherapeutic is not considered an autoimmune response. Rather, an immune response to a biotherapeutic is a normal immune response. A biotherapeutic may be composed of sugars, amino acids, proteins, lipids or nucleic acids or complex combinations of these substances. Unlike an engineered autoantigen, a biotherapeutic is not intended as an autoimmune-suppressive mimic of a non-suppressive and endogenous disease-driving antigen. Nonlimiting examples of biotherapeutics include protein therapeutics, e.g., antibody therapeutics, fusion protein therapeutics, enzyme therapeutics, viral therapeutics, cell therapeutics, and nucleic acid therapeutics.

[0112] Specific examples of biotherapeutics include a monoclonal antibody, a bispecific antibody, an scFv, a Fab, a camelid, or a nanobody, e.g., adalimumab, infliximab, cetuximab, natalizumab, moxetumomab pasudotox, atezolizumab, nivolumab, abciximab, Brentuximab, Certolizumab pegol, elotuzumab, benralizumab, vedolizumab, galcanezumab, rituximab, alemtuzumab, dupilumab, golimumab, obinutuzumab, tildrakizumab, erenumab, mepolizumab, tamucirumab, ranibizumab, ustekinumab, reslizumab, ipilimumab, alirocumab, belimumab, panitumumab, avelumab, necitumumab, mogamulizumab, olaratumab, brodalumab, eculizumab, pertuzumab, pembrolizumab, or tocilizumab. In certain embodiments, the biotherapeutic is erythropoietin, thrombopoietin, human growth hormone, tissue factor, I FN £-lb, IFN£-la, IL-2 or the IL-2 mimetic aldesleukin, exenatide, a I biglutide, alefacept, palifermin, or belatacept.Atty Dkt No.: ADTH-007WO

[0113] In certain embodiments, the biotherapeutic is an enzyme, such as, asparaginase Erwinia chrysanthemi, phenylalanine ammonia-lyase, alpha-galactosidase A, acid a-glucosidase (GAA), glucocerebrosidase (GCase), aspartylglucosaminidase (AGA), alpha-L-iduronidase, iduronate sulfatase, sulfaminase, a-N-acetylglucosaminidase (NAGLU), heparin acetyle CoA: a-glucosaminide N-acetyltransferase (HGSNAT), N-acetylglucosamine 6-sulfatase (GNS), N-glucosamine 3-O-sulfatase (arylsulfatase G or ARSG), N-acetylgalactosamine 6-sulfatase, betagalactosidase, N-acetylgalactosamine 4-sulfatase, beta-glucuronidase, Factor VIII, Factor IX, palmitoyl protein thioesterase (PPT1), Tripeptidyl peptidase (TPP1), Pseudomonas elastase (PaE), Pseudomonas alkaline protease (PaAP), or Streptococcal pyrogenic exotoxin B (SpeB).. In certain embodiments, the biotherapeutic is not Factor VIII.

[0114] In some embodiments, an autoantigen, as provided herein, is a naturally occurring antigen in a healthy individual. Using PANTHER, (Protein ANalysis Through Evolutionary Relationships), autoantigens can be classified into the following varieties based on function played by the antigen in-vivo that may have a role to play as, for example, an enzyme, intercellular adhesive protein, cell junction protein, cytoskeletal protein, extracellular matrix protein, cellular receptor, transcription or translational protein, gene editing protein, structural protein, or the like.

[0115] Autoantigens have been found to be associated with several autoimmune disorders. A comprehensive list of disorders and associated autoantigens can be found at the database AAgAtlas 1.0 database accessed by typing into a web browser http followedby: / / biokb. ncpsb.org / followed by aagatlas / ). Nonlimiting examples of autoantigens and their associated disorders include: p53-associated autoimmune diseases lupus and scleroderma’ Desmoglein (Dsg) 1 and 3 autoantigens associated with Pemphigus vulgaris’ autoantigens Gliadin and type 2 transglutaminase associated with Celiac disease’ autoantigens PDC-E2 (Pyruvate dehydrogenase complex component E2) and BCOADC-E2 (Branched chain 2-oxo-acid dehydrogenase complex component E2) associated with Primary Biliary Cholangitis’ autoantigens PLA2R (Phospholipase A2 Receptor) and THSD7A (thrombospondin type-1 domain containing protein 7A) associated with Membranous Nephropathy’ autoantigen TSHR (Thyroid-Stimulating Hormone Receptor) associated with Graves' Disease’ autoantigens AChR (Acetylcholine Receptor), MuSK (Muscle-Specific Kinase), and LRP4 ( associated with Myasthenia Gravis’ and autoantigens associated with rheumatoid arthritis (RA) (e.g., citru 11 i nated peptides and proteins, carbamylated proteins, acetylated proteins) and systemicAtty Dkt No.: ADTH-007WO lupus erythematosus (SLE) (e.g., anti-nuclear antibodies, anti-dsDNA antibodies, antinucleosome antibodies, and others), and the like.

[0116] In certain aspects, an engineered autoantigen that suppresses an ongoing autoimmune response to the autoantigen in a subject includes a siglec ligand. The engineered autoantigen is configured to both bind to BCRs on a B cell that recognizes the autoantigen and to bind to a siglec present on the B cell. The autoantigen portion of the engineered autoantigen provides specificity for targeting only B cells that bind to the autoantigen while the siglec ligand, while not specific to a particular B cell clone, may bind to any B cell expressing the siglec, prevents activation of the B cell. In some instances, the siglec ligand provides a therapeutic benefit to the individual by suppressing the individual's immune response to the autoantigen, where the immune response is reduced by 50% or more when the engineered autoantigen is administered to an individual relative to when the individual is administered the nonengineered version of the autoantigen. Further, in some instances, the immune reaction is reduced by 60%, 70%, 80% or more, for example 85%, 90%, 95% or more, in certain cases 98%, 99%, or 100%, i.e., such that the immune response is undetectable, i.e., the autoantigen is rendered nonimmunogenic.

[0117] In some aspects of the disclosure, an engineered autoantigen is provided, wherein the engineered autoantigen (referred to interchangeably as the "clonally immunosuppressive autoantigen", "hypoimmunogenic autoantigen", "modified autoantigen" or simply "subject autoantigen") is engineered to have an altered Sialic acid-binding immunoglobulin-type lectin (Siglec) ligand (sigL) profile.

[0118] Thus, disclosed herein are engineered autoantigens which may retain the epitope(s) recognized by autoimmune antibodies, while comprising one or more modifications comprising addition of a sigL that render the autoantigen capable of suppressing an antigen-specific immune response in an individual to which it has been administered as compared to the unmodified autoantigen. In some embodiments, the immune response is a humoral immune response i.e., a B cell-driven response, e.g., an IgG response.Engineered and hypoimmunogenic

[0119] The term "engineered" refers to a biotherapeutic that has been designed and built to comprise one or more modifications relative to biotherapeutic that has not been so engineered, i.e. a parental biotherapeutic, which is also referred to herein as an unengineered biotherapeutic.Atty Dkt No.: ADTH-007WO

[0120] By a "hypoimmunogenic" composition, it is meant a composition that suppresses an unwanted, drug-specific immune response in an individual relative to a reference composition, e.g. a corresponding nonengineered composition, when administered to the individual’ for example, reducing an immune response by 50% or more relative to a reference, e.g. a nonengineered biotherapeutic, in some instances 60%, 70%, 80% or more, for example 85%, 90%, 95% or more, in certain cases 98%, 99%, or 100%, i.e. such that the immune response is undetectable, i.e. the biotherapeutic is nonimmunogenic. Thus, disclosed herein are engineered biotherapeutics which retain pharmacologic activity while comprising one or more modifications that render the biotherapeutic capable of suppressing a drug-specific immune response in an individual to which it has been administered as compared to the unmodified biotherapeutic. In some embodiments, the immune response is a humoral immune response i.e., a B cell-driven response, e.g. an IgG response.PHARMACEUTICAL COMPOSITIONS

[0121] P rovided are pharmaceutical compositions comprising: a conjugate as described herein’ and a pharmaceutical excipient.

[0122] In methods of treating an individual with the subject hypoimmunogenic biotherapeutic, the patient will typically be administered a pharmaceutical composition comprising the subject hypoimmunogenic biotherapeutic. By a pharmaceutical composition, it is meant an engineered hypoimmunogenic biotherapeutic of the present disclosure that has been formulated in a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[0123] The pharmaceutical compositions of the disclosure are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described. Administration of the compounds of the disclosure or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities. While human dosage levels have yet to be optimized for the compounds of the disclosure, these can be readily extrapolated from doses administered to a relevant animal model, e.g. mice that results in treatment of the disease orAtty Dkt No.: ADTH-007WO disorder in that animal model. Generally, an individual human dose is from about 0.01 to 2.0 mg / kg of body weight, preferably about 0.1 to 1.5 mg / kg of body weight, and most preferably about 0.3 to 1.0 mg / kg of body weight. Treatment can be administered for a single day or a period of days, and can be repeated at intervals of several days, one or several weeks, or one or several months. Administration can be as a single dose (e.g., as a bolus) or as an initial bolus followed by continuous infusion of the remaining portion of a complete dose over time, e.g., 1 to 7 days. The amount of active compound administered will, of course, be dependent on any or all of the following: the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. It will also be appreciated that amounts administered will depend upon the molecular weight of the biotherapeutic, the amount of Siglec ligand covalently bound, and the size of the linker.

[0124] While all typical routes of administration are contemplated (e.g. oral, topical, transdermal, injection (intramuscular, intravenous, or intra-arterial)), it is presently preferred to provide liquid dosage forms suitable for injection. Generally, depending on the intended mode of administration, the pharmaceutically acceptable composition will contain about 0.1% to 95%, preferably about 0.5% to 50%, by weight of the subject hypoimmunogenic biotherapeutic of the disclosure, the remainder being suitable pharmaceutical excipients, carriers, etc. Dosage forms or compositions containing active ingredient in the range of 0.005% to 95% with the balance made up from non-toxic carrier can be prepared.

[0125] The subject pharmaceutical compositions can be administered either alone or in combination with other pharmaceutical agents. These compositions can include other medicinal agents, pharmaceutical agents, carriers, and the like, including, but not limited to other active agents that can act as immune-modulating agents and more specifically can have inhibitory effects on B-cells, including anti-folates, immune suppressants, cyostatics, mitotic inhibitors, and anti-metabolites, or combinations thereof.

[0126] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active composition of the disclosure (e.g., a lyophilized powder) and optional pharmaceutical adjuvants in a carrier, such as, for example, water (water for injection), saline, aqueous dextrose, glycerol, glycols, ethanol or the like (excluding galactoses), to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, stabilizing agents, solubilizing agents, pH buffering agents and theAtty Dkt No.: ADTH-007WO like, for example, sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate and triethanolamine oleate, etc., osmolytes, amino acids, sugars and carbohydrates, proteins and polymers, salts, surfactants, chelators and antioxidants, preservatives, and specific ligands. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art° for example, see Remington: The Science and Practice of Pharmacy, Pharmaceutical Press, 22nd Edition, 2012. The composition or formulation to be administered will, in any event, contain a quantity of the active compound in an amount effective to treat the symptoms of the subject being treated.METHODS OF MANUFACTURE

[0127] Also provided are methods of making the conjugates disclosed herein. Provided is a method of making a conjugate, comprising: covalently attaching a SigLE as described herein to a biologically active substance, thereby making the SigLE Conjugate. In an exemplary embodiment, the SigLE is according to Formula (I) or (la), wherein each Q, Q1, D, D1, D2, D3, M, b, j, k, and Z are as described herein. In an exemplary embodiment, Z is a chemoselective functional group which reacts with the polypeptide to produce a covalent bond. In an exemplary embodiment, Z is a chemoselective functional group which reacts with an amine (e.g. primary amine) or a thiol to produce a covalent bond.

[0128] Examples of Q-D2-Z, Q1-D1-Z, and Qx-D3-Z of use in making the SigLE Conjugates are found in Examples 20-35. Other Q-D2-Z, Q1-D1-Z, and Q1-D3-Z of use in making the SigLE Conjugates are found in WO 2024 / 259007. Specific Q-D2-Z, Q1-D1-Z, and Qx-D3-Z examples from WO 2024 / 259007 are compounds:Atty Dkt No.: ADTH-007WO(227M)°Atty Dkt No.: ADTH-007WO

[0129] The polypeptides may be present in a solution which allows for dimers to form and for formation of tetramers from the dimers. The tetramers may be separated from any monomers and dimers via a standard method, e.g., purification based on size and / or charge.

[0130] Conditions for attaching SigLEs to a N-terminus, lysine side chain, or cysteine side chain of a polypeptide are provided in the Examples. Conditions when utilizing a squaramate as a chemoselective functional group can involve using a 50 mM PBS 100 mM sodium carbonate 10% v / v DMSO, pH 9.5 at 25 °C with a reaction time of at least about 4 hours which an appropriate ratio of SigLE to polypeptide to produce the desired SigLE-to-polypeptide ratio in the SigLE Conjugate.Atty Dkt No.: ADTH-007WO

[0131] Additional conditions for making SigLE Conjugates are found in the Bioconjugation and Crosslinking Technical Handbook (ThermoFisher Scientific, 2025) and Bioconjugate Techniques (Greg Hermanson, 3rdEdition), each of which are herein incorporated by reference for all purposes.

[0132] Methods of covalently binding SigLEs to biologically active substances (e.g. biotherapeutics) or connectors are well appreciated in the art, any of which may be deployed to modify a biotherapeutic of choice to become an engineered hypoimmunogenic biotherapeutic of the present disclosure. For example, the modification may be performed by engineered biosynthesis. By "biosynthesis", it is meant a synthesis process that is mediated by cells. For example, in the Golgi apparatus, a subset of the 20 known sialyltransferases attach sialic acids to underlying monosaccharides such as galactose via three different types of linkage (a2,3, a2,6, and a2,8). By engineered biosynthesis, it is meant a synthesis process that is mediated by cells that have been engineered to perform the process, in some instances de novo, in other instances, in a modified way. Thus, for example, a producer cell line may be genetically engineering to express one or more sialyl transferases, e.g. sialyltransferase (EC 2.4.99), beta-galactosamide alpha-2, 6-sialyltransferase (EC 2.4.99.1), alpha-N-acetylgalactosaminide alpha-2, 6-sialyltransferase (EC 2.4.99.3), beta-galactoside alpha-2, 3-sialyltransferase (EC 2.4.99.4), N-acetyllactosaminide alpha-2, 3-sialyltransferase (EC 2.4.99.6), alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase (EC 2.4.99.8)° lactosylceramide alpha-2, 3-sialyltransferase (EC 2.4.99.9), or other enzymes in an enzymatic pathway, e.g. CMP-Neu5Ac hydroxylase, sialate-4-O-acetyl transferase, sialate-4-O-acetylesterase, sialate-7(9)-O-acetyltransferase, sialate-8-O-methyl transferase, sialate-9-)-acetyltransferase, etc. that drives the covalent binding of a specific sialic acid to the biotherapeutic or that targets specific novel amino acid residues for covalent modification with sialic acid. As another example, a producer cell line could be fed a precursor substrate that will be incorporated by the producer line into the manufactured biotherapeutic as a specific Siglec ligand. Any producer cell that finds use in the expression of proteins for use as therapeutic biotherapeutics may be used in this process, for example a mammalian cell (CHO, HEK, etc.), an insect cell (SF9, etc.), a bacterium, a protozoan (Leishmania, etc.), as disclosed in, e.g. WO2017093291, W02019002512, WO2019234021, the full disclosures of which are incorporated herein in their entirety by reference.Atty Dkt No.: ADTH-007WO

[0133] As another example, the modification may be performed by chemical conjugation. By "chemical conjugation", it is meant a process that occurs exogenous to a cell. Thus, for example, the Siglec ligand might be enzymatically or chemically linked to the biotherapeutic after biosynthesis from producer cell line. Nonlimiting examples of such in vitro processes are disclosed in US Patent No. 7,220,555, US Patent No. 6,376,475B, and US Patent No. 5,409,817, the full disclosures of which are incorporated herein by reference. In some such embodiments, a connector may be deployed to covalently link the sialic acid to the biotherapeutic. Many examples of connector exist in the art, any of which may be used to chemically conjugate sialic acid(s) to the biotherapeutic to arrive at hypoimmunogenic biotherapeutics of the present disclosure.

[0134] As a third example, specifically directed to embodiments in which the Siglec ligand is a peptide or polypeptide sequence, e.g. an scFv or peptide derived from epratuzumab, e.g. PV1, PV2 or PV3, the modification may be performed by genetic engineering of the biotherapeutic to comprise the peptide / polypeptide sequence within the biotherapeutic. For example, the polynucleotide used to produce the biotherapeutic may be modified by standard molecular biology cloning techniques to include a polynucleotide sequence encoding the peptide / polypeptide in the same translational reading frame (" In frame"), such that upon transcription and translation of the biotherapeutic in a producing cell, the biotherapeutic will comprise the peptide / polypeptide sequence covalently associated with amino acids that make up the biotherapeutic, resulting in a biotherapeutic that is hypoimmunogenic. Preferably, the peptide / polypeptide sequence will be genetically engineered into a domain of the biotherapeutic that is not responsible for the therapeutic effect of the biotherapeutic, e.g. the enzymatic domain of an enzyme, the Fab or more specifically CDR domains of an antibody, etc. In the instance of modifying a viral particle, the peptide / polypeptide sequence will preferably be genetically engineered into a capsid or envelop protein so as to be exposed to the exterior of the viral particle, e.g. into an exposed loop of a viral capsid protein, a surface-exposed tegument protein, etc. Such structural features are well understood by one of ordinary skill in the art of viral therapies.METHODS OF USE

[0135] Provided are methods of using the conjugates. Provided is a method of treating a patient for a condition, the method comprising: administering to the patient a conjugate as described herein.Atty Dkt No.: ADTH-007WO

[0136] The hypoimmunogenic compositions of the present disclosure find particular use in the treatment of diseases that require repeat or chronic administration of the therapeutic to be effective. There are many instances of such conditions, of which a few nonlimiting examples are provided below and elsewhere. It is expected that the ordinarily skilled artisan will be able to extrapolate from these examples to other indications and biotherapeutics as known in the art.

[0137] For example, the individual may be suffering from a chronic autoimmune or inflammatory disease, e.g. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. In such instances, the method may comprise administering to the individual a hypoimmunogenic TN Fa-specific antibody, e.g. a hypoimmunogenic adalimumab engineered from adalimumab, or a hypoimmunogenic infliximab engineered from infliximab, in an amount effective to treat the chronic immune disease.

[0138] As another example, the individual may be suffering from a leukemia, e.g. ALL. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic asparaginase from Erwinia chrysanthemi in an amount effective to treat the leukemia.

[0139] As another example, the individual may be suffering from a colorectal cancer, a nonsmall cell lung cancer, or a head and neck cancer. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic cetuximab in an amount effective to treat the colorectal cancer, non-small cell lung cancer, or head and neck cancer.

[0140] As another example, the individual may be suffering from multiple sclerosis. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic natalizumab, an engineered hypoimmunogenic I FN P-lb, or an engineered hypoimmunogenic IFN [3-la in an amount effective to treat the multiple sclerosis.

[0141] As another example, the individual may be the recipient of an organ transplant and in need of an immunosuppressive agent that protects the transplanted tissue from rejection by the individual's immune system. In such instances, the method may comprise administering to the individual an engineered hypoimmunogenic IdeS in an amount effective to prevent an antibody response to the transplanted tissue. In some embodiments, the transplanted organ is an allogeneic graft. In some embodiments, the transplanted organ is a xenogeneic graft. InAtty Dkt No.: ADTH-007WO some embodiments, the organ is selected from kidney, heart, lung, liver, pancreas, trachea, vascular tissue, skin, bone, cartilage, adrenal tissue, fetal thymus, and cornea.

[0142] As another example, the individual may be suffering from Type 2 Diabetes. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic exenatide or engineered hypoimmunogenic a I biglutide in an amount effective to treat the diabetes.

[0143] As another example, the individual may be suffering from a complement-mediated disease. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic complement degrading protease, e.g. from a pathogen such as a bacterial pathogen or fungal pathogen (e.g. Pseudomonas Elastase (PaE), Pseudomonas Alkaline protease (PaAP), Streptococcal pyrogenic Exotoxin B (SpeB), a gingipain from Porphyromonas gingivalis, Aspergillus Alkaline protease 1 (Alpl), C. albicans Secreted aspartyl proteinases 1 (Sapl), 2 (Sap2), and 3 (Sap3), in an amount effective to degrade complement and treat the disease.

[0144] As another example, the individual may be suffering from an enzyme deficiency. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic enzyme in an amount effective to treat the deficiency. Nonlimiting examples of such enzyme deficiencies would include PKU, wherein a hypoimmunogenic phenylalanine ammonia-lyase would be administered" Fabry disease, wherein a hypoimmunogenic alpha-galactosidase A would be administered” Pompe disease, wherein a hypoimmunogenic acid a-glucosidase (GAA) would be administered” Gaucher disease, wherein a hypoimmunogenic glucocerebrosidase (GCase) would be administered” Aspartylglucosaminuria, wherein a hypoimmunogenic aspartylglucosaminidase (AGA) would be administered” Hypophosphatasia (HPP), wherein a hypoimmunogenic asfotase would be administered” MPS I, wherein a hypoimmunogenic alpha-L-iduronidase would be administered” MPS II, wherein a hypoimmunogenic iduronate sulfatase would be administered” MPS Illa, wherein a hypoimmunogenic sulfaminase would be administered” MPS 11 IB, wherein a hypoimmunogenic a-N-acetylglucosaminidase (NAGLU) would be administered” MPS I IIC, wherein a hypoimmunogenic heparin acetyle CoA: a-glucosaminide N-acetyltransferase (HGSNAT) would be administered” MPS HID, wherein a hypoimmunogenic N-acetylglucosamine 6-sulfatase (GNS) would be administered” MPS HIE, wherein a hypoimmunogenic N-glucosamine 3-O-sulfatase (arylsulfatase G or ARSG) would be administered” MPS IVA, whereinAtty Dkt No.: ADTH-007WO a hypoimmunogenic N-acetylgalactosamine 6-sulfatase would be administered' MPS IVB, wherein a hypoimmunogenic beta-galactosidase would be administered' MPS VI, wherein a hypoimmunogenic N-acetylgalactosamine 4-sulfatase would be administered' MPS VI, wherein a hypoimmunogenic beta-glucuronidase would be administered' Hemophilia A, wherein a hypoimmunogenic Factor VIII would be administered' Hemophilia B, wherein a hypoimmunogenic Factor IX would be administered' the CLN1 form of Batten Disease, wherein a hypoimmunogenic palmitoyl protein thioesterase (PPT1) would be administered' the CLN2 form of Batten Disease, wherein a hypoimmunogenic Tripeptidyl peptidase (TPP1) would be administered' arginase-1 deficiency, wherein a hypoimmunogenic arginase-1 or pegzilarginase would be administered' and cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria, wherein a hypoimmunogenic cystathionine beta synthase or Aeglea product AGLE-177 is administered.

[0145] As another example, the individual may be suffering from disease that would benefit from a gene therapy, e.g. a genetic disease, or a complex disease (i.e. not restricted to being associated with a specific genetic etiology) in which chronic expression of a therapeutic RNA or protein would treat the condition. In such instances, the method would comprise administering to the individual an engineered hypoimmunogenic viral particle comprising a polynucleotide sequence (a "transgene") encoding the therapeutic gene product of interest, in an amount effective to treat the disease. Nonlimiting examples of suitable transgenes / gene products that one might deliver via the subject hypoimmunogenic viral particle include those associated with muscular dystrophy, cystic fibrosis, familial hypercholesterolemia, and rare or orphan diseases. Examples of such rare disease may include spinal muscular atrophy (SMA), Huntingdon's Disease, Rett Syndrome (e.g., methyl-CpG-binding protein 2 (MeCP2)° UniProtKB - P51608), Amyotrophic Lateral Sclerosis (ALS), Duchenne Type Muscular dystrophy, Friedrichs Ataxia (e.g., frataxin), ATXN2 associated with spinocerebellar ataxia type 2 (SCA2) / ALS°TDP-43 associated with ALS, progranulin (PRGN) (associated with non- Alzheimer's cerebral degenerations, including, frontotemporal dementia (FTD), progressive non-fluent aphasia (PNFA) and semantic dementia), among others. See, e.g., www.orpha.net / consor / cgi-bin / Disease_Search_List.php° rarediseases.info.nih.gov / diseases.

[0146] Other useful therapeutic gene products that could be encoded by the transgene also include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, glucagon-like peptide 1 (GLP-1), growth hormone (GH), parathyroid hormone (PTH),Atty Dkt No.: ADTH-007WO growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor a (TGFa), platelet-derived growth factor (PDGF), insulin growth factors I and II (IGF-I and IGF-II), any one of the transforming growth factor b superfamily, including TGF b, activins, inhibins, or any of the bone morphogenic proteins (BMP) BMPs 1-15, any one of the heregluin / neuregulin / ARIA / neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGE), brain-derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor (CNTF), glial cell line derived neurotrophic factor (GDNF), neurturin, agrin, any one of the family of semaphorins / collapsins, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog and tyrosine hydroxylase.

[0147] Other useful transgenes include those that encode proteins that regulate the immune system including, without limitation, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1 through IL-25 (including, IL-2, IL-4, IL-12, and IL-18), monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factors a and b, interferons a, b, and g, stem cell factor, Hk-2 / f It3 ligand. Gene products produced by the immune system are also useful in the invention. These include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules, as well as engineered immunoglobulins and MHC molecules. Useful gene products also include complement regulatory proteins such as complement regulatory proteins, membrane cofactor protein (MCP), decay accelerating factor (DAF), CR1, CF2 and CD59.

[0148] Still other useful transgenes include those that encode gene products for any one of the receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins.

[0149] Still other useful transgenes include those encoding receptors for cholesterol regulation, including the low density lipoprotein (LDL) receptor, high density lipoprotein (HDL) receptor, the very low density lipoprotein (VLDL) receptor, and the scavenger receptor. The invention also encompasses gene products such as members of the steroid hormone receptorAtty Dkt No.: ADTH-007WO superfamily including glucocorticoid receptors and estrogen receptors, Vitamin D receptors and other nuclear receptors. In addition, useful gene products include transcription factors such as jun,fos, max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD and myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C / EBP, SP1, CCAAT-box binding proteins, interferon regulation factor ( IRF-1), Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, e.g., GATA-3, and the forkhead family of winged helix proteins.

[0150] Other useful gene products include, carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, arginase, fumarylacetacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-e-phosphatase, porphobilinogen deaminase, Factor VIII, Factor IX, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-coA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, betaglucosidase, pyruvate carboxylate, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, a cystic fibrosis transmembrane regulator (CFTR) sequence, and a dystrophin sequence or functional fragment thereof. Still other useful gene products include enzymes such as may be useful in enzyme replacement therapy, which is useful in a variety of conditions resulting from deficient activity of enzyme. For example, enzymes that contain mannose-6-phosphate may be utilized in therapies for lysosomal storage diseases (e.g., a suitable gene includes that encodes b-glucuronidase (GUSB)). In another example, the gene product is ubiquitin protein ligase E3A (UBE3A). Still useful gene products include UDP Glucuronosyltransferase Family 1 Member Al (UGT1A1).

[0151] In some embodiment, the gene product is not Factor VIII.

[0152] Other useful gene products include non-naturally occurring polypeptides, such as chimeric or hybrid polypeptides having a non-naturally occurring amino acid sequence containing insertions, deletions or amino acid substitutions. For example, single-chain engineered immunoglobulins could be useful in certain immunocompromised patients. Other types of non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to reduce overexpression of a target.

[0153] Reduction and / or modulation of expression of a gene is particularly desirable for treatment of hyperproliferative conditions characterized by hyperproliferating cells, as are cancers and psoriasis. Target polypeptides include those polypeptides which are producedAtty Dkt No.: ADTH-007WO exclusively or at higher levels in hyperproliferative cells as compared to normal cells. Target antigens include polypeptides encoded by oncogenes such as myb, myc, fyn, and the translocation gene bcr / abl, ras, src, P53, neu, trk and EGRF. In addition to oncogene products as target antigens, target polypeptides for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used as target antigens for autoimmune disease. Other tumor-associated polypeptides can be used as target polypeptides such as polypeptides which are found at higher levels in tumor cells including the polypeptide recognized by monoclonal antibody 17-1A and folate binding polypeptides.

[0154] Other suitable transgenes include those which encode therapeutics that may be useful for treating individuals suffering from autoimmune diseases and disorders by conferring a broad based protective immune response against targets that are associated with autoimmunity including cell receptors and cells which produce self-directed antibodies. T cell mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis. Each of these diseases is characterized by T cell receptors (TCRs) that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases.

[0155] Still other useful gene products include those used for treatment of hemophilia, including hemophilia B (including Factor IX) and hemophilia A (including Factor VIII and its variants, such as the light chain and heavy chain of the heterodimer and the B-deleted domain” US Patent No. 6,200,560 and US Patent No. 6,221,349). In some embodiments, the minigene comprises first 57 base pairs of the Factor VIII heavy chain which encodes the 10 amino acid signal sequence, as well as the human growth hormone (hGH) polyadenylation sequence. In alternative embodiments, the minigene further comprises the Al and A2 domains, as well as 5 amino acids from the N-terminus of the B domain, and / or 85 amino acids of the C-terminus of the B domain, as well as the A3, Cl and C2 domains. In yet other embodiments, the nucleic acids encoding Factor VIII heavy chain and light chain are provided in a single mini gene separated by 42 nucleic acids coding for 14 amino acids of the B domain [US Patent No.6,200,560],Atty Dkt No.: ADTH-007WO

[0156] Further illustrative genes which may be delivered via the hypoimmunogenic viral particle include, without limitation, glucose-6-phosphatase, associated with glycogen storage disease or deficiency type 1A (GSD1), phosphoenolpyruvate-carboxy kinase (PEPCK), associated with PEPCK deficiency’ cyclin-dependent kinase-like 5 (CDKL5), also known as serine / threonine kinase 9 (STK9) associated with seizures and severe neurodevelopmental impairment0galactose-1 phosphate uridyl transferase, associated with galactosemia0phenylalanine hydroxylase (PAH), associated with phenylketonuria (PKU)° gene products associated with Primary Hyperoxaluria Type 1 including Hydroxy acid Oxidase 1 (GO / HAOI) and AGXT, branched chain alpha-ketoacid dehydrogenase, including BCKDH, BCKDH-E2, BAKDH-Ela, and BAKDH-Elb, associated with Maple syrup urine disease" fumarylacetoacetate hydrolase, associated with tyrosinemia type 1° methylmalonyl-CoA mutase, associated with methylmalonic acidemia” medium chain acyl CoA dehydrogenase, associated with medium chain acetyl CoA deficiency0ornithine transcarbamylase (OTC), associated with ornithine transcarbamylase deficiency” argininosuccinic acid synthetase (ASS1), associated with citrullinemia” lecithin-cholesterol acyltransferase (LCAT) deficiency” amethylmalonic acidemia (MMA)° NPC1 associated with Niemann-Pick disease, type Cl)° propionic academia (PA)° TTR associated with Transthyretin (TTR)-related Hereditary Amyloidosis” low density lipoprotein receptor (LDLR) protein, associated with familial hypercholesterolemia (FH), LDLR variant, such as those described in WO 2015 / 164778° PCSK9° ApoE and ApoC proteins, associated with dementia” UDP-glucouronosyltransferase, associated with Crigler-Najjar disease” adenosine deaminase, associated with severe combined immunodeficiency disease” hypoxanthine guanine phosphoribosyl transferase, associated with Gout and Lesch-Nyan syndrome” biotimidase, associated with biotimidase deficiency” alpha-galactosidase A (a-Gal A) associated with Fabry disease)” beta-galactosidase (GLB1) associated with GM1 gangliosidosis” ATP7B associated with Wilson's Disease” beta-glucocerebrosidase, associated with Gaucher disease type 2 and 3° peroxisome membrane protein 70 kDa, associated with Zellweger syndrome” arylsulfatase A (ARSA) associated with metachromatic leukodystrophy, galactocerebrosidase (GALC) enzyme associated with Krabbe disease, alpha-glucosidase (GAA) associated with Pompe disease” sphingomyelinase (SMPD1) gene associated with Nieman Pick disease type A” argininosuccsinate synthase associated with adult onset type II citrullinemia (CTLN2)” carbamoyl-phosphate synthase 1 (CPS1) associated with urea cycle disorders” survival motor neuron (SMN) protein, associated with spinal muscular atrophy” ceramidase associated with Farber lipogranulomatosis” b-hexosaminidase associated with GM2 gangliosidosis and Tay-Atty Dkt No.: ADTH-007WOSachs and Sandhoff diseases” aspartylglucosaminidase associated with aspartyl-glucosaminuria a-fucosidase associated with fucosidosis” a-mannosidase associated with alpha-mannosidosis” porphobilinogen deaminase, associated with acute intermittent porphyria (AIP)” alpha- 1 antitrypsin for treatment of alpha- 1 antitrypsin deficiency (emphysema)” erythropoietin for treatment of anemia due to thalassemia or to renal failure” vascular endothelial growth factor, angiopoietin-1, and fibroblast growth factor for the treatment of ischemic diseases” thrombomodulin and tissue factor pathway inhibitor for the treatment of occluded blood vessels as seen in, for example, atherosclerosis, thrombosis, or embolisms” aromatic amino acid decarboxylase (AADC), and tyrosine hydroxylase (TH) for the treatment of Parkinson's disease” the beta adrenergic receptor, anti-sense to, or a mutant form of, phospholamban, the sarco(endo)plasmic reticulum adenosine triphosphatase-2 (SERCA2), and the cardiac adenylyl cyclase for the treatment of congestive heart failure” a tumor suppressor gene such as p53 for the treatment of various cancers” a cytokine such as one of the various interleukins for the treatment of inflammatory and immune disorders and cancers” dystrophin or minidystrophin and utrophin or miniutrophin for the treatment of muscular dystrophies” and, insulin or GLP-1 for the treatment of diabetes.EMBODIMENTS

[0157] Aspects of embodiments of the present invention are described by, but not limited to, the following clauses:1. A compound having a structure of Formula (I) or (la):Z is a chemoselective functional group or Zl'-T-Z2, wherein Zl' is a diradical group, T is absent or a diradical group, and Z2 is a chemoselective functional group”*5D is, wherein5represents covalent connection to M, and represents covalent connection to Z”b is an integer from 1 to 5°j is an integer from 0 to 15°k is an integer from 1 to 5°Atty Dkt No.: ADTH-007WO when j is 0, each of the members of D1are not absent”when j is 0, and k is 1, each of the members of D1are not absent and at least two of the members of D are not absent”M is a lysine residue, or a portion thereof”***each D2is independently selectedwherein? represents, **covalent connection to Q, and < represents covalent connection to M,AAx1— E1— Y— X2— E2—each D3is > wherein ' represents covalent connection to M, andAA5 represents covalent connection to D1”each Q is independently H, substituted or unsubstituted C1-C10 alkyl,AAAA-1AAA AAA— x1— E1— Y— x2— E2— ID1is independently selected wherein representsAAAA>covalent connection to D3, and? represents covalent connection to Q1”Q1is H, substituted or unsubstituted C1-C10 alkyl,each A1is independently absent or alkylene”each A2is independently absent, alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof”each R2is independently -COOH, -P(O)(OH)2, -OSO2OH, -CfOjNHSChH, tetrazole, an ester, or a substituted version thereof”each R3is independently H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof”each R4is independently hydroxy, alkoxy, amino, amide, or a substituted version thereof” each R5is independently H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene- 1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof”Atty Dkt No.: ADTH-007WO each R7is independently hydroxy or halo°each X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-° each E1is independently absent, -(substituted or unsubstituted Ci-Cg alkyleneoxy)g-, - (substituted or unsubstituted Ci-Cg alkylene)g-, -(substituted or unsubstituted Ci-Ce alkyleneoxy ^(substituted or unsubstituted Ci-Cg alkylene)q-, -(substituted or unsubstituted Ci-Ce alkylene)gO-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)g(substituted or unsubstituted Ci-Cs alkylene)qO-, -(substituted or unsubstituted Ci-Cs alkylene)gO(substituted or unsubstituted Ci-Cg alkylene)q-, benzyl, -(substituted or unsubstituted Ci-Cg alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted Ci-Cg alkyleneoxy )gbenzyloxy, cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C=C-, -CH2C=C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methlyene)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)n-, -(substituted or unsubstituted Ci-Cg alkylene),,-, wherein n is an integer ranging from 1 to 10°each X2is independently absent, 0, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m-, - (substituted or unsubstituted Ci-Cg alkylene)m-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)™-, -(substituted or unsubstituted Ci-Ce alkylene)mO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-Cg alkylene)™-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted Ci-Ce alkylene)mNHC(O)-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)NH-, - (substituted or unsubstituted Ci-Cg alkylene)mC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(0)-, -(substituted or unsubstituted Ci-Cg alkylene)mC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)O-, -Atty Dkt No.: ADTH-007WO(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wOC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cs alkyleneoxy)mtriazole-, -(substituted or unsubstituted Ci-Cs alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wtriazole-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-triazole-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-Cg alkylene)w-triazole, -(substituted or unsubstituted Ci-Cg alkylene)m-triazole, -(substituted or unsubstituted Ci-Ce alkylene)mOtriazole-, triazole, -(methylene)triazole-, - (methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each E2is independently absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h-, - (substituted or unsubstituted Ci-Cg alkylene)h-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xO-, -(substituted or unsubstituted Ci-Cg alkylene)hO(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-C6alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -Atty Dkt No.: ADTH-007WO(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(0)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)(substituted or unsubstituted Ci-C alkylene)x-, -(substituted or unsubstituted Ci-C alkyleneoxy)hC(O)O-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)hC(0)0(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hOC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O-, -(substituted or unsubstituted Ci-C alkylene)hOC(O)NH-, -(substituted or unsubstituted Ci-C alkyleneoxy)h(substituted or unsubstituted Ci-C alkylene)xOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH(substituted or unsubstituted Ci-Cg a I kylene)x-, - (substituted or unsubstituted Ci-C alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xOC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-C alkyleneoxy)hNHC(0)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-C alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-C alkylene)x-, (substituted or unsubstituted Ci-Cg alkylene)C(O)N(substituted or unsubstituted Ci-Cg al kylenejz-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36wherein the molecular mass of the compound of Formula (I) or (la) is at least 3,000 Da or a pharmaceutically acceptable salt thereof.Atty Dkt No.: ADTH-007WO2. The compound of clause 1, wherein Z is pentafluorophenyl ester, para-nitro phenyl ester, or maleimide.3. The compound of a preceding clause, wherein R2is -COOH, R3is H, R4is hydroxy, R5is -NHC(O)R5awherein R5ais substituted or unsubstituted Ci-Ce alkyl, and R7is hydroxy.4. The compound of a preceding clause, wherein Q and Q1are each independently selected5. The compound of a preceding clause, wherein the molecular mass of the compound of Formula (I) or (la) is from 3,000 Da to 50,000 Da.6. The compound of a preceding clause, wherein the molecular mass of the compound of Formula (I) or (la) is from 5,000 Da to 45,000 Da, from 5,000 Da to 30,000 Da, from 5,000 Da to 15,000 Da, from 5,000 Da to 10,000 Da, 10,000 Da to 45,000 Da, from 10,000 Da to 30,000 Da, from 10,000 Da to 15,000 Da, from 7,500 Da to 12,500 Da, and from 12,500 Da to 25,000 Da.7. The compound of a preceding clause, whereinwhen E1is substituted or unsubstituted Ci-Ce alkyleneoxy, g is 24 or less°when X2is substituted or unsubstituted Ci-Cg alkyleneoxy, m is 24 or less’ andwhen E2is substituted or unsubstituted Ci-Cg alkyleneoxy, h is 24 or less.8. The compound of a preceding clause, whereineach X1is independently absent, O, S, triazole, -CH(OH)-, -CH?-, -CHF-, -NH-, or -CF?-° each E1is independently absent, -(CH? CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(OCH2CH2)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH?)q(OCH? CH2)gO-, - (CH2CH2O)g(CH2)qO(CH2)q-, -(OCH2CH2)g(CH2)qO(CH2)q-, -(CH2)q(OCH2CH2)gO(CH2)q-, - (CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, - (CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36°each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C C-, -CH2CEC-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -Atty Dkt No.: ADTH-007WO(alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(rriethylene)-, -(CH2CH2O)n-, -(CH2)n-, wherein n is an integer ranging from 1 to 10°each X2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)m-, -(CH2)m-, - (CH2CH2O)m(CH2)w-, -(OCH2CH2)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, - (OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)m(CH2)wO(CH2)w-, - (OCH2CH2)m(CH2)wO(CH2)w-, -(CH2)w(OCH2CH2)mO(CH2)w-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, - (OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, - (CH2)w(OCH2CH2)mNHC(O)-, -(CH2)mNHC(O)(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)(CH2)w-, -(CH2CH2O)mC(O)NH-, - (OCH2CH2)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, - (OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)NH(CH2)w-, - (OCH2CH2)mC(O)NH(CH2)w-, -(CH2)mC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wC(O)NH(CH2)w-, - (OCH2CH2)m(CH2)wC(O)NH(CH2)w-, -(CH2)w(OCH2CH2)mC(O)NH(CH2)w-, -(CH2CH2O)mC(O)-, - (CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, - (CH2CH2O)mC(O)O-, -(CH2)mC(O)(CH2)w-, -(CH2CH2O)m(CH2)wC(O)(CH2)w-, - (OCH2CH2)m(CH2)wC(O)(CH2)w-, -(CH2)w(OCH2CH2)mC(O)(CH2)w-, -(CH2CH2O)mC(O)O(CH2)w-, - (CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, - (CH2)w(OCH2CH2)mC(O)O-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, - (OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(OCH2CH2)mNHC(O)O-, - (CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, - (CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mNHC(O)O(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)O(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)O(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)O(CH2)w-, - (OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, - (OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wOC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wOC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mOC(O)NH(CH2)w-, -(OCH2CH2)mNHC(O)NH-, -(CH2)mNHC(O)NH-, - (CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, - (CH2)w(OCH2CH2)mNHC(O)NH-, -(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2)mNHC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wNHC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, - (OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, -(CH2CH2O)m(CH2)wO-triazole-, -Atty Dkt No.: ADTH-007WO(CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each E2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(OCH2CH2)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, - (CH2)x(OCH2CH2)hO-, -(CH2CH2O)h(CH2)xO(CH2)x-, -(OCH2CH2)h(CH2)xO(CH2)x-, - (CH2)x(OCH2CH2)hO(CH2)x-, -(CH2)hO(CH2)x-, -(CH2)hNHC(O)-, -(OCH2CH2)hNHC(O)-, - (CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, - (CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, - (CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(OCH2CH2)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, - (CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, - (CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, - (CH2)x(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)hC(O)-, (CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, - (OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2CH2O)hC(O)O-, -(CH2)hC(O)(CH2)x-, - (CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, - (CH2CH2O)hC(O)O(CH2)x-,-(CH2)hC(O)O-, -(CH2CH2O)h(CH2)xC(O)O-, -(OCH2CH2)h(CH2)xC(O)O-, -(CH2)x(OCH2CH2)hC(O)O-, -(CH2)hOC(O)-, -(CH2CH2O)h(CH2)xOC(O)-, -(OCH2CH2)h(CH2)xOC(O)-, -(CH2)x(OCH2CH2)hOC(O)-, -(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O-, - (CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, - (CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH-, - (CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-, - (CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, - (CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2)x(OCH2CH2)hNHC(O)NH-, - (OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or - (alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° or a pharmaceutically acceptable salt thereof.Atty Dkt No.: ADTH-007WO9. The compound of clause 8, whereinwhen E1is CH2CH2O, g is 24 or less°when X2is CH2CH2O, m is 24 or less° andwhen E2is CH2CH2O, h is 24 or less.10. A compound having a structure of Formula (II) or (Ila):BAS is a biologically active substance”’ wherein ^represents covalent connection to E2, andrepresents covalent connection to BAS°D is, wherein? represents covalent connection to M, and < represents covalent connection to Z°b is an integer from 1 to 5°j is an integer from 0 to 15°k is an integer from 1 to 5°when j is 0, each of the members of D1are not absent”when j is 0, and k is 1, each of the members of D1are not absent and at least two of the members of D are not absent’M is a lysine residue, or a portion thereof”—X1—E1—Y—X2—E2—each D2is independently selected5wherein ^ represents, **covalent connection to Q, and 2 represents covalent connection to M,AAX1-E1-Y-X2-EAAeach D3is ’ wherein < represents covalent connection to M, andAA* represents covalent connection to D1’Atty Dkt No.: ADTH-007WOeach Q is independently H, substituted or unsubstituted C1-C10 alkyl,?D1is independently selectedwherein representscovalent connection to D3, and? represents covalent connection to Q1”Q1is H, substituted or unsubstituted C1-C10 alkyl,each A1is independently absent or alkylene”each A2is independently absent, alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof”each R2is independently -COOH, -P(O)(OH)2, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereof”each R3is independently H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof”each R4is independently hydroxy, alkoxy, amino, amide, or a substituted version thereof” each R5is independently H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene- 1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof”each R7is independently hydroxy or halo”each X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-” each E1is independently absent, -(substituted or unsubstituted Ci-Ce alkyleneoxy)g-, - (substituted or unsubstituted Ci-Ce alkylene)g-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)g(substituted or unsubstituted Ci-Cg alkylene)q-, -(substituted or unsubstituted Ci-Ce alkylene)gO-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)g(substituted or unsubstituted Ci-Cg alkylene)qO-, -(substituted or unsubstituted Ci-Cg alkylene)gO(substituted or unsubstituted Ci-Cg alkylene)q-, benzyl, -(substituted or unsubstituted Ci-Cg alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted Ci-Ce alkyleneoxy )gbenzyloxy, cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C C-, -CH2CEC-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, -Atty Dkt No.: ADTH-007WO(alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(rriethlyene)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)n-, -(substituted or unsubstituted Ci-Cg alkylene)n-, wherein n is an integer ranging from 1 to 10°each X2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m-, - (substituted or unsubstituted Ci-Cg alkylene)m-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)w-, -(substituted or unsubstituted Ci-Ce alkylene)mO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)wO-, -(substituted or unsubstituted Ci-C alkylene)mO(substituted or unsubstituted Ci-C alkylene)w-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)-, - (substituted or unsubstituted Ci-C alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)wNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)NH-, - (substituted or unsubstituted Ci-Cg alkylene)mC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(0)-, -(substituted or unsubstituted Ci-Cg alkylene)mC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)O-, - (substituted or unsubstituted Ci-C alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)wNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mtriazole-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wtriazole-, -(substituted or unsubstituted Ci-C alkyleneoxy)m(substituted or unsubstituted Ci-C alkylene)wO-triazole-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-C alkylene)w-triazole, -(substituted or unsubstituted Ci-Cg alkylene)m-triazole, -(substituted or unsubstituted Ci-C alkylene)mOtriazole-, triazole, -(methylene)triazole-, -Atty Dkt No.: ADTH-007WO(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each E2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h-, - (substituted or unsubstituted Ci-Cg alkylene)h-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cs alkylene)hO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xO-, -(substituted or unsubstituted Ci-Cg alkylene)hO(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted C1-C5 alkylene)xNHC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH-, -(substituted or unsubstituted Ci-Cs alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)(substituted or unsubstituted Ci-Cg a I kylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)O-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)O(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hOC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O-, -Atty Dkt No.: ADTH-007WO(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)O(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted C1-C5 alkylene)xOC(O)NH(substituted or unsubstituted Ci-Cg a I kylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(0)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Cg alkylene)*-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, (substituted or unsubstituted C1-C5 alkylene)C(O)N(substituted or unsubstituted Ci-Cg alkylene^-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36wherein the molecular massis at least 3,000 Da.11. The compound of clause 10, wherein12. The compound of clause 10 or 11, wherein R2is -COOH, R3is H, R4is hydroxy, R5is - NHC(O)R5awherein R5ais substituted or unsubstituted Ci-Cg alkyl, and R7is hydroxy.Atty Dkt No.: ADTH-007WO13. The compound of any one of clauses 10-12, wherein Q and Q1are each independently selected from:14. The compound of any one of clauses 10-13, wherein the BAS is a protein (such as an enzyme or an antibody) or a nanoparticle.15. The compound of any one of clauses 10-14, wherein the molecular mass offrom 3,000 Da to 50,000 Da.16. The compound of any one of clauses 10-15, wherein the molecular mass ofis from 5,000 Da to 45,000 Da, from 5,000 Da to 30,000 Da, from 5,000 Da to 15,000 Da, from 5,000 Da to 10,000 Da, 10,000Da to 45,000 Da, from 10,000 Da to 30,000 Da, from 10,000 Da to 15,000 Da, from 7,500 Da to12,500 Da, and from 12,500 Da to 25,000 Da.17. The compound of any one of clauses 10-16, whereinwhen E1is substituted or unsubstituted Ci-Cg alkyleneoxy, g is 24 or less”when X2is substituted or unsubstituted Ci-Cg alkyleneoxy, m is 24 or less” andwhen E2is substituted or unsubstituted Ci-Cg alkyleneoxy, h is 24 or less.18. The compound of any one of clauses 10-17, whereineach X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-° each E1is independently absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(OCH2CH2)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, - (CH2CH2O)g(CH2)qO(CH2)q-, -(OCH2CH2)g(CH2)qO(CH2)q-, -(CH2)q(OCH2CH2)gO(CH2)q-, - (CH2)gO(CH2)q-, benzyl, -(CH₂CH₂O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, - (CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl, wherein g is an integer rangingAtty Dkt No.: ADTH-007WO from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36°each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C=C-, -CH2C=C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(CH2CH2O)n-, -(CH2)n-, wherein n is an integer ranging from 1 to 10°each X2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)m-, -(CH2)m-, - (CH2CH2O)m(CH2)w-, -(OCH2CH2)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, - (OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)m(CH2)wO(CH2)w-, - (OCH2CH2)m(CH2)wO(CH2)w-, -(CH2)w(OCH2CH2)mO(CH2)w-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, - (OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, - (CH2)w(OCH2CH2)mNHC(O)-, -(CH2)mNHC(O)(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)(CH2)w-, -(CH2CH2O)mC(O)NH-, - (OCH2CH2)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, - (OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)NH(CH2)w-, - (OCH2CH2)mC(O)NH(CH2)w-, -(CH2)mC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wC(O)NH(CH2)w-, - (OCH2CH2)m(CH2)wC(O)NH(CH2)w-, -(CH2)w(OCH2CH2)mC(O)NH(CH2)w-, -(CH2CH2O)mC(O)-, - (CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, - (CH2CH2O)mC(O)O-, -(CH2)mC(O)(CH2)w-, -(CH2CH2O)m(CH2)wC(O)(CH2)w-, - (OCH2CH2)m(CH2)wC(O)(CH2)w-, -(CH2)w(OCH2CH2)mC(O)(CH2)w-, -(CH2CH2O)mC(O)O(CH2)w-, - (CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, - (CH2)w(OCH2CH2)mC(O)O-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, - (OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(OCH2CH2)mNHC(O)O-, - (CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, - (CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mNHC(O)O(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)O(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)O(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)O(CH2)w-, - (OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, - (OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wOC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wOC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mOC(O)NH(CH2)w-, -(OCH2CH2)mNHC(O)NH-, -(CH2)mNHC(O)NH-, - (CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, -Atty Dkt No.: ADTH-007WO(CH2)w(OCH2CH2)mNHC(O)NH-, -(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2)mNHC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wNHC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mNHC(O)NH(CH2)w- / -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, - (OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, -(CH2CH2O)m(CH2)wO-triazole-, - (CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° each E2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(OCH2CH2)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, - (CH2)x(OCH2CH2)hO-, -(CH2CH2O)h(CH2)xO(CH2)x-, -(OCH2CH2)h(CH2)xO(CH2)x-, - (CH2)x(OCH2CH2)hO(CH2)x-, -(CH2)hO(CH2)x-, -(CH2)hNHC(O)-, -(OCH2CH2)hNHC(O)-, - (CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, - (CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, - (CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(OCH2CH2)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, - (CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, - (CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, - (CH2)x(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)hC(O)-, (CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, - (OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2CH2O)hC(O)O-, -(CH2)hC(O)(CH2)x-, - (CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, - (CH2CH2O)hC(O)O(CH2)x-,-(CH2)hC(O)O-, -(CH2CH2O)h(CH2)xC(O)O-, -(OCH2CH2)h(CH2)xC(O)O-, -(CH2)x(OCH2CH2)hC(O)O-, -(CH2)hOC(O)-, -(CH2CH2O)h(CH2)xOC(O)-, -(OCH2CH2)h(CH2)xOC(O)-, -(CH2)x(OCH2CH2)hOC(O)-, -(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O-, - (CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, - (CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH-, - (CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-, - (CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, - (CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2)x(OCH2CH2)hNHC(O)NH-, - (OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or -Atty Dkt No.: ADTH-007WO(alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36° or a pharmaceutically acceptable salt thereof.19. The compound of clause 18, whereinwhen E1is CH2CH2O, g is 24 or less”when X2is CH2CH2O, m is 24 or less° andwhen E2is CH2CH2O, h is 24 or less.20. A pharmaceutical composition comprising a compound of any one of clauses 10-19 and a pharmaceutically acceptable carrier.21. A method of treating a subject in need thereof for a disorder / disease, the method comprising administering to the subject the compound of any one of clauses 10-19, or the pharmaceutical composition of clause 20.22. The method of clause 21, wherein the disorder / disease is selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, phenylketonuria, juvenile idiopathic arthritis, leukemia, colorectal cancer, a non-small cell lung cancer, a head and neck cancer, multiple sclerosis, or Type 2 Diabetes, gout, immune thrombocytopenia, organ transplantation (e.g., kidney), NMOSD / neuromyelitis optica, anti-phospholipid syndrome, membrane nephritis, myasthenia gravis, and pemphigus vulgaris.EXAMPLES

[0158] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for.General Synthetic Procedures

[0159] Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g., Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, FifthAtty Dkt No.: ADTH-007WOEdition, Wiley-lnterscience, 2001° or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).

[0160] During any of the processes for preparation of the subject compounds, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as J. F. W. McOmie, " Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, " Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in " The Peptides"” Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in " Methoden der organischen Chemie", Houben-Weyl, 4th edition, Vol. 15 / 1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, " Aminosauren, Peptide, Proteine", Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and / or in Jochen Lehmann, " Chemie der Kohlenhydrate: Monosaccharide and Derivate", Georg Thieme Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

[0161] The subject compounds can be synthesized via a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared by conventional synthetic methods. A variety of examples of synthetic routes that can be used to synthesize the compounds disclosed herein are described in the schemes below.

[0162] All synthetic chemistry was performed in standard laboratory glassware, under inert atmosphere and anhydrous conditions unless indicated otherwise in the examples. Commercial reagents were used as received.

[0163] Analytical LC / MS was performed either on a Shimadzu LCMS-2020 equipped with a Phenomenex Jupiter® 3 pm C18300 A, LC Column 50 x 2 mm, using LabSolutions software. Retention times were determined from the extracted 214 and / or 254 nm UV chromatogram or an Agilent 1290 Infinity RRLC attached with Agilent 6120 Mass detector and Diode array Detector and equipped with a YMC Triart C18 (150 x 4.6mm), 5 pm column. Unless specified, the LC / MS analytical method on the Shimadzu used a gradient 5-100% acetonitrile in water (+0.1% TFA) over 4.25 mins. LC / MS analytical method on the Agilent 6120 used a gradient 10-100% acetonitrile in water (+0.05% TFA) over 11 mins. HPLC was performed on an Agilent 1260 infinity series HPLC with PDA detector equipped with a YMCTriart C18 (150 x 4.6mm), 5 pm column. Analytical method on the Agilent 1260 used a gradient 10-95% acetonitrile in waterAtty Dkt No.: ADTH-007WO(+0.1% TFA) over 10 mins. Prep HPLC was performed either on a Teledyne ISCO ACCQPrep™ HP150 system (with 200-400 nm - UV PDA and ELSD detector) equipped with a Phenomenex Gemini® 10 pm NX-C18110 A, LC column 250 x 50 mm, AXIA, a Gilson system using a 215 liquid handler, 333 and 334 pumps, UV / VIS-155 detector equipped with the same type of column and Trilution Ic software, or a Shimadzu LC 20 AP with SPD 20 A UV Detector equipped with a Waters™ Sunfire C18 (250 x 30mm), 5 pm column. Unless specified, prep HPLC purification used a gradient acetonitrile in water (+0.1% TFA).1H NMR was performed either on a Bruker 400 MHz Advance, a Bruker 500 MHz or a Bruker Fourier 300 MHz using Topspin software. Analytical thin layer chromatography was performed on silica (Sigma Aldrich TLC Silica gel 60 F254 aluminum or glass TLC plate, silica gel coated with fluorescent indicator F254) and was visualized under UV light then stained with either potassium permanganate or phosphomolybdic acid stain solutions. Silica gel chromatography was performed with Teledyne ISCO CombiFlash Rf+ automated chromatography for gradient elution. Removal of aqueous and high boiling point solvents was usually performed by lyophilization using a Labconco Freezone® 4.5 Plus -84 °C connected to a Labconco Rotary Vane Vacuum Pump, 195 LPM.Example 1: Concept for class of Siglec-2 (CD22) engaging biotherapeutics bearing Siglec-2 Ligand Extended Structures that are suppressed for Anti-Drug Antibody responses

[0164] The B cell and its clonotypic B cell receptor sit at the heart of antibody-based immune responses to foreign agents. Anti-drug antibodies are a ubiquitous challenge to drug exposure for many biotherapeutic drug classes, including monoclonal antibodies, bispecific and multispecific antibodies, enzyme replacement therapy drugs, recombinant microbial enzymes, protein-Fc fusion proteins, intracellular delivery constructs, and gene therapy vectors.

[0165] A novel class of biomolecules and biotherapeutics similar to those using the previously described SigLE Conjugates, with suppressed or ablated humoral immunogenicity has been designed, based on the principles that B cell clones with the potential to differentiate into antidrug antibody-secreting plasma cells can be inhibited through Siglec inhibitory receptor recruitment to clonotypic anti-drug B cell receptors. The Siglecs are a class of sialic acidbinding lectin proteins, expressed on most or all types of hematopoietic cells.

[0166] In the current invention, further development of SigL-bearing biotherapeutics is described with extended SigL (SigLE) structures that can more efficiently co-engage the B cell receptor and Siglec-2 owing to their greater reach (longer size, greater flexibility) for Siglec-2 receptors when bound to the BCR. In some cases, SigLEs also carry more than one Siglec ligandAtty Dkt No.: ADTH-007WO moiety per structure, enabling an even greater stoichiometry of Siglec-2 recruitment to B cell receptor complexes, and a consequently potentiated inhibition of anti-drug B cell activation.

[0167] FIG.1 depicts one aspect of the model for Siglec-2-engaging biotherapeutics with suppressed anti-drug antibody responses. For non-SigL-bearing biotherapeutics, drug-specific B cells are activated by standard drugs, leading to anti-drug antibodies. In contrast, B cell receptor — SigLE co-engagers (including Drug-SigLE Conjugates) suppress or silence drugspecific B cell activation by virtue of the physical recruitment of the inhibitory Siglec-2 receptor to the B cell receptor complex. Such suppression of anti-drug B cell clones results in a consequent suppression of anti-drug antibodies (ADA).

[0168] FIG.2 depicts a model for differences in drug-specific B cell suppression with SigLE Conjugates versus "conventional" short linker SigL molecule conjugates. SigLE Conjugates can enable B cell suppression across all possible anti-drug B cell clones with a smaller number of protein linkage sites (e.g., lysine or cysteine) than would be required with a shorter, "conventional" SigL. FIG.2A illustrates a test case where a given antigen / therapeutic is conjugated with shorter, "conventional" SigLs. Four different conjugates, each bearing one SigL group, are shown. Each single-SigL conjugate is able to effect suppression of a given "epitope region" distal enough from the Siglec-2 interaction site to allow for Siglec-2 recruitment to the drug-BCR complex with any B cell receptors engaging within the defined epitope region. In this theoretical example, each SigL-restricted epitope region is a subset of the full potential epitope space of the test antigen. In total, the 4 defined SigL sites allow for full epitope coverage of the test antigen / therapeutic. Thus, for a given single-SigL conjugate at a given site, B cell clone suppression and consequent ADA suppression are achieved only for B cells targeting that SigL's given epitope region. In this test case, to effect ADA suppression across all possible epitopes requires a test antigen / therapeutic bearing 4 SigLs at the 4 nonoverlapping attachment sites. FIG.2B illustrates a related test case where the same given antigen / therapeutic is conjugated with SigLE instead of shorter, "conventional" SigLs. Because of its greater length and flexibility relative to a "conventional" SigL, a SigLE can recruit Siglec-2 to the BCR signaling complex for a larger set of clonotypic BCRs that bind to a larger set of antigen / therapeutic epitope regions. As a result of each SigLE's larger coverable epitope region (relative to a "conventional" SigL), fewer conjugation sites on the test antigen / therapeutic are required to effect full ADA suppression for all possible B cell epitopes. Thus, a SigLE for the test article / therapeutic can be engineered with full ADA suppression butAtty Dkt No.: ADTH-007WO with fewer modification / conjugation sites than would be needed with a non-polymer SigL (FIG.2B versus FIG. 2A). Accordingly, in this test case, to effect ADA suppression across all possible epitopes, it is sufficient to conjugate only 2 SigLEs, rather than 4 SigLs, to the antigen / therapeutic. SigLE Conjugates may therefore enable drug ADA suppression with a lower number of conjugation sites or potentially with a deeper ADA suppression effect. The examples below demonstrate the use of such SigLEs to effectively suppress anti-drug antibodies with fewer conjugation sites.Example 2: Synthesis of compound 14 (CMP014)Atty Dkt No.: ADTH-007WOAmide coupling reactions using HATU

[0169] To a solution of carboxylic acid N-Boc-6-azido-L-norleucine (169 mg, 620 umol) and amine Azido-PEG12-amine (400 mg, 651 umol) in DMF (3.10 mL) was added HATU (283 mg,Atty Dkt No.: ADTH-007WO744 umol) followed by N, N-Diisopropylethylamine (324 uL, 1.86 mmol) dropwise at room temperature. The reaction was stirred for 1 hour to 12 h until full conversion was observed by LCMS. The reaction mixture was then quenched with aqueous saturated NaHCCb (5 mL) resulting in the precipitation of a white salt. The mixture was filtered, concentrated then purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (1) in 76% yield (429 mg).

[0170] Using the same procedure, the reaction of 2 (789 mg, 1.03 mmol), Boc-amino-PEG12-carboxylic acid (810 mg, 1.13 mmol), HATU (468 mg, 1.23 mmol), and DIEA (536 uL, 3.08 mmol) in DMF-DCM (8 mL° 1:3) afforded (3) in 81% (1.21 g).

[0171] The reaction of 4 (1.04 g, 761 umol), N-Boc-6-azido-L-norleucine (249 mg, 913 umol), HATU (463 mg, 1.22 mmol) and DIEA (596 uL, 3.42 mmol) in DMF (2 mL) afforded (5) in 65% (798 mg).

[0172] The reaction of 8 (252 mg, 119 umol), N-Boc-6-azido-L-norleucine (38.8 mg, 143 umol), HATU (72.3 mg, 190 umol) and DIEA (93.2 uL, 535 umol) in DMF (2.4 mL) afforded (9) in 90% (254 mg).

[0173] The reaction of 10 (172 mg, 59.7 umol), Boc-amino-PEG12-carboxylic acid (19.5 mg, 71.7 umol), HATU (36.3 mg, 95.6 umol) and DIEA (46.8 uL, 269 umol) in DMF (1.2 mL) afforded (11) in 94% (176 mg).

[0174] The reaction of 12 (29.3 mg, 10.2 umol), N-Boc-6-azido-L-norleucine (3.33 mg, 12.2 umol), HATU (6.20 mg, 16.3 umol) and DIEA (7.98 uL, 45.8 umol) in DMF (204 uL) afforded (13) in 81% (25.8 mg).Amide coupling reactions using NHS esters

[0175] To a solution of ammonium (6) (241 mg, 159 umol) and Boc-Amino-PEG12-NHS ester (149 mg, 182 umol) in anhydrous DCM (3.17 mL) was added DIEA (55.2 uL, 317 umol) dropwise at room temperature and the reaction was overnight. The solvent was concentrated, and the crude residue obtained was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford a mixture of the desired product (7) in 95% yield (335 mg).Boc deprotection

[0176] To a solution of (1) (429 mg, 494 umol) in DCM (10 mL) was added Trifluoroacetic acid (1.13 mL, 14.8 mmol) dropwise at 0 °C. The cooling bath was removed, and the reactionAtty Dkt No.: ADTH-007WO mixture was stirred for 3 to 6 h at room temperature then concentrated. The crude residue obtained was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (2) in 87% yield (380 mg) as a TFA salt.

[0177] Using the same procedure, deprotection of 3 (60.7 mg, 41.3 umol) using TFA (63.3 uL,827 umol) in DCM (0.85 mL) afforded 4 in 90% yield (50.9 mg).

[0178] Deprotection of 5 (51.2 mg, 31.5 umol) using TFA (72.4 uL, 946 umol)in DCM (0.65 mL) afforded 6 in 80% yield (38.4 mg).

[0179] Deprotection of 7 (64.0 mg, 28.8 umol) using TFA (66.1 uL, 864 umol) in DCM (0.60 mL) afforded 8 in 87% yield (53 mg).

[0180] Deprotection of 9 (64.0 mg, 28.8 umol) using TFA (48.4 uL, 632 umol) in DCM (0.45 mL) afforded 10 in 70% yield (33.6 mg).

[0181] Deprotection of 11 (31.6 mg, 11.7 umol) using TFA (26.8 uL, 351 umol) in DCM (0.25 mL) afforded 12 in 87% yield (29.3 mg).

[0182] Deprotection of 13 (176 mg, 56.2 umol) using TFA (194 uL, 2.53 mmol) in DCM (2.8 mL) afforded 14 in 88% yield (149 mg).Example 3: Synthesis of compound 16 (CMP016)Atty Dkt No.: ADTH-007WO

[0183] Tetra kis(acetonitrile)copper( I ) hexafluorophosphate (41.1 mg, 110 umol) was added to a solution of (6) (37.3 mg, 24.5 umol) and alkyne (15) (50.5 mg, 78.4 umol) in NMP (1.22 mL) at room temperature. The reaction mixture was stirred for 45 min at room temperature then diluted with acetic acid (0.25 mL). The catalyst was filtered off and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (16) in 57% yield (48.0 mg).Example 4: Synthesis of compound 17 (CMP017)DIEA, DMF, rt

[0184] To a solution of amine (16) Maleimide-PEG24-NHSester (19.1 mg, 13.7 umol) and Maleimide-PEG24-NHSester (19.1 mg, 13.7 umol) in anhydrous DMF (700 uL) was added DIEA (11.9 uL, 68.6 umol) at room temperature. After 5 h at room temperature, the mixture was filtered, and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (17) in 50% yield (32.4 mg).Atty Dkt No.: ADTH-007WOExample 5: Synthesis of compound 18 (CMP018)

[0185] Tetrakis(acetonitrile)copper(l) hexafluorophosphate (51.6 mg, 138 urriol) was added at room temperature to a mixture of penta azide (14) (46.6 mg, 15.4 umol) and alkyne (15) (51.1 mg, 79.2 umol) in NMP (0.8 mL). The reaction mixture was stirred for 45 min at room temperature then diluted with acetic acid (0.25 mL). The catalyst was filtered off and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (18) in 38% yield (37 mg).Atty Dkt No.: ADTH-007WOExample 6: Synthesis of compound 19 (CMP019)DIEA, DMF, rt

[0186] To a solution of amine (18) (37.0 mg, 5.92 umol) and Maleimide-PEG24-NHS (8.24 mg, 5.92 umol) in anhydrous DMF (296 uL) was added DIEA (5.15 uL, 29.6 umol) at room temperature. After 5 h at room temperature, the mixture was filtered, and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TEA) as eluents to afford the desired product (19) in 60% yield (26.6 mg).Atty Dkt No.: ADTH-007WOExample 7: Synthesis of compound 21 (CMP021)Tetrakis(acetonitrile)copper(l)hexafluorophosphateNMP, rt

[0187] Tetrakis(acetonitrile)copper(l) hexafluorophosphate (55.5 mg, 149 urriol) was added at room temperature to a mixture of alkyne (20) (60.0 mg, 103 umol) and triple azide (6) (50.4 mg, 33.1 umol) in NMP (1.65 mL). The reaction mixture was stirred for 45 min at room temperature then diluted with acetic acid (0.25 mL). The catalyst was filtered off and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (21) in 68% yield (74.1 mg).Atty Dkt No.: ADTH-007WOExample 8: Synthesis of compound 22 (CMP022)DIEA, DMF, rt

[0188] To a solution of amine (21) (52.4 mg, 16.0 umol) and N, N-Diisopropylethylamine (13.9 uL, 80.0 umol) in anhydrous DMF (800 uL) was added Maleimide-PEG24-NHS (24.5 mg, 17.6 umol) at room temperature. The reaction was stirred for 4 h at room temperature, filtered then purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (22) in 71% yield (51.7 mg).Example 9: Synthesis of compound 23 (CMP023)

[0189] Synthesized as described in PCT application no. WO2022150726A1.Atty Dkt No.: ADTH-007WOExample 10: Synthesis of compound 24 (CMP024)DIEA, DMF, rt

[0190] To a solution of amine (18) (30.6 mg, 4.89 umol) and Maleimide-PEG24-triazole-PEG24-NHS (14.3 mg, 5.63 umol) in anhydrous DMF (245 uL) was added DIEA (8.52 uL, 48.9 umol) at room temperature. After 16 h at room temperature, the mixture was filtered, and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TEA) as eluents to afford the desired product (24) in 41% yield (17.5 mg).Atty Dkt No.: ADTH-007WOExample 11: Synthesis of compound 25 (CMP025)

[0191] To a solution of amine (18) (37.0 mg, 5.92 umol) and Maleimide-PEGn-NHS(MW=3400) (20.3 mg, 5.92 umol) in anhydrous DMF (296 uL) was added DIEA (10.3 uL, 59.2 umol) at room temperature. After 16 h at room temperature, the mixture was filtered, and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product in 40% yield (22.6 mg).Atty Dkt No.: ADTH-007WOExample 12: Synthesis of compound 26 (CMP026)

[0192] Tetrakis(acetonitrile)copper(l) hexafluorophosphate (51.6 mg, 138 umol) was added at room temperature to a mixture of penta azide (14) (46.6 mg, 15.4 umol) and alkyne (15) (51.1 mg, 79.2 umol) in NMP (0.8 mL). The reaction mixture was stirred for 45 min at room temperature then diluted with acetic acid (0.25 mL). The catalyst was filtered off and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product (18) in 38% yield (37 mg).Atty Dkt No.: ADTH-007WOExample 13: Synthesis of compound 27 (CMP027)(n - 70).

[0193] To a solution of amine (26) (60.8 mg, 10.2 umol) and Maleimide-PEGn-NHS(MW=3400) (35.6 mg, 10.4 umol) in anhydrous DMF (510 uL) was added DIEA (17.8 uL, 102 umol) at room temperature. After 16 h at room temperature, the mixture was filtered, and the filtrate was purified by C18 reverse-phase column chromatography using water and acetonitrile (+0.1% TFA) as eluents to afford the desired product in 40% yield (38.0 mg).Atty Dkt No.: ADTH-007WOExample 14: Synthesis of Linear Compounds

[0194] Below is a scheme describing the synthesis of compounds of the invention.Atty Dkt No.: ADTH-007WOAtty Dkt No.: ADTH-007WOExample 15: Production of Antibody (anti-human IgM and Adalimumab) conjugates

[0195] The purpose of this example is to demonstrate the expression, purification, and conjugation of various antibodies with various Siglec Ligand Extended structures (SigLEs) and Siglec Ligands (SigLs) that are used in these examples.Materials and Methods

[0196] For antibody expression (anti-human IgM and Adalimumab), the ExpiFectamine 293 Transfection kit (Life Technologies, A14524) was used to transfect suspension Expi293F cells (Life Technologies, A14527) with Heavy Chain and Light Chain plasmids (pTT5 vector) at a 1:1 ratio. Media was harvested 3-6 days post-transfection by centrifugation and filtered using 0.2 pm PES vacuum sterile single-use filter unit (ThermoScientific, Cat. No. 5670020).

[0197] Purification was performed with 1.5 mL MabSelect Sure resin (Cytiva / GE Cat #: 17-5438-03) for each 250 mL culture supernatant. Briefly, each column was equilibrated with PBS pH 7.2 and loaded with culture supernatant. After the loading step, the column was washed with PBS pH 7.2 and eluted with 10 mL IgG Elution buffer (Thermo Scientific, Cat. No. 21004). The pH of the elution pool was adjusted with 1 mL 1 M Sodium Phosphate pH 6.5 for each 10 mL elution pool. Finally, buffer exchange was performed with PBS pH 7.2 using a 30 kDa Amicon Ultra-15 Centrifugal Filter Unit.Atty Dkt No.: ADTH-007WO

[0198] Analysis of endotoxin content was performed using the Charles River Endosafe PTS 0.01-1 EU / ml detection. Size exclusion chromatography was performed on an Agilent Chemstation HPLC-SEC with a Sepax-Zenix SEC-300, 200mm x 7.8mm ID, 3uM column. Capillary gel electrophoresis (cGE) was performed on a Caliper LabChip GXII Protein 200 with the Perkin Elmer Chip (Cat. No. 760499). LC-MS analysis was performed on Agilent 6545XT (G6549A), HPLC: Agilent AdvanceBio Desalting-RP, Column, 2.1mm X 12mm (PL612-1102).Protein-SigL & Protein-SigLE conjugation to site-specific cysteines

[0199] Several mutation sites were employed in the antibodies to incorporate new cysteine sites: in the light chain, K183C, and in the heavy chain, A140C, K290C, or L443C. The cysteine-engineered protein was diluted in a solution containing 1 mM diethylenetriaminepentaacetic acid (DTPA) and 100 mM HEPES at pH 7.0. To this mixture, tris(2-carboxyethyl)phosphine) (TCEP) was added in a 20-fold molar excess above protein. The resulting mixture was incubated at 37 °C for 5 h. After incubation, excess TCEP was removed by repeat centrifugation and buffer exchange with PBS at pH 7.2.

[0200] The reduced protein was then re-oxidized in a solution containing PBS, pH 7.2, 1 mM DTPA, and 2 mM dehydroascorbic acid (DHA), and incubated at 4 °C for 16 h. Maleimide-conjugatable Siglec Ligands or Siglec Ligand Polymers in 10% v / v dimethylacetamide (DMA) were added to the reaction mixtures at a molar ratio of 10 - 60 times above protein, based on the desired degree of labeling. Reactions were incubated at 25 °C for 2 h. After the incubation period, 4-fold excess N-Ethylmaleimide (NEM) was added to quench any unreacted maleimide linkers. The neutralized reactions were incubated at 25 °C for an additional 15 min.

[0201] Quenched conjugation reactions are purified by preparative size exclusion chromatography at 4°C using either Superdex 200 Increase 10 / 300 GL or HiLoad 16 / 600 Superdex 200 pg at a flow rate of 1.0 mL / min, with PBS pH 7.2.Analysis of Protein-SigL Conjugates and Protein-SigLE Conjugates

[0202] The " LDR", or Ligand-to-Drug ratio, was measured for each conjugate preparation by LC / MS, by evaluating the relative abundances of species varying in the degree of conjugation, as described here. Such a series of molecular species can be represented as:Atty Dkt No.: ADTH-007WO

[0203] In this statement, each biotherapeutic, Y (adalimumab, in this case), is covalently bound to a SigL or SigLE as defined by XnL, where X is a sialic acid species of valency, n, with a SigL-to-biotherapeutic or SigLE-to-biotherapeutic ratio that varies between 1 and m. All species have the same Sialic Acid valency, n (monovalent, bivalent, or trivalent).

[0204] As a total measure of the degree of conjugation in such an ensemble of species with varying degrees of conjugation, the LDR can be defined as follows: LDR is a weighted average of the individual SigL-to-biotherapeutic or SigLE-to-biotherapeutic ratios (integer value m) in a mixture of species varying in said ratio, and Pi (0 < P;< 1, with X"=i Pi = 1) representing the fractional abundance of each species in the mixture:

[0205] Protein-SigL Conjugates and Protein-SigLE Conjugates were analyzed using the following parameters: LC-MS: Mass spectrometer: Agilent 6545XT (G6549A)° HPLC: Agilent AdvanceBio Desalting-RP, Column, 2.1mm X 12mm (PL612-1102)” 2.1 mm x 12.5 mm, flow rate 400 ul / min, Sample load: 5ug° Buffer A: Water + 0.1% Formic Acid° Buffer B: Acetonitrile + 0.1% Formic Acid. Analytical SEC: Superose 6 Increase 10 / 300 GL° Injection Volume: 25uL at 1 mg / mL of sample’ Buffer: PBS, pH 7.2° Flow rate: 0.75 mL / min. SDS-PAGE: 4-12% Bis-Tris 10-well gel in MES° Samples boiled 5 minutes at 90 °C in loading solution. Endotoxin Measurement: Charles River Endosafe PTS Cartridge 0.05-5 EU / ml, at 1:50 ml / ml dilution of the original sample concentration.Results and conclusions

[0206] The results in Table 1 below show a summary of conjugates that were described herein:Table 1: Summary of conjugates used in examplesAtty Dkt No.: ADTH-007WO

[0207] All conjugates were purified to homogeneity for oligomeric species, with the intended oligomeric structure (e.g., monomer, dimer, trimer) being purified by preparative size exclusion chromatography. All control protein preparations and conjugate preparations were >99% pure by analytical SEC.Example 16: Suppression of B cell receptor (BCR)-mediated activation of human primary B cells by anti-IgM antibody conjugates to SigLs and SigLEsPurpose:

[0208] A reductionist model system was used to study BCR - CD22 coclustering mechanisms and the molecular requirements for protein-SigL / SigLE conjugates achievement of effective B cell suppression. This example illustrates how BCR inactivation by anti-human-IgM-SigLE and anti-human-IgM-SigL conjugates is influenced by both the conjugation site and SigL / SigLE linker length. The anti-IgM B cell activation assay offers a controlled system in which the B cell receptor binds a spatially-defined "epitope"— specifically, the CDRs of the anti-IgM antibody. As the IgM BCR-anti-IgM contact site, the anti-IgM antibody paratope or CDRs act as a proxy for a given antigen epitope that interacts with a clonotypic B cell receptor. By precisely controlling the location of epitope engagement, the effects of systematic variation of SigL / SigLE conjugation site and linker length on inhibition of BCR activation can be studied. Notably, theAtty Dkt No.: ADTH-007WO optimal linker length for suppressing activation depends on the specific location of conjugate relative to the BCR binding site on the antigen.Materials and Methods:

[0209] Anti-IgM and Anti-IgM-SigL / SigLE conjugate test articles were prepared as described in Example 15. Human PBMCs (StemExpress) were plated at a concentration of 200,000 cells per well in round bottom 96 well plates in complete RPMI media. Cells were stimulated for 18 hours by the addition of increasing concentration of anti-human IgM or Siglec ligand-conjugated anti-human IgM. Human B-cell activation was assessed by flow cytometry. To measure B-cell activation following the described stimulation, cells were washed twice by spinning cells at 350xg for 5 minutes and rinsing with PBS. Cells were resuspended in staining buffer (1% bovine serum albumin / 0.1% sodium azide / phosphate buffered saline) and incubated with Fc-block (BD Biosciences) for five minutes before the addition of anti-CD19 and anti-CD69 antibodies (BD Biosciences, Biolegend, Fisher). Cells were incubated in the dark for an additional 30 minutes at room temperature, then washed three times with staining buffer and then analyzed on ZE5 (BioRad). Data analysis was performed using FlowJo (vl0.8.0) software.

[0210] Competition of SigLE-conjugated and SigL-conjugated anti-human IgM binding was carried out on human PBMCs from the same donors used in assays described above. For this assay, cells were seeded at a concentration of 200,000 cells per well in round bottom 96 well plates in complete RPMI media. Cells were subsequently incubated with human Fc-block (BD Biosciences) for five minutes. Following this incubation period, 2.4 nM anti-human-IgM-Alexa Fluor 647 was added to the cells along with RPMI alone or an increasing titration of non-fluorescently labeled SigL-conjugated anti-human IgM and anti-CD19-Bril lia nt Violet 421. Cells were incubated at 4°C for 30 minutes in the dark. After incubation, cells were washed twice by centrifugation with staining buffer (1% bovine serum albumin / 0.1% sodium azide / 1 x phosphate buffered saline) and antibody binding was analyzed by flow cytometry (ZE5, BioRad) by determination of the median fluorescence intensity (MFI) of at least 5,000 cells.Results and Conclusions

[0211] FIG. 11 shows the site-specific cysteine locations on the anti-IgM antibody that were used for SigLE and SigL conjugation. The light chain K183C and heavy chain site A140C are the closest sites to the CDRs that will bind and activate the BCR. The heavy chain sites, K290C, and L443C, are located further from the BCR binding at 10.2 and 13.2 nm, respectively. These sitesAtty Dkt No.: ADTH-007WO enable analysis of Siglec-2 receptor engagement and BCR activation inhibition relative to the BCR binding location on the antibody structure.

[0212] FIG. 12, panels A-D shows B-cell stimulatory activities of anti-IgM and anti-lgM-Siglec-2 Ligand Extended structure (SigLE) and Siglec-2 Ligand (SigL) conjugates in dose titration experiments with an activation readout of CD69 upregulation. CD69 levels on the different treatment groups are evaluated through the percentage of cells that are CD69-positive. FIG.12, panel A shows responses with SigLE or SigL conjugated to the light chain K183C position. Suppression of BCR activation was minimal for SigL with a PEG4 linker (CJ001), SigLE with a PEG48 linker (CJ002), and SigLE with a PEG72 linker (CJ003), even with increasing numbers of SigLs displayed on the antibody. Only when the SigLE linker length reached PEG96 (CJ004) and PEG118 (CJ005) was there any significant suppression of BCR activation, although only as high as 50% inhibition. FIG. 12, panel B shows a similar trend where inhibition of BCR activation is only achieved when SigLE linkers are PEG48 (CJ007) and PEG72 (CJ008) but only reached a maximum of 54% inhibition. Moreover, as the modification site moves further away from the BCR binding site, as in FIG. 12, panels C-D, inhibition increases for all groups, with PEG48 (CJ010, CJ013) and PEG72 (CJ011, CJ014) SigLE conjugates achieving complete inhibition in both positions. However, PEG4 SigL conjugate inhibition was weak at the K290C position (CJ009), whereas at the L443C position PEG4 SigL conjugate shows 95% inhibition of BCR activation. The trend is summarized in FIG. 13, where longer linkers are required when the SigL or SigLE is nearer to the site of BCR binding, but short linkers are sufficient when SigL / SigLE is far from the BCR binding site. Moreover, these differences in activity cannot be attributed to SigLs or SigLEs blocking binding of anti-IgM to BCR. FIG. 14, panels A-D clearly show that binding was maintained for all conjugates in comparison to unmodified anti-IgM.

[0213] This example demonstrates a direct correlation between linker length, the distance from the BCR binding site, and the extent of BCR activation inhibition for the BCR-CD22 clustering mechanism that is used by SigL / SigLE conjugates for suppression of B cell-driven immunogenicity. When the conjugate site is near to the epitope binding site of the BCR, a longer linker must be employed to co-engage with Siglec-2, but when the epitope binding site is further from the conjugation site, shorter linkers can be used to co-engage with Siglec-2. This example demonstrates the advantage of extended SigLE constructs in facilitating Siglec-2-BCR co-localization and consequent B cell suppression, particularly in cases where shorter SigLs alone are insufficient to span the inter-receptor distance.Atty Dkt No.: ADTH-007WOExample 17: Surface Plasmon Resonance binding analysis of SigL- and SigLE- conjugated Adalimumab to TNFa ligandPurpose:

[0214] This example demonstrates that Adalimumab retains its binding to human TNFa when conjugated with SigLEs and SigLs, regardless of linker length or the number of SigLEs / SigLs attached.Materials and Methods

[0215] Adalimumab conjugates were prepared as described with maleimide conjugation to engineered cysteine sites, L443C and K183C, in the heavy chain and light chain, respectively. A total of four conjugatable cysteine sites were present per antibody. Control adalimumab was cysteine capped at L443C and K183C with N-ethylmaleimide (NEM).

[0216] Binding experiments were performed on a Biacore 8K+ using a Cytiva Protein A Chip Series S (Cat# 29127555). Adalimumab and Adalimumab conjugates were diluted in running buffer (HBS-EP+) and scouted for a concentration yielding about 50 RU of response after 20 seconds of injection at 30 pL / min on the active surface (flow cell 2). For kinetic binding analysis experiments, Human TNFa (hTNFa) was serially diluted in running buffer from 500 nM to 15.625 nM and then injected across both the reference (flow cell 1) and active surface (flow cell 2) for 120 seconds at 30 pL / min, and allowed to dissociate for 600 sec. Regeneration of the surfaces was achieved with a 30 sec pulse of 10mM Glycine, pH 1.5 at 30 pL / min across both flow cells. Sensorgrams were fitted to a 1:1 binding model in Biacore Insight Evaluation Software Version 3.0.11.15423. Normalized responses were calculated by dividing the theoretical max response by the actual response of each concentration of hTNFa immediately after the association phase. The theoretical max response was calculated by dividing the molecular weight of the analyte (hTNFa) by the molecular weight of the ligand (Adalimumab / Adalimumab conjugates) and multiplying by the capture level.Results and Conclusions

[0217] FIG.15, panel A shows the normalized binding responses of Adalimumab and Adalimumab conjugates to hTNFa. Binding is equivalent with and without conjugation of PEG4-SigLl (CJ015) SigL or PEG48-SigL3 (CJ016) SigLE, demonstrating that conjugation of a multivalent polymer does not perturb hTNFa binding.Atty Dkt No.: ADTH-007WOExample 18: In vivo suppression of anti-drug antibody in mice treated with Siglec Ligand polymer Adalimumab conjugatesPurpose:

[0218] The purpose of this example was to demonstrate suppression of immunogenicity in mice dosed with Adalimumab-SigLE or Adalimumab-SigL Conjugates. Parental adalimumab hlgGl is highly immunogenic in mice, with a strong immunoglobulin response after a single dose. This and the subsequent example set out to corroborate the in vitro B cell suppressive effects shown in Example 10 with in vivo assessment of effects on immunogenicity for SigLE and SigL Conjugates with different proteins. Furthermore, these examples show that multivalent display of SigLEs can enhance ADA suppression and protein exposure, even when the number of conjugation sites is limited.Materials and Methods

[0219] To evaluate the production of anti-drug antibodies specific to adalimumab and / or adalimumab-SigL or -SigLE Conjugates, C57BL / 6 mice were immunized through subcutaneous injections with adalimumab or Siglec-2 ligand-conjugated adalimumab. On study day -1, animals were randomized into treatment groups based on body weight. On study day 0, animals were bled for baseline serum and then injected subcutaneously with adalimumab or the adalimumab-SigL or -SigLE Conjugates. The individual antigens were prepared by making antigen solution in sterile PBS pH 7.4. Animals were then injected with antigen subcutaneously weekly (days 0, 7, 14, 21) with 0.1 mL on each side of the rear flank near base of tail. The total dose based on a 25 g mouse would be 4 mg / kg. Submandibular blood collection was performed weekly (days 6, 13, 20, 27, 34, 41) throughout the study under inhaled isoflurane anesthesia. Whole blood was collected into Microvette EDTA capillary collection tubes (Sarstedt Inc) and then further processed following the manufacturer's instructions for serum collection. Samples were stored at -80 °C until analysis was performed.

[0220] ADA assays were performed on 96-well assay plates (Nunc Plates, Black 96-Well Immuno Plates, Thermo Scientific, Cat. No. 437111) coated with antigen, as follows. A mixture of adalimumab and adalimumab conjugates was generated containing an equal concentration of antigens, with final mixture concentration of 5 pg / mL, and plates were coated with 100 pL / well. All coated antigens were diluted in PBS pH 7.2 and incubated overnight at 4 °C. The following day, plate coating solution was removed, and plates were blocked with 200 pL / well of 3% BSA, 20 pM EDTA, 0.1% Tween-20 in PBS for 1 hour at room temperature. SerumAtty Dkt No.: ADTH-007WO samples were diluted 1:185 in 3% BSA, 20 pM EDTA, 0.1% Tween-20 in PBS and added in threefold serial dilutions. Plates were incubated 1 hour at room temperature, then washed with PBS buffer with 0.05% Tween-20. After washing, 100 pL of 1:2500 diluted Donkey Anti-Mouse lgG(H+L)-HRP (SouthernBiotech, Cat. No. 6411-05) was added and incubated for 1 hour at room temperature. After washing the assay plates, 100 pL of QuantaBlu Substrate Solution (Thermo Scientific, Cat. No. 15169) was added to each well and incubated for 15 minutes. The excitation and emission settings for the QuantaBlu Fluorogenic Peroxide Substrates are 325nm and 420nm and the relative florescence units were measured using a SpectraMax plate reader. Serum dilution curves were generated for days 20, 27, 34, and 41. The titer cut point was determined by calculating the mean of the naive, untreated mice and adding twice the standard deviation of the untreated samples.Results and Conclusions

[0221] FIG.15, panel B shows the ADA titer time course for mice on days 20-41. These mice received doses of antigen on days 0, 7, 14, and 21. Adalimumab shows high titers at all timepoints. The SigL conjugate, Adalimumab PEG4-SigLl (CJ015), with an LDR of 3.8, shows lower overall ADA titers at all timepoints, but titers increase throughout the time course. In contrast, Adalimumab SigLE PEG48-SigL3 (CJ016), LDR 14.4 (4 conjugation sites), demonstrates the lowest titers throughout the time course and titers plateau at day 35 and 41. These results for suppression of immunogenicity in mice correlate with the in vitro B cell activation results in Example 10° decoration of an immunogenic antibody with SigLEs is sufficient to strongly suppress immunogenicity. Moreover, the large, multivalent SigLE PEG48-SigL3 enhances ADA suppression by enabling a higher number of SigL molecules to be conjugated at a limited number of sites, and potentially by providing greater B cell epitope coverage on the adalimumab antibody.Example 19: Pharmacokinetic Analysis of Adalimumab and SigL / SigLE-Conjugated Adalimumab in C57BL / 6 MicePurpose:

[0222] The purpose of this example is to demonstrate improvements in exposure and pharmacokinetics of Adalimumab conjugated to either PEG4-SigLl (SigL) or PEG48-SigL3 (SigLE) Adalimumab conjugate relative to parental Adalimumab not bearing Siglec ligands.Atty Dkt No.: ADTH-007WOMaterials and Methods:

[0223] The molecule preparation is described Example 12. Pharmacokinetic monitoring was carried out in C57BL / 6 mice following weekly subcutaneous administration of adalimumab or conjugates. Animal dosing and sample collection was as described in Example 11 above. Levels of Adalimumab and SigLE- or SigL-conjugated Adalimumab in plasma samples were measured using an AlphaLISA human IgG assay (Perkin Elmer) following manufacturer's protocols.Results and Conclusions:

[0224] FIG. 15, panel C depicts analysis of serum pharmacokinetics for Adalimumab and Adalimumab-SigL / SigLE conjugates in mice. Clearly, the control Adalimumab displays significantly increased clearance, with all animals falling below the limit of quantitation (BLOQ) at study day 20, 6 days following the second boost. This is likely due to the high ADA titers observed with Adalimumab, as shown in Example 11. Adalimumab conjugated with a standard PEG4-SigLl (CJ015) SigL also shows increased clearance following the third boost. Interestingly, SigLE PEG48-SigL3-conjugated Adalimumab maintains exposure throughout the study, even following the final boost. This is likely due to the significantly lower ADA titers observed in this group. Overall, this demonstrates that conjugating a multivalent SigLE to just four sites can significantly increase exposure by effectively suppressing ADA responses.EXAMPLE 20: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 1).Atty Dkt No.: ADTH-007WOSynthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (3)

[0225] To a stirred solution (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l, 2-diyl diacetate (1) (3 g, 3.92 mmol), 2-(2-(prop-2-yn-l-yloxy)ethoxy)ethan-l-ol (2) (0.68 g, 4.7 mmol) and Silver (1+) trifluoro methane sulfonate (AgOTf) (2.51 g, 9.80 mmol) in anhydrous dichloromethane (36 m L) and anhydrous acetonitrile (54 mL) was added activated 4 A powdered molecular sieves (5 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The reaction mixture was cooled to -78 °C, iodine monobromide (1.22 g, 5.88 mmol) dissolved in dichloromethane (4 mL) was added dropwise, and the resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched by addition of triethylamine (1.3 mL) and allowed to stir at room temperature for 1 h. The reaction mixture was filtered, the filtrate was washed with aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (3) as off-white solid, Yield: 1.3 g, 43%.Synthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (4)

[0226] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (3) (1.3 g, 1.66 mmol) in methanol (16 mL) and water (4 mL) was added 25% sodium methoxide in methanol (2.27 mL, 9.96 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 6 h. After completion the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6, the suspensionAtty Dkt No.: ADTH-007WO was filtered and the filtrate was concentrated to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid (4) as off-white solid, Yield: 700 mg, 70%. LCMS (ESI±) m / z 603.5 [M+H]+.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy) tetrahydro-2H-pyran-2-carboxylic acid fCMPD ID 1)

[0227] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (4) (300 mg, 0.49 mmol) and perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (5) (224 mg, 0.49 mmol) in N-Methyl-2-Pyrrilidone (3 mL) was added Tetrakis (acetonitrile) copper (I) hexafluoro phosphate (278mg, 0.75 mmol) and the reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 1 as an off-white solid. Yield: 67 mg, 12.7%. LCMS (ESI+) m / z 1060.6 [M+H]+.XH NMR (400 MHz, MeOD) 68.06 (s, 1H), 7.31 (d, J = 1.9 Hz, 4H), 4.66 (s, 2H), 4.59 (t, J = 5.1 Hz, 2H), 4.03 (s, 2H), 3.89 (dt, J = 13.2, 5.5 Hz, 8H), 3.81 (d, J = 9.7 Hz, 1H), 3.73 (d, J = 9.5 Hz, 9H), 3.69 - 3.60 (m, 10H), 3.54 (s, 2H), 3.38 (dd, J = 8.5, 1.8 Hz, 1H), 3.25 (dd, J = 13.9, 8.1 Hz, 1H), 2.99 (t, J = 5.9 Hz, 2H), 2.78 - 2.70 (m, 1H), 1.76 (t, J = 11.8 Hz, 1H), 1.31 (s, 1H).Atty Dkt No.: ADTH-007WOEXAMPLE 21: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((6-(4-(14-oxo-14-(perfluorophenoxy)-2,5,8,ll-tetraoxatetradecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 2).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((6-(4-(14-oxo-14-(perfluorophenoxy)-2,5,8,ll-tetraoxatetradecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylicacid (CMPD ID 2)

[0228] To a stirred solution of (2R,4S,5R,6R)-2-((6-azidohexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hyd roxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (150 mg, 0.24 mmol), perfluorophenyl 4,7,10,13-tetraoxahexadec-15-ynoate (1) (106 mg, 0.24 mmol), and Tetra kis(acetonitrile)copper(l) hexafluorophosphate (139 mg, 0.37 mmol) in anhydrous NMP (2 mL) and the reaction mixture was stirred at room temperature for 2 h under nitrogen atmosphere. After completion, the reaction mixture was purified by prep-HPLC purification by using acetonitrile and water (+0.05%, TFA) to afford the desired product CMPD ID 2 as off white solid, Yield: 70 mg, 27%. LCMS (ESI-) m / z 1026.6 [M-H]-.1H NMR (401 MHz, MeOD) 67.99 (s, 1H), 7.30 (s, 4H), 4.65 (s, 2H), 4.40 (t, J = 7.1 Hz, 2H), 4.04 (s, 2H), 3.93 - 3.88 (m, 2H), 3.88 - 3.77 (m, 3H), 3.77 - 3.72 (m, 1H), 3.72 - 3.59 (m, 11H), 3.54 (s, 2H), 3.46 - 3.35 (m, 1H), 3.31 - 3.19 (m, 2H), 2.98 (t, J = 5.9 Hz, 2H), 2.72 (dd, J = 12.9, 4.1 Hz, 1H), 1.91 (p, J = 7.2 Hz, 2H), 1.79 - 1.68 (m, 1H), 1.55 (p, J = 6.7 Hz, 2H), 1.44 - 1.29 (m, 5H).Atty Dkt No.: ADTH-007WOEXAMPLE 22: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 3).Synthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1)

[0229] To a stirred solution of methyl (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-2-((6-((2-((2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylate (3.1 g, 3.13 mmol) in MeOH (9 mL) and water (1 mL) was added LiOH. H₂O (385 mg, 9.39 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated under reduced pressure and the crude residue obtainedAtty Dkt No.: ADTH-007WO was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1) as an off white solid. Yield: 2.4 g, 78%. LCMS (ESI+) m / z 974.1 [M-H] '.Synthesis of(2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (2)

[0230] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-2-((6-((2-((2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1) (2.4 g, 2.46 mmol) in anhydrous DCM (20 mL) was added TFA (0.9 m L, 7.37 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the reaction mixture was concentrated under reduced pressure and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (2) as an off white solid, Yield: 1.2 g, 56%. LCMS (ESI+) m / z 876.0 [M+H] +Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 3)

[0231] To a stirred solution of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (2) (200 mg, 0.23 mmol) in N, N-dimethyl formamide (10 mL) was added bis(perfluorophenyl) 3,3'-oxydipropionate (564 mg, 1.14 mmol) at -20 °C then added DIEA (0.12 mL, 0.92 mmol) at same temperature. The resulting reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents toAtty Dkt No.: ADTH-007WO afford the desired product CMPD ID 3 as an off-white solid. Yield: 121 mg, 45%; LCMS (ESI-) m / z 1184.0 [M-H] '.1H NMR (400 MHz, MeOD): 67.87 (t, J = 1.6 Hz, 1H), 7.77 (dt, J = 7.6 Hz, 1.6 Hz, 1H), 7.56-7.53 (m, 1H), 7.46 (t, J = 8 Hz, 1H), 4.04 (s, 3H), 3.87-3.81 (m, 6H), 3.80-3.75 (m, 5H), 3.66-3.59 (m, 15H), 3.54 (t, J = 5.6 Hz, 3H), 3.52-3.45 (m, 3H), 3.35 (t, J = 5.6 Hz, 2H), 3.98 (t, J = 6 Hz, 2H), 2.72 (dd, J = 12.7, 4.1 Hz, 1H), 2.48 (t, J = 6 Hz, 2H), 1.76 (t, J = 11.9 Hz, 1H), 1.68-1.54 (m, 4H), 1.47-1.38 (m, 4H).EXAMPLE 23: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(15,21-dioxo-21-(perfluorophenoxy)-2,5,8,ll,18-pentaoxa-14-azahenicosyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 4).Atty Dkt No.: ADTH-007WOSynthesis of(lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-azidohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (2)

[0232] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (5 g, 6.53 mmol) and 6-azidohexan-l-ol (1) (1.12 g, 7.84 mmol) in anhydrous acetonitrile (90 ml_) and anhydrous dichloromethane (60 mL) were added 4 A powdered molecular sieves (10 g) and Ag(OTf) (4.18 g, 16.32 mmol) under nitrogen. The reaction mixture was stirred for 1 h, cooled to -78 °C and a solution of iodine monobromide (2.02 g, 9.79 mmol) in dichloromethane (5 ml) was added dropwise at the same temperature. The reaction mixture was stirred at the same temperature for another 2 h. After completion, the reaction mixture was diluted with dichloromethane (30 ml), quenched with triethylamine, and filtered. The filtrate was washed with 10% aqueous of Sodium thio-sulfate solution, dried over sodium sulfate, filtered then concentrated. The crude residue obtained was purified by C-18 reverse phase column chromatography using acetonitrile and water (0.05%, TFA) as eluents to afford (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-azidohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l, 2-diyl diacetate (2) as yellow solid, Yield-2.9 g, 57%; LCMS (ESI±) m / z 783.9 [M+H]+.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (4)

[0233] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-azidohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l, 2-diyl diacetate (2) (2.9 g, 3.69 mmol), and tert-butyl (3,6,9,12-tetraoxapentadec-14-yn-l-yl)carbamate (3) (1.22 g, 3.69 mmol) in anhydrous NMP (3 mL) was added Tetra kis(acetonitrile)copper(l) hexafluorophosphate (2.06 g, 5.53 mmol) at room temperature and the reaction mixture was stirred at room temperature for 1 h under nitrogen. After completion the reaction mixture was concentrated under reduced pressure. The crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (1R,2R)-1-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-(methoxycarbonyl) tetrahydroAtty Dkt No.: ADTH-007WO2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (4) as a pale yellow solid, Yield: 2.5 g, 61%;Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5)

[0234] To a stirred solution (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (4) (2.5 g, 2.24 mmol) in methanol (10 mL) and water (1 mL) was added NaOMe (25% in MeOH) (2.38 mL, 11.21 mmol) dropwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 6 h. After completion, the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated under reduced pressure and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(17,17-dimethy l-15-oxo-2, 5, 8, 11, 16-pentaoxa-14-azaoctadecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (5) as an off white solid, Yield: 1.6 g, 76%; LCMS (ESI-) m / z 931.1 [M-H]’.Synthesis of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (6)

[0235] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(17,17-dimethyl-15-oxo-2,5,8,ll,16-pentaoxa-14-azaoctadecyl)-lH-1,2,3-triazol-l-yl) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5) (1.6 g, 1.7 mmol) in anhydrous dichloromethane (9 mL) was added trifluoroacetic acid (1 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by prep-HPLC (15-80% acetonitrile in water, +0.05 % TFA) as eluents to afford the desired product (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (6) as an off white solid, Yield: 800 mg, 56%; LCMS (ESI-) m / z 831.1 [M-H] '.Atty Dkt No.: ADTH-007WOSynthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(15,21-dioxo-21-(perfluorophenoxy)-2,5,8,ll,18-pentaoxa-14-azahenicosyl)-lH-l,2,3-triazol-l-yl) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 4)

[0236] To a stirred solution of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (6) (200 mg, 0.24 mmol) in N, N-dimethyl formamide (10 mL) was added bis(perfluoro phenyl) 3,3'-oxydipropionate (593 mg, 1.2 mmol) at -20 °C then DIEA (0.12 mL, 0.96 mmol) at same temperature. The resulting reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TEA) as eluents to afford the desired product CMPD ID 4 as an off-white solid, Yield: 141 mg, 51%; LCMS (ESI+) m / z 1142.9 [M+H]+.1H NMR (400 MHz, MeOD) 68.01 (s, 1H), 7.30 (s, 4H), 4.66 (s, 2H), 4.41 (t, J = 7.1 Hz, 2H), 4.04 (s, 2H), 3.92 -3.83 (m, 5H), 3.77 (td, J = 5.5, 2.1 Hz, 3H), 3.72 - 3.59 (m, 14H), 3.56 - 3.51 (m, 4H), 3.44 - 3.34 (m, 4H), 3.28 - 3.18 (m, 1H), 2.99 (t, J = 5.9 Hz, 2H), 2.72 (dd, J = 12.8, 4.3 Hz, 1H), 2.48 (t, J = 6.2 Hz, 2H), 2.02 - 1.85 (m, 2H), 1.74 (dd, J = 12.7, 11.4 Hz, 1H), 1.55 (p, J = 6.7 Hz, 2H), 1.40 (td, J = 10.6, 4.3 Hz, 2H), 1.32 (dd, J = 10.3, 4.7 Hz, 2H).Atty Dkt No.: ADTH-007WOEXAMPLE 24: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophcnoxy)-3,6,9,12,19-pcntaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 5).Synthesis of bis(perfluorophenyl) 3,3'-oxydipropionate (2)

[0237] To a stirred solution of 3,3'-oxydipropionic acid (1) (1 g, 6.16 mmol) in EtOAc (20 mL) was added 2,3,4,5,6-pentafluorophenol (2.83 g, 15.41 mmol), followed by dropwise addition of N, N'-Di-isopropyl carbodiimide (2.33 g, 18.50 mmol) at 0 °C. The resulting reaction mixture was stirred for 1 hour at the room temperature. After completion, the reaction mixture was filtered, the filtrate was concentrated and the residue obtained was purified by silica gel column chromatography to afford the desired product bis(perfluorophenyl) 3,3'-oxydipropionate (2), as white solid Yield: 1.5 g, 49%.1H NMR (400 MHz, CDCI3): 63.91 (t, J = 12.4 Hz, 4H), 2.97 (t, J = 12 Hz, 4H).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-!., 2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl) methoxy) ethoxy) ethoxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 5)

[0238] To a stirred solution of (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hyd roxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (200 mg, 0.23 mmol) in N, N-dimethyl formamide (10 mL) wereAtty Dkt No.: ADTH-007WO successively added bis(perfluorophenyl) 3,3'-oxydipropionate (2) (569 mg, 1.16 mmol) then DIEA (0.16 m L, 0.92 mmol) at -20 °C. The resulting reaction mixture was stirred at -20 °C for 1.5 h. After completion, the reaction mixture was concentrated and the crude residue obtained was purified by C18 reverse phase column chromatography using acetonitrile and water (+0.05%, TEA) as eluents to afford the desired product CMPD ID 5 as an off-white solid. Yield: 152 mg, 56%; LCMS (ESI-) m / z 1172.9 [M-H] ’.XH NMR (400 MHz, MeOD): 68.07 (s, 1H), 7.33-7.28 (m, 4H), 4.66 (s, 2H), 4.60 (t, J = 4.8 Hz, 2H), 4.03 (s, 2H), 3.90 (t, J = 5.2 Hz, 4H), 3.87-3.82 (m, 4H), 3.71-3.65 (m, 4H), 3.64-3.59 (m, 15H), 3.55-3.52 (m, 4H), 3.40-3.33 (m, 3H), 3.29-3.22 (m, 1H), 3.00 (t, J = 6 Hz, 2H), 2.74 (dd, J = 12.7, 4.1 Hz, 1H), 2.47 (t, J = 6 Hz, 2H), 1.76 (t, J = 11.9 Hz, 1H).EXAMPLE 25: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 6).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 6)

[0239] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-5-(2-(dimethylamino)acetamido)-4-hydroxy-2-((6-(prop-2-yn-l-yloxy)hexyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (22.9 mg, 35.7 umol), perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (1) (17.9 mg, 39.2 umol) in anhydrous NMP (475 uL) was added Tetrakis(acetonitrile) copper (I) hexafluorophosphate (33.2 mg, 89.2 umol) and the reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TEA) as eluents toAtty Dkt No.: ADTH-007WO afford the desired product CMPD ID 6 as a white solid, Yield: 24.9 mg, 64%. LCMS (ESI+) m / z 1099.40 [M+H]+.XH NMR (500 MHz, MeOD) 68.01 (s, 1H), 7.30 - 7.28 (m, 4H), 4.57 (t, J = 5.0 Hz, 2H), 4.56 (s, 2H), 3.95 - 3.80 (m, 8H), 3.76 - 3.71 (m, 1H), 3.70 - 3.67 (m, 1H), 3.65 - 3.57 (m, 14H), 3.52 (s, 2H), 3.50 (t, J = 7.5 Hz, 2H), 3.45 - 3.41 (m, 1H), 3.33 - 3.31 (m, 1H), 3.25 -3.21 (m, 1H), 2.97 (t, J = 6.0 Hz, 1H), 2.89 (s, 6H), 2.78 (dd, J = 12.0 Hz, 4.5 Hz, 1H), 1.64 (t, J = 12.0 Hz, 1H), 1.61 - 1.59 (m, 2H), 1.54 - 1.51 (m, 2H), 1.35 - 1.34 (m, 4H).EXAMPLE 26: (2R,4S,5R,6R)-6-((lR,2R)-l,2-dihydroxy-3-(l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((4-(2-(l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)ethoxy)benzyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 7).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-l,2-dihydroxy-3-(l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-((4-(2-(l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)ethoxy)benzyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 7)

[0240] To a stirred solution of (2R,4S,5R,6R)-2-((4-(but-3-yn-l-yloxy)benzyl)oxy)-6-((lR,2R)-l,2-dihydroxy-3-(l-phenylcyclopropane-l-carboxamido)propyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (50.2 mg, 80.1 umol), perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (1) (40.3 mg, 88.1 umol) in anhydrous NMP (1.07 mL) was added Tetrakis(acetonitrile) copper (I) hexafluorophosphate (74.6 mg, 0.200 mmol) and the reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 7 as a white solid, Yield: 56.7 mg, 65%. LCMS (ESI+) m / z 1084.40 [M+H]+.XH NMR (500 MHz, MeOD) 87.91 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.41 - 7.40 (m, 2H), 7.38 - 7.36 (m, 2H), 7.31 - 7.28 (m, 1H), 7.23 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 4.68 (d, J = 11.0 Hz, 1H), 4.55 (t, J = 5.0 Hz, 2H), 4.38 (d, J = 11.0 Hz,Atty Dkt No.: ADTH-007WO1 H ), 4.24 (t, J = 6.0 Hz, 2H), 4.04 (s, 2H), 3.87 - 3.81 (m, 5H), 3.80 - 3.75 (m, 2H), 3.69 - 3.67 (m, 1H), 3.63 - 3.59 (m, 4H), 3.59 - 3.50 (m, 9H), 3.31 - 3.26 (m, 2H), 3.17 (t, J = 6.5 Hz, 2H), 2.94 (t, J = 6.0 Hz, 2H), 2.73 (dd, J = 12.0 Hz, 4.5 Hz, 1H), 1.75 (t, J = 12.0 Hz, 1H), 1.51 - 1.49 (m, 2H), 1.07 - 1.05 (m, 2H).EXAMPLE 27: (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 8).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 8)

[0241] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (200 mg, 0.340 mmol), perfluorophenyl l-azido-3,6,9,12-tetraoxapentadecan-15-oate (1) (155 mg, 0.340 mmol) in anhydrous NMP (2 mL) was added Tetrakis(acetonitrile) copper (I) hexafluorophosphate (190 mg, 0.51 mmol) and the reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 8 as an off white solid, Yield: 70 mg, 20%. LCMS (ESI+) m / z 1046.6 [M+H]+.XH NMR (401 MHz, MeOD) 68.05 (s, 1H), 7.87 (t, J = 1.9 Hz, 1H), 7.77 (dt, J = 7.7, 1.4 Hz, 1H), 7.55 (ddd, J = 8.1, 2.3, 1.2 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 4.64 (s, 2H), 4.59 (t, J = 5.0 Hz, 2H), 4.04 (s, 3H), 3.90 (d, J = 5.1 Hz, 2H), 3.93 - 3.82 (m,Atty Dkt No.: ADTH-007WO7H), 3.68 - 3.56 (m, 20H), 3.52 (d, J = 7.8 Hz, 1H), 3.48 - 3.43 (m, 1H), 2.98 (t, J = 6.0 Hz, 1H), 2.80 - 2.72 (m, 1H), 1.76 (s, 1H).EXAMPLE 28: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 9).Synthesis of(2R / 4S,5R,6R)-6-((lR,2R)-3-(2-([l,l,-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)~2-(2-(2~((l-(2-(2-(2-(2,5-dioxo-2,5-dihydro-lH-pyrrol~l- yl)acetam)do)ethoxy)ethyl)-lH-l,2,3-triazo!-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2- hydroxyacetamido)tetfahydm-2H-pyran-2-cairboxyiic acid CMPD iD 3

[0242] To a solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (22.6 mg, 26.2 umol) in DMF (655 uL) was added maleimidoacetic acid N-hydroxysuccinimide ester (6.93 mg, 27.5 umol). The mixture was cooled down to 0 °C and stirred for 10 min. DIEA (13.7 uL, 78.6 umol) was added and the mixture was stirred for lh30 at 0 °C. The reaction mixture was filtered, and the filtrate was purified C18 reverse phase column chromatography using acetonitrile and water (+0.05 % TEA) as eluents. The fractions containing the desired product were lyophilized to afford CMPD ID 9 as a white solid. Yield: 18.9 mg, 72%; LCMS (ESI) m / z 1000.40 [M+H]+.XH NMR (500 MHz, MeOD): 88.03 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.60-7.56 (m, 5H), 7.43 -7.37 (m, 5H), 7.31 (t, J = 7.0 Hz, 1H), 6.87 (s, 2H), 4.62 (s, 2H), 4.58 (t, J = 5.0 Hz, 2H), 4.15 (s, 2H), 4.01 (s, 2H), 3.92 - 3.87 (m, 4H), 3.85 - 3.79 (m, 2H), 3.74 -3.72 (m, 1H), 3.69 - 3.66 (m, 1H), 3.65 - 3.56 (m, 18H), 3.52 (t, J = 5.5 Hz, 2H), 3.39 - 3.37 (m, 1H), 3.36 (t, J = 5.5 Hz, 2H), 3.27-3.23 (m, 1H), 2.71 (dd, J = 12.5, 4.0 Hz, 1H), 1.75 (t, J = 12.5 Hz, 1H).Atty Dkt No.: ADTH-007WOEXAMPLE 29: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 10).Synthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(16,22-dioxo-22-(perfluorophenoxy)-3,6,9,12,19-pentaoxa-15-azadocosyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 10)

[0243] To a solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-([l,l'-biphenyl]-4-yl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (89.0 mg, 98.1 umol) in DMF (2.80 mL) was added Bis-PEGl-PFP ester (242 mg, 491 umol). The mixture was cooled down to -20 °C and stirred for 10 min. DIEA (68.4 uL, 393 umol) was added and the mixture was stirred for 2 h at -20 °C. The mixture was then allowed to warm up to room temperature, filtered and purified by preparatory HPLC using acetonitrile and water (+0.05 % TFA) as eluents to afford the desired product CMPD ID 10 as a white solid.Yield: 52.0 mg, 44%; LCMS (ESI) m / z 1217.50 [M+H] +. 1H NMR (500 MHz, MeOD): 58.02 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.60-7.56 (m, 5H), 7.43 - 7.37 (m, 5H), 7.31 (t, J = 7.0 Hz, 1H), 4.62 (s, 2H), 4.56 (t, J = 5.0 Hz, 2H), 4.01 (s, 2H), 3.90 - 3.86 (m, 4H), 3.85 - 3.79 (m, 4H), 3.74 (t, J = 6.0 Hz, 2H), 3.74 - 3.72 (m, 1H), 3.69 - 3.56 (m, 22H), 3.51 (t, J = 6.0 Hz, 2H), 3.39 - 3.37 (m, 1H), 3.34 (t, J = 6.0 Hz, 2H), 3.27-3.23 (m, 1H), 3.00 (t, J = 6.0 Hz, 2H), 2.74 (dd, J = 12, 4.5 Hz, 1H), 2.45 (t, J = 6.0 Hz, 2H), 1.75 (t, J = 12 Hz, 1H).Atty Dkt No.: ADTH-007WOEXAMPLE 30: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-{{l-(18-{2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 11).Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(18-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 11)

[0244] To a solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)-2-(2-(2-((l-(15-oxo-15-(perfluorophenoxy)-3,6,9,12-tetraoxapentadecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-2-carboxylic acid (45.8 mg, 43.2 umol) in DMF(1.08 mL) was added n-(2-aminoethyl)maleimide trifluoroacetate salt (11.5 mg, 45.4 umol). The mixture was cooled down to 0 °C and stirred for 10 min. DIEA (22.6 uL, 130 umol) was added and the mixture was stirred for 1 h at 0 °C. The reaction mixture was filtered, and the filtrate was purified by C18 reverse phase column chromatography using acetonitrile and water (+0.1% TFA) as eluents. The fractions containing the desired product were lyophilized to afford CMPD ID 11 as a white solid. Yield: 35.0 mg, 80%; LCMS (ESI) m / z 1016.40 [M+H]+.XH NMR (500 MHz, MeOD): 88.05 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.31-7.27 (m, 4H), 6.81 (s, 2H), 4.65 (s, 2H), 4.59 (t, J = 5.0 Hz, 2H), 4.02 (s, 2H), 3.90 - 3.87 (m, 4H), 3.86 - 3.79 (m, 2H), 3.74 - 3.71 (m, 1H), 3.67 - 3.64 (m, 7H), 3.63 - 3.56 (m, 17H), 3.53 (s, 2H), 3.38 - 3.35 (m, 3H), 3.26-3.21 (m, 1H), 2.72 (dd, J = 12, 4.5 Hz, 1H), 2.36 (t, J = 6.0 Hz, 2H), 1.75 (t, J = 12 Hz, 1H).Atty Dkt No.: ADTH-007WOEXAMPLE 31: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-{{l-(l-{2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 12).Synthesis of tert-butyl (14-(4-((2-(2-hydroxyethoxy) ethoxy) methyl)-lH-l,2,3-triazol-l-yl)-3,6,9,12-tetraoxatetradecyl) carbamate (1)

[0245] To a stirred solution tert-butyl (3-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-2-methoxypropyl)carbamate (10 g, 43.43 mmol), 2-(2-(prop-2-yn-l-yloxy)ethoxy)ethan-l-ol (6.2 g, 43.43 mmol), Tetrakis(acetonitrile)copper(l) hexafluorophosphate (24.2 g, 65.14 mmol) inAtty Dkt No.: ADTH-007WO anhydrous NMP (60 mL) and the reaction mixture was stirred at room temperature for 2 h under nitrogen. After completion, the reaction mixture was filtered, the filtrate was concentrated under reduced pressure. The crude residue was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product tert-butyl (14-(4-((2-(2-hydroxyethoxy)ethoxy)methyl)-lH-l,2,3-triazol-l-yl)-3,6,9,12-tetraoxatetradecyl)carbamate (1) as a gummy liquid, Yield: 8.0 g, 57%; LCMS (ESI+) m / z 507.4 [M+H]+.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2)

[0246] To a stirred solution (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (10 g, 13.07 mmol), tert-butyl (14-(4-((2-(2-hydroxyethoxy)ethoxy)methyl)-lH-l,2,3-triazol-l-yl)-3,6,9,12-tetraoxatetradecyl)carbamate (1) (7394 g, 15.68 mmol), Silver (1+) trifluoro methane sulfonate (AgOTf) (8.39 g, 32.67 mmol) in anhydrous dichloromethane (60 mL) and anhydrous acetonitrile (120 mL) was added activated 4 A powdered molecular sieves (10 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The solution was cooled to -78 °C, iodine monobromide (4.0 g, 32.67 mmol) dissolved in dichloromethane (10 mL) was added dropwise and the resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (10 mL) and stirred at room temperature. The reaction mixture was filtered, the filtrate was washed with 10% aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered then concentrated under reduced pressure. The crude residue was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-aza nonadeca n-19-yl)-lH-l, 2, 3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6- (methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2) as a pale yellow solid, Yield: 5 g, 33%; LCMS (ESI+) m / z 1148.0 [M+H]+.Atty Dkt No.: ADTH-007WOSynthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3)

[0247] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l,2-diyl diacetate (2) (5.0 g, 4.36 mmol) in anhydrous MeOH (20 mL) and water (3 ml_) was added NaOMe (5 mL, 25% in MeOH) at room temperature and the resulting reaction mixture was stirred at room temperature for 6 h. After completion, the reaction mixture was treated with an acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated under reduced pressure and the crude was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-(2-(2-((l-(2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3) as a off white solid, Yield: 3.7 g, 87%. LCMS (ESI+) m / z 965.6 [M+H]+.Synthesis of (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (4)

[0248] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihyd roxypropyl)-2-(2-(2-((l-(2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (3) (3.7 g, 3.83 mmol) in anhydrous DCM (30 mL) was added TFA (1.31 g, 11.50 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the reaction mixture was concentrated under reduced pressure and the crude was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (2R,4S,5R,6R)-2-(2-(2-((l-(14-amino-3,6,9,12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (4) as a brown solid, Yield: 1.2 g, 36%. LCMS (ESI+) m / z 865.6 [M+H]+.Atty Dkt No.: ADTH-007WOSynthesis of(2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2- (2-(2-((l-(l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 12)

[0249] To a stirred solution of (2Rz4S,5Rz6R)-2-(2-(2-((l-(14-amino-3,6z9z12-tetraoxatetradecyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-lz2-dihydroxypropyl)-4-hydroxy-5-(2-hyd roxyacetamido)tetrahydro- 2H-pyran-2-carboxylic acid (4) (3.0g, 3.47 mmol), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate 13a (874 mg, 3.47 mmol), in anhydrous DMF (10 mL) was added TEA (1.05 g, 10.40 mmol) at room temperature and the resulting reaction mixture was stirred at room temperature for 1 h. After completion, the reaction mixture was concentrated under reduced pressure and the crude residue obtained was purified by prep HPLC using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product CMPD ID 12 as an off white solid. Yield: 513 mg, 15 %. LCMS (ESI+) m / z 1002.5 [M+H]+.1H NMR (400 MHz, Methanol-d4) 6 8.06 (s, 1H), 7.33-7.28 (m, 4H), 6.90 (s, 2H), 4.66 (s, 2H), 4.60 (t, J = 5.2 Hz, 2H), 4.18 (s, 2H), 4.03 (s, 2H), 3.91 (t, J = 5.2 Hz, 4H), 3.87 - 3.85 (m, 2H), 3.82 (s, 1H), 3.72 (s, 5H), 3.68 - 3.60 (m, 15H), 3.56 - 3.54 (m, 4H), 3.38 - 3.36 (m, 3H), 3.33 - 3.28 (m, 1H), 2.71 (dd, J = 12.8, 4.5 Hz, 1H), 1.76 (s, 1H).EXAMPLE 32: (2Rz4Sz5R,6R)-6-((lRz2R)-3-(3-chlorobenzamido)-lz2-dihydroxypropyl)-2-((6-((2-((l-(2,5-dioxo-2z5-dihydro-lH-pyrrol-l-yl)-2-oxo-6z9z12z15-tetraoxa-3-azaheptadecan-17-yl)amino)-3z4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2- hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 13).Atty Dkt No.: ADTH-007WOStep-1Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (2)

[0250] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6- (methoxycarbonyl)-6-(p-tolylthio)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-1, 2-diyl diacetate (18 g, 23.96 mmol), tert-butyl (6-hydroxyhexyl)carbamate (1) (6.23 g, 28.75 mmol) and Silver (1+) trifluoro methane sulfonate (AgOTf) (15.33 g, 59.9 mmol) in anhydrous dichloromethane (216 m L) and anhydrous acetonitrile (324 m L) was added activated 4 AAtty Dkt No.: ADTH-007WO powdered molecular sieves (15 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The solution was cooled to -78 °C, iodine monobromide (7.1 g, 35.94 mmol) dissolved in dichloromethane (7 mL) was added dropwise, and the resulting mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched by the addition of triethylamine (7 mL) and allowed to stir at room temperature for 5 min. The reaction mixture was filtered, the filtrate was washed with aqueous sodium thiosulfate solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (1R,2R)-1-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (2) as off-white solid, Yield: 9.8 g, 48%. LCMS (ESI-) m / z 842.7 [M-H]Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (3)

[0251] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((tert-butoxycarbonyl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (2) (9.8 g, 11.61 mmol) in anhydrous dichloromethane (100 mL) was added trifluoro acetic acid (4 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the solvent was concentrated to afford the desired product as a crude (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (3) as brown gummy solid, Yield: 7.9 g, 91%;Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-l-en-1-yl) amino) hexyl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido) propane-1, 2-diyl diacetate (4)

[0252] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-aminohexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l, 2-diyl diacetate (3) (7.9 g, 10.62 mmol) in ethanol (80 mL) were added triethylamine (7.60 ml, 53.09 mmol) and tert-butyl (14-((2-ethoxy-3,4-dioxocyclobut-l-en-l-yl)amino)-3,6,9,12-tetraoxatetradecyl)carbamate (4.88 g, 10.62 mmol) and the resulting reaction mixture was stirred at 50 °C for 6 h. After completion, the reaction mixture wasAtty Dkt No.: ADTH-007WO concentrated and the crude residue obtained was purified by C18 reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford the desired product (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (4) as pale yellow solid, Yield: 7.5 g, 61%.Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-1-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5)

[0253] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-4-acetoxy-3-(2-acetoxyacetamido)-6-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (4) (7.5 g, 6.47 mmol) in methanol (75 mL) and water (7.0 mL) was added 25% sodium methoxide in methanol (8.39 mL, 38.86 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 6 h. After completion the reaction mixture was treated with acidic resin (Dowex 50, H+) until pH~6, the suspension was filtered, and the filtrate was concentrated to afford the desired product (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5) as pale yellow solid, Yield: 5.5 g, 88%; LCMS (ESI-) m / z 974.8 [M-H] ’.Synthesis of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (6)

[0254] To a stirred solution of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihyd roxypropyl)-2-((6-((2-((2, 2-dimethy l-4-oxo-3,8,ll, 14, 17-pentaoxa-5-azanonadecan-19-yl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (5) (5.5 g, 5.63 mmol) in anhydrous dichloromethane (55 mL) was added trifluoro acetic acid (1.92 mL) dropwise at 0 °C and the resulting reaction mixture was stirred at room temperature for 3 h. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05% TFA) to afford the desired product (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl) amino)-3,4-dioxocyclobut-l-en-l-yl) amino) hexyl) oxy)-6-((lR,2R)-3-(3-Atty Dkt No.: ADTH-007WO chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido) tetrahydro-2H-pyran-2-carboxylic acid (6) as pale yellow solid, Yield: 3.9 g, 77%; LCMS (ESI±) m / z 876.6 [M+H]Synthesis of (2R,4S,5R,6R)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((6-((2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-17-yl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 13)

[0255] To a stirred solution of (2R,4S,5R,6R)-2-((6-((2-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-3,4-dioxocyclobut-l-en-l-yl)amino)hexyl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (6) (1.5 g, 1.7 mmol.), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (430 mg, 1.7 mmol) in anhydrous DMF (15 mL) was added TEA (0.72 mL, 5.14 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 45 min. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLCto afford the desired product CMPD ID 13 as an off white solid, Yield: 576 mg, 33%. LCMS (ESI-) m / z 1011.7 [M-H]’. 'H NMR (400 MHz, MeOD): 57.87 (t, J = 3.6 Hz, 1H), 7.77 (dt, J = 7.6 Hz, 1.6 Hz, 1H), 7.57-7.54 (m, 1H), 7.46 (t, J = 15.6 Hz, 1H), 6.90 (s, 2H), 4.19 (s, 2H), 4.04 (s, 3H), 3.87-3.76 (m, 7H), 3.67-3.62 (m, 16H), 3.61-3.43 (m, 5H), 3.41-3.38 (t, 2H), 2.72 (dd, J = 12.7, 4.1 Hz, 1H),, 1.76 (t, J = 11.9 Hz, 1H), 1.68-1.54 (m, 4H), 1.47-1.38 (m, 4H).EXAMPLE 33: (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(16-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-2,5,8,ll-tetraoxa-14-azahexadecyl)-lH-l,2,3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 14).Atty Dkt No.: ADTH-007WOSynthesis (2R,4S,5R,6R)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((6-(4-(16-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-15-oxo-2,5,8,ll-tetraoxa-14-azahexadecyl)-lH- 1.2.3-triazol-l-yl)hexyl)oxy)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 14)

[0256] To a stirred solution of (2R,4S,5R,6R)-2-((6-(4-(13-amino-2,5,8,ll-tetraoxatridecyl)-lH- 1.2.3-triazol-l-yl)hexyl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxy-5-(2-hydroxyacetamido)tetrahydro-2H-pyran-2-carboxylic acid (1.5 g, 1.8 mmol.), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (454 mg, 1.80 mmol) in anhydrous DMF (15 mL) was added TEA (0.78 mL, 5.4 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 45 min. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC to afford the desired product CMPD ID 14 as an off white solid, Yield: 545 mg, 31%. LCMS (ESI-) m / z 968.7 [M-H]-.1H NMR (400 MHz, MeOD): 67.99 (s, 1H), 7.31 (s, 4H), 6.89 (s, 2H), 4.66 (s, 2H), 4.41 (t, J=14 Hz, 2H), 4.18 (s, 2H), 4.04 (s, 2H), 3.89 - 3.81 (m, 3H), 3.78 - 3.72 (m, 2H), 3.71 - 3.61 (m, 14H), 3.56-3.54 (m, 4H), 3.42 - 3.36 (m, 4H), 3.27 (dt, J = 6.9, 3.4 Hz, 1H), 2.71 (dd, J = 12.7, 4.5 Hz, 1H), 1.91 (t, J = 14.4 Hz, 2H), 1.76 (t, J = 12.0 Hz, 1H), 1.55-1.32 (m, 6H).EXAMPLE 34: (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,18-dioxo-6,9,12,15-tetraoxa-3,19-diazatetracosan-24-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 15).Atty Dkt No.: ADTH-007WOSynthesis of perfluorophenyl 2, 2-dimethyl-4-oxo-3, 8, 11,14, 17-pentaoxa-5-azaicosan-20-oate (2)

[0257] To a stirred solution of 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oic acid (1) (5 g, 13.6 mmol) and penta-fluoro phenol (2.5 g, 13.6 mmol) in dry Ethyl acetate (50 mL) was added di-isopropyl carbodimide (2.58 g, 20.4 mmol) dropwise at 0 °C. The reaction mixture was stirred at room temperature for next 6 h. After completion, the reaction mixture was filtered, filtrate was concentrated to get the crude material, which was purified by Silica gel column chromatography, eluting with 20% EA in Hexane, to afford perfluorophenyl 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oate (2) as off white semi solid, Yield: 5 g, 69.4%; LCMS (ESI±) m / z 533.65 [M+2]+.Synthesis of tert-butyl (21-hydroxy-15-oxo-3,6,9,12-tetraoxa-16-azahenicosyl) carbamate (4)

[0258] To a stirred solution of perfluorophenyl 2,2-dimethyl-4-oxo-3,8,ll,14,17-pentaoxa-5-azaicosan-20-oate (2) (4 g, 7.52 mmol) N, N-dimethyl formamide were added 5-aminopentan-l-ol (3) (3.11 g, 6.77 mmol) and triethylamine (3.25 ml, 22.58 mmol) at 0 °C. The resultingAtty Dkt No.: ADTH-007WO reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was purified by C-18 reverse phase column chromatography by using acetonitrile and water (+0.05%, TFA) as eluents to afford tert-butyl (21-hydroxy-15-oxo-3,6,9,12-tetraoxa-16-azahenicosyl) carbamate (4) as white solid, Yield: 4 g.1H NMR (400 MHz, DMSO): 67.79 (t, J = 5.2 Hz, 1H), 6.75 (t, J = 5.6, 1H), 5.6 (s, 1H), 3.59 (t, J = 6.4 Hz, 2H), 3.50 - 3.45 (m, 12H), 3.39-3.31 (m, 4H), 3.17-2.99 (m, 4H), 2.29 (t, J = 6.4 Hz, 2H), 1.44-1.36 (m, 13H), 1.20-1.14 (m, 3H)Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,20-dioxo-3,8, 11,14, 17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (6)

[0259] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl)acetamido)propane-l, 2-diyl diacetate (5) (2.0 g, 2.82 mmol) and tert-butyl (21-hydroxy-15-oxo-3,6,9,12-tetraoxa-16-azahenicosyl)carbamate (4) (1.91 g, 1.41 mmol) in anhydrous dichloromethane (12 mL) and anhydrous acetonitrile (24 mL) were added Silver (+1) trifluoro methane sulfonate Ag(OTf) (1.80 g, 7.07 mmol) and activated 4 A powdered molecular sieves (5 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen atmosphere. Then the reaction mixture was cooled to -78 °C and iodine monobromide (0.87 g, 4.24 mmol, 1.5 eq.) solution in dichloromethane (4 ml) was added dropwise. The reaction mixture was stirred at the same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (5 mL), filtered, filtrate was washed by 10% Sodium thiosulfate solution, dried over sodium sulfate, filtered and concentrated to get the crude material, which was purified by C-18 reverse phase column chromatography, using acetonitrile and water (+0.05%, TFA) as eluents to afford (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (6) as yellow solid. Yield: 1.2 g, 41%, LCMS (ESI±) m / z 1035.4 [M+H]+.Synthesis of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7)

[0260] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-6-(methoxycarbonyl) tetrahydro-2H-pyran-2-yl)-3-(2-(4-chlorophenyl) acetamido) propane-1, 2-diyl diacetate (6) (1 g, 0.96 mmol) in tetrahydrofuran (5 mL) was added lithium hydroxide monohydrate (243 mg, 5.80 mmol) solution in water. The reaction mixture was stirred at roomAtty Dkt No.: ADTH-007WO temperature for 16 h. After completion the reaction mixture was treated with acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered, the filtrate was concentrated, to afford (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7), Yield: 850 mg, 98%; LCMS (ESI±) m / z 895.7 [M+H]+.Synthesis of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-!, 2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8)

[0261] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihyd roxypropyl)-2-((2,2-dimethyl-4,20-dioxo-3,8,ll,14,17-pentaoxa-5,21-diazahexacosan-26-yl) oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7) (0.85 g, 9.51 mmol) in anhydrous dichloromethane (5 ml_), was added trifluoroacetic acid (0.33 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated to get crude material which was dissolved in methanol and neutralized with Tetra alkyl ammonium carbonate, the polymer-bound resin. Reaction mixture was filtered and filtrate was concentrated to get (2R,4S,5R,6R)-5-acetamido-2-((l-amino-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl) oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl) acetamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) as yellow solid, Yield-650 mg, 86%; LCMS (ESI±) m / z 796.6 [M+H]+.Synthesis of(2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,18-dioxo-6,9,!2,15-tetraoxa-3,19-diazatetracosan-24-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 15)

[0262] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-15-oxo-3,6,9,12-tetraoxa-16-azahenicosan-21-yl)oxy)-6-((lR,2R)-3-(2-(4-chlorophenyl)acetamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) (250 mg, 0.31 mmol.), 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (79 mg, 0.31 mmol) in anhydrous DMF (2.5 mL) was added TEA (13 mg, 0.94 mmol) at 0 °C and the resulting reaction mixture was stirred at room temperature for 1 h. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 15 as an off white solid, Yield: 103 mg, 34%. LCMS (ESI-) m / z 928.7 [M-HJ'TH NMR (400 MHz, MeOD): 67.31 (s, 4H), 6.90 (s, 2H), 4.18 (s, 2H), 3.92-3.87 (m, 1H), 3.82-3.72 (m, 5H), 3.71-3.61 (m, 14H), 3.59-3.55 (m,Atty Dkt No.: ADTH-007WO4H), 3.44-3.38 (m, 3H), 3.31-3.28 (m, 1H), 3.18 (t, J = 6.8 Hz, 2H), 2.71 (dd, J = 12.8, 4.2 Hz, 1H),2.44 (t, J = 6 Hz, 2H), 1.99 (s, 3H), 1.78 - 1.69 (m, 1H), 1.61 - 1.49 (m, 4H), 1.45 - 1.37 (m, 2H).EXAMPLE 35: (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazapentacosan-25-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 16).Synthesis of perfluorophenyl 7-hydroxyheptanoate (2)

[0263] To a stirred solution of 7-hydroxyheptanoic acid (1) (5 g, 34 mmol) in EtOAc (50 mL) was added 2,3,4,5,6-pentafluorophenol (6.25 g, 34 mmol), followed by dropwise addition of N, N'-Atty Dkt No.: ADTH-007WODi-isopropyl carbodiimide (6.43 g, 51 mmol) at 0 °C. The resulting reaction mixture was stirred for 4 h at the same temperature. After completion, the reaction mixture was filtered, residue was washed with ethyl acetate, filtrate was concentrated to afford perfluorophenyl 7-hydroxyhepta noate (2), which was used as such in the next step, Yield: 7 g, 65%.Synthesis of tert-butyl (22-hydroxy-16-oxo-3,6,9,12-tetraoxa-15-azadocosyl) carbamate (4)

[0264] To a stirred solution of perfluorophenyl 7-hydroxyheptanoate (2) (7 g, 22 mmol) in DMF (70 mL) were added tert-butyl (14-amino-3,6,9,12-tetraoxatetradecyl)carbamate (3) (7.5 g, 22 mmol), DIEA (6 mL, 33 mmol) at 0 °C and the reaction mixture was stirred at the same temperature for next 2 h. After completion, the reaction mixture was purified by CIS reverse phase column chromatography using water and acetonitrile (+0.05% TFA) as eluents to afford tert-butyl (22-hydroxy-16-oxo-3,6,9,12-tetraoxa-15-azadocosyl) carbamate (4) as off-white solid. Yield: 7 g, 67%; LCMS (ESI+) m / z 465.5 [M+H]+.Synthesis of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,21-dioxo-3,8, 11,14, 17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido}propane-l,2-diyl diacetate (6)

[0265] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-(methoxycarbonyl)-6-(p-tolylthio)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-1,2-diyl diacetate (5) (3.0 g, 4.33 mmol) and tert-butyl (22-hydroxy-16-oxo-3,6,9,12-tetraoxa-15-azadocosyl)carbamate (4) (2.41 g, 5.19 mmol) in anhydrous dichloromethane (36 mL) and anhydrous acetonitrile (54 mL) were added Silver (+1) trifluoro methane sulfonate (AgOTf) (2.77 g, 10.8 mmol) and activated 4A powdered molecular sieves (5 g) and the reaction mixture was stirred at room temperature for 1 h under nitrogen atmosphere. Then the solution was cooled to -78 °C and iodine monobromide (1.33 g, 6.50 mmol) solution in dichloromethane (4 mL) was added dropwise. The resulting mixture was stirred at same temperature for 2 h. After completion, the reaction mixture was quenched with triethylamine (5 mL) and stirred at room temperature for 1 h. Then the reaction mixture was filtered, the filtrate was washed by 10% Sodium thiosulfate solution, dried over sodium sulfate, filtered and concentrated to get the crude material, which was purified by C-18 reverse phase column chromatography, using acetonitrile and water (+0.05%, TFA) as eluents to afford (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (6) as off-White solid, Yield: 2.2 g, 49%; LCMS (ESI+) m / z 1033.8 [M+H]+.Atty Dkt No.: ADTH-007WOSynthesis of(2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7)

[0266] To a stirred solution of (lR,2R)-l-((2R,3R,4S,6R)-3-acetamido-4-acetoxy-6-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)-3-(3-chlorobenzamido)propane-l,2-diyl diacetate (6) (1.8 g, 1.74 mmol) in methanol (15 mL) and water (3 mL) was added 25% sodium methoxide in methanol (2.09 mL, 8.71 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 16 h. After completion the reaction mixture was treated with acidic resin (Dowex 50, H+) until pH~6 and the suspension was filtered. The filtrate was concentrated and purified by C18 reverse phase using water and acetonitrile (+0.05% TFA) as eluents to afford (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7) as off-white solid, Yield: 1.3 g, 83 %; LCMS (ESI±) m / z 891.8 [M-H]’.Synthesis of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-16-oxo-3,6,9,12-tetraoxa-15-azadocosan-22-yl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8)

[0267] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((2,2-dimethyl-4,21-dioxo-3,8,ll,14,17-pentaoxa-5,20-diazaheptacosan-27-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (7) (2 g, 2.23 mmol) in anhydrous dichloromethane (20 mL) was added trifluoro acetic acid (1.03 mL, 13.43 mmol) at 0°C. The reaction mixture was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated and purified by C18 reverse phase using water and acetonitrile (+0.05% TFA) as eluents to afford (2R,4S,5R,6R)-5-acetamido-2-((l-amino-16-oxo-3,6,9,12-tetraoxa-15-azadocosan-22-yl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) as off-White solid, Yield: 1.5 g, %; LCMS (ESI+) m / z 793.6 [M+H]+.Synthesis of (2R,4S,5R,6R)-5-acetamido-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-2-((l-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)-2,19-dioxo-6,9,12,15-tetraoxa-3,18-diazapentacosan-25-yl)oxy)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (CMPD ID 16)

[0268] To a stirred solution of (2R,4S,5R,6R)-5-acetamido-2-((l-amino-16-oxo-3,6,9,12-tetraoxa-15-azadocosan-22-yl)oxy)-6-((lR,2R)-3-(3-chlorobenzamido)-l,2-dihydroxypropyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid (8) (250 mg, 0.315 mmol) and 2,5-dioxopyrrolidin-l-yl 2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)acetate (79 mg, 0.315 mmol) inAtty Dkt No.: ADTH-007WO anhydrous DMF (2 mL) was added TEA (0.13 ml_, 0.945 mmol) at 0°C and the resulting reaction mixture was stirred at room temperature for lh. After completion, the solvent was concentrated and the crude residue obtained was purified by prep-HPLC using acetonitrile and water (+0.05%, TFA) as eluents to afford the desired product CMPD ID 16 as an off white solid, Yield: 470 mg, 40 %. LCMS (ESI+) m / z 930.4 [M+H]+.XH NMR (401 MHz, MeOD) 67.88 (t, J = 1.9 Hz, 1H), 7.78 (dt, J = 7.8, 1.4 Hz, 1H), 7.56 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 6.91 (s, 2H), 4.19 (s, 2H), 4.08 - 3.99 (m, 1H), 3.85 - 3.73 (m, 3H), 3.73 - 3.60 (m, 15H), 3.60 -3.50 (m, 6H), 3.48 - 3.44 (m, 1H), 2.72 (dd, J = 12.7, 4.5 Hz, 1H), 2.19 (t, J = 7.5 Hz, 2H), 2.01 (s, 3H), 1.74 (dd, J = 12.7, 11.6 Hz, 1H), 1.58 (dq, J = 22.5, 7.1 Hz, 4H), 1.42 - 1.29 (m, 5H).

[0269] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

[0270] Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions.Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims.

[0271] The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims. In the claims, 35 U. S. C. §112(f) is expressly defined as being invoked for a limitation in the claim only when the exact phrase "means for"Atty Dkt No.: ADTH-007WO or the exact phrase "step for" is recited at the beginning of such limitation in the claim; if such exact phrase is not used in a limitation in the claim, then 35 U. S. C. § 112(f) is not invoked.

Claims

1. Atty Dkt No.: ADTH-007WOCLAIMS:

1. A compound having a structure of Formula (I) or (la):Z is a chemoselective functional group or Zl'-T-Z2, wherein Zl' is a diradical group, T is absent or a diradical group, and Z2 is a chemoselective functional group;§D iswherein? represents covalent connection to M, and? represents covalent connection to Z;b is an integer from 1 to 5;j is an integer from 0 to 15;k is an integer from 1 to 5;when j is 0, each of the members of D1are not absent;when j is 0, and k is 1, each of the members of D1are not absent and at least two of the members of D are not absent;at least oneM is a lysine residue, or a portion thereof;*** -i -i <■> **x1— E1— Y— x2— E2—each D2is independently selected whereinrepresentscovalent connection to Q, and4represents covalent connection to M,each D3iswherein5represents covalent connection to M, and5 represents covalent connection to D1;each Q is independently H, substituted or unsubstituted Ci-Cio alkyl,?D1is independently selectedwherein? representscovalent connection to D3, and? represents covalent connection to Q1;Atty Dkt No.: ADTH-007WOQ1is H, substituted or unsubstituted Ci-Cio alkyl,each A1is independently absent or alkylene;each A2is independently absent, alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof;each R2is independently -COOH, -P(O)(OH)z, -OSO2OH, -C(O)NHSOzH, tetrazole, an ester, or a substituted version thereof;each R3is independently H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof;each R4is independently hydroxy, alkoxy, amino, amide, or a substituted version thereof; each R5is independently H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene- 1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof;each R7is independently hydroxy or halo;each X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-; each E1is independently absent, -(substituted or unsubstituted Ci-Cg alkyleneoxy)g-, - (substituted or unsubstituted Ci-Cg alkylene)g-, -(substituted or unsubstituted Ci-Ce alkyleneoxy ^(substituted or unsubstituted Ci-Ce alkylene)q-, -(substituted or unsubstituted Ci-Cs alkylene)gO-, -(substituted or unsubstituted Ci-Cs alkyleneoxy)g(substituted or unsubstituted Ci-Cg alkylene)qO-, -(substituted or unsubstituted Ci-Cg alkylene)gO(substituted or unsubstituted Ci-Cg alkylene)q-, benzyl, -(substituted or unsubstituted Ci-Cg alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted Ci-Cg alkyleneoxy )gbenzyloxy, cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C=C-, -CH2C C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(al kylene)triazole(a Ikylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methlyene)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)n-, -(substituted or unsubstituted Ci-Cg alkylene)n-, wherein n is an integer ranging from 1 to 10;each X2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m-, -Atty Dkt No.: ADTH-007WO(substituted or unsubstituted Ci-Cg alkylene)m-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)™-, -(substituted or unsubstituted Ci-C5alkylene)mO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wO-, -(substituted or unsubstituted Ci-Ce alkylene)mO(substituted or unsubstituted Ci-Cg alkylene)™-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted Ci-Ce alkylene)mNHC(O)-, - (substituted or unsubstituted Ci-Cs alkyleneoxy)m(substituted or unsubstituted Ci-Cs alkylene)wNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)NH-, - (substituted or unsubstituted Ci-Cg alkylene)mC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(0)-, -(substituted or unsubstituted Ci-Ce alkylene)mC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)O-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkylene)mOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mtriazole-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wtriazole-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-triazole-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-Cg alkylene)w-triazole, -(substituted or unsubstituted Ci-Ce alkylene)m-triazole, -(substituted or unsubstituted Ci-Cg alkylene)mOtriazole-, triazole, -(methylene)triazole-, - (methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; each E2is independently absent, 0, -NH-, -C(O)NH-, -C(0)-, -0C(0)0-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h-, - (substituted or unsubstituted Ci-Cg alkylene)h-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted orAtty Dkt No.: ADTH-007WO unsubstituted Ci-Cg alkylene)xO-, -(substituted or unsubstituted Ci-Cg alkylene)hO(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-C5alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)(substituted or unsubstituted Ci-Cs alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(0)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-C6alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xC(O)(substituted or unsubstituted Ci-Cg a I kyle ne)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)C)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(0)0(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hOC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted C1-C5 alkylene)xNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkylene)hOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O(substituted or unsubstituted C1-C5 alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -Atty Dkt No.: ADTH-007WO(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xOC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(0)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-C alkylene)x-, (substituted or unsubstituted Ci-Cg alkylene)C(O)N(substituted or unsubstituted Ci-Cg alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36wherein the molecular mass of the compound of Formula (I) or (la) is at least 3,000 Da or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein Z is pentafluorophenyl ester, para-nitro phenyl ester, or maleimide.

3. The compound of a preceding claim, wherein R2is -COOH, R3is H, R4is hydroxy, R5is -NHC(O)R5awherein R5ais substituted or unsubstituted Ci-Cg alkyl, and R7is hydroxy.

4. The compound of a preceding claim, wherein Q and Q1are each independently selected from:

5. The compound of a preceding claim, wherein the molecular mass of the compound of Formula (I) or (la) is from 3,000 Da to 50,000 Da.Atty Dkt No.: ADTH-007WO6. The compound of a preceding claim, wherein the molecular mass of the compound of Formula (I) or (la) is from 5,000 Da to 45,000 Da, from 5,000 Da to 30,000 Da, from 5,000 Da to 15,000 Da, from 5,000 Da to 10,000 Da, 10,000 Da to 45,000 Da, from 10,000 Da to 30,000 Da, from 10,000 Da to 15,000 Da, from 7,500 Da to 12,500 Da, and from 12,500 Da to 25,000 Da.

7. The compound of a preceding claim, whereinwhen E1is substituted or unsubstituted Ci-Cg alkyleneoxy, g is 24 or less;when X2is substituted or unsubstituted Ci-Cg alkyleneoxy, m is 24 or less; andwhen E2is substituted or unsubstituted Ci-Cg alkyleneoxy, h is 24 or less.

8. The compound of a preceding claim, whereineach X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-; each E1is independently absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(OCH2CH2)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, - (CH2CH2O)g(CH2)qO(CH2)q-, -(OCH2CH2)g(CH2)qO(CH2)q-, -(CH2)q(OCH2CH2)gO(CH2)q-, - (CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, - (CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36;each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C C-, -CH2CEC-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(CH2CH2O)n-, -(CH2)n-, wherein n is an integer ranging from 1 to 10;each X2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)m-, -(CH2)m-, - (CH2CH2O)m(CH2)w-, -(OCH2CH2)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, - (OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)m(CH2)wO(CH2)w-, - (OCH2CH2)m(CH2)wO(CH2)w-, -(CH2)w(OCH2CH2)mO(CH2)w-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, - (OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, - (CH2)w(OCH2CH2)mNHC(O)-, -(CH2)mNHC(O)(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)(CH2)w-, -(CH2CH2O)mC(O)NH-, - (OCH2CH2)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, -Atty Dkt No.: ADTH-007WO(OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)NH(CH2)w-, - (OCH2CH2)mC(O)NH(CH2)w-, -(CH2)mC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wC(O)NH(CH2)w-, - (OCH2CH2)m(CH2)wC(O)NH(CH2)w- / -(CH2)w(OCH2CH2)mC(O)NH(CH2)w-, -(CH2CH2O)mC(O)-, - (CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, - (CH2CH2O)mC(O)O-, -(CH2)mC(O)(CH2)w-, -(CH2CH2O)m(CH2)wC(O)(CH2)w-, - (OCH2CH2)m(CH2)wC(O)(CH2)w-, -(CH2)w(OCH2CH2)mC(O)(CH2)w-, -(CH2CH2O)mC(O)O(CH2)w-, - (CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, - (CH2)w(OCH2CH2)mC(O)O-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, - (OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(OCH2CH2)mNHC(O)O-, - (CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, - (CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mNHC(O)O(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)O(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)O(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)O(CH2)w-, - (OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, - (OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wOC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wOC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mOC(O)NH(CH2)w- / -(OCH2CH2)mNHC(O)NH-, -(CH2)mNHC(O)NH-, - (CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, - (CH2)w(OCH2CH2)mNHC(O)NH-, -(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2)mNHC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wNHC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, - (OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, -(CH2CH2O)m(CH2)wO-triazole-, - (CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; each E2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(OCH2CH2)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, - (CH2)x(OCH2CH2)hO-, -(CH2CH2O)h(CH2)xO(CH2)x-, -(OCH2CH2)h(CH2)xO(CH2)x-, - (CH2)x(OCH2CH2)hO(CH2)x-, -(CH2)hO(CH2)x-, -(CH2)hNHC(O)-, -(OCH2CH2)hNHC(O)-, - (CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, - (CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, - (CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(OCH2CH2)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, -Atty Dkt No.: ADTH-007WO(CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, - (CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, - (CH2)x(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)hC(O)-, (CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, - (OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2CH2O)hC(O)O-, -(CH2)hC(O)(CH2)x-, - (CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, - (CH2CH2O)hC(O)O(CH2)x-,-(CH2)hC(O)O- / -(CH2CH2O)h(CH2)xC(O)O-, -(OCH2CH2)h(CH2)xC(O)O-, -(CH2)x(OCH2CH2)hC(O)O-, -(CH2)hOC(O)-, -(CH2CH2O)h(CH2)xOC(O)-, -(OCH2CH2)h(CH2)xOC(O)-, -(CH2)x(OCH2CH2)hOC(O)-, -(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O-, - (CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, - (CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH-, - (CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-, - (CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, - (CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2)x(OCH2CH2)hNHC(O)NH-, - (OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or -(alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8, whereinwhen E1is CH2CH2O, g is 24 or less;when X2is CH2CH2O, m is 24 or less; andwhen E2is CH2CH2O, h is 24 or less.

10. A compound having a structure of Formula (II) or (Ila):BAS is a biologically active substance;Atty Dkt No.: ADTH-007WO** >wherein ^represents covalent connection to E2, andrepresents covalent connection to BAS;— X1— E1— Y— X2— E2—D is wherein? represents covalent connection to M, and represents covalent connection to Z;b is an integer from 1 to 5;j is an integer from 0 to 15;k is an integer from 1 to 5;when j is 0, each of the members of D1are not absent;when j is 0, and k is 1, each of the members of D1are not absent and at least two of the members of D are not absent;M is a lysine residue, or a portion thereof;—X1—E1—Y—X2—E2—each D2is independently selected * wherein? represents. **covalent connection to Q, and « represents covalent connection to M,AA^-X1-E1-Y-X2-E2— IAAeach D3is wherein * represents covalent connection to M, and represents covalent connection to D1;each Q is independently H, substituted or unsubstituted Ci-Cio alkyl,?D1is independently selectedwherein * represents covalent connection to D3, andrepresents covalent connection to Q1;Q1is H, substituted or unsubstituted Ci-Cio alkyl,each A1is independently absent or alkylene;Atty Dkt No.: ADTH-007WO each A2is independently absent, alkyl, aryl, heteroaryl, cycloalkyl, or a substituted version thereof;each R2is independently -COOH, -P(O)(OH)2, -OSO2OH, -C(O)NHSO2H, tetrazole, an ester, or a substituted version thereof;each R3is independently H, alkyl, alkoxy, -S(alkyl), amino, halo, cyano, ester, amide, or a substituted version thereof;each R4is independently hydroxy, alkoxy, amino, amide, or a substituted version thereof; each R5is independently H, amino, ureido, amide, thioamide, oxamide, -NH(cyclobut-3-ene- 1, 2-dione), sulfonamide, phosphoramide, alkylamine, triazole, tetrazole, or substituted version thereof;each R7is independently hydroxy or halo;each X1is independently absent, O, S, triazole, -CH(OH)-, -CH2-, -CHF-, -NH-, or -CF2-; each E1is independently absent, -(substituted or unsubstituted Ci-Cg alkyleneoxy)g-, - (substituted or unsubstituted Ci-Cg alkylene)g-, -(substituted or unsubstituted Ci-Ce alkyleneoxy ^(substituted or unsubstituted Ci-Cg alkylene)q-, -(substituted or unsubstituted Ci-Ce alkylene)gO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)g(substituted or unsubstituted Ci-Cg alkylene)qO-, -(substituted or unsubstituted Ci-Cg alkylene)gO(substituted or unsubstituted Ci-Cg alkylene)q-, benzyl, -(substituted or unsubstituted Ci-Cg alkyleneoxy)gbenzyl-, benzyloxy, -(substituted or unsubstituted Ci-Ce alkyleneoxy )gbenzyloxy, cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C=C-, -CH2C=C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(alkylene)triazole(alkylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methlyene)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)n-, -(substituted or unsubstituted Ci-Ce alkylene)n-, wherein n is an integer ranging from 1 to 10;each X2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m-, - (substituted or unsubstituted Ci-Cg alkylene)m-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)w-, -(substituted or unsubstituted Ci-Cg alkylene)mO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-, -(substituted or unsubstituted Ci-CgAtty Dkt No.: ADTH-007WO alkylene)mO(substituted or unsubstituted Ci-Ce alkylene)w-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mNHC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)-, - (substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)mC(O)NH-, - (substituted or unsubstituted Ci-Cg alkylene)mC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wC(O)NH-, -(substituted or unsubstituted Ci-Cs alkyleneoxy)mC(O)-, -(substituted or unsubstituted Ci-Cs alkylene)mC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)mNHC(O)O-, - (substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)O-, -(substituted or unsubstituted Ci-Ce alkylene)mOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wOC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)mtriazole-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)m(substituted or unsubstituted Ci-Ce alkylene)wtriazole-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)m(substituted or unsubstituted Ci-Cg alkylene)wO-triazole-, -(substituted or unsubstituted Ci-Cg alkylene)mO(substituted or unsubstituted Ci-Ce alkylene)w-triazole, -(substituted or unsubstituted Ci-Ce alkylene)m-triazole, -(substituted or unsubstituted Ci-Ce alkylene)mOtriazole-, triazole, -(methylene)triazole-, - (methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; each E2is independently absent, O, -NH-, -C(O)NH-, -C(O)-, -OC(O)O-, -NHC(O)-, -NHC(O)O-, - OP(O)(OH)O-, -NHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h-, - (substituted or unsubstituted Ci-Cg alkylene)h-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Ce alkylene)hO-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xO-, -(substituted or unsubstituted Ci-Cg alkylene)hO(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(O)-, -(substituted or unsubstituted Ci-Ce alkylene)hNHC(O)-, - (substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-CeAtty Dkt No.: ADTH-007WO alkylene)xNHC(O)-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)hC(O)NH-, -(substituted or unsubstituted Ci-Ce alkylene)hC(O)NH-, -(substituted or unsubstituted Ci-Cs alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted C1-C5 alkylene)xC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)-, -(substituted or unsubstituted Ci-Cg alkylene)hC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkylene)hC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xC(O)(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)C)-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hOC(O)(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkylene)hNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)O-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xOC(O)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)O(substituted or unsubstituted C1-C5 alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)O(substituted or unsubstituted Ci-Cg alkylene)x-, -(substituted or unsubstituted Ci-Cg alkylene)hOC(O)NH(substituted or unsubstituted Ci-Cg a I kylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted C1-C5 alkylene)xOC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)hNHC(0)NH-, -(substituted or unsubstituted Ci-Cg alkylene)hNHC(O)NH-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted orAtty Dkt No.: ADTH-007WO unsubstituted Ci-Cg alkylene)xNHC(O)NH-, -(substituted or unsubstituted Ci-Cg alkyleneoxy)h(substituted or unsubstituted Ci-Cg alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Ce alkylene)x-, -(substituted or unsubstituted Ci-Ce alkyleneoxy)h(substituted or unsubstituted Ci-Ce alkylene)xNHC(O)NH(substituted or unsubstituted Ci-Cg alkylene)x-, (substituted or unsubstituted C1-C5 alkylene)C(O)N(substituted or unsubstituted Ci-Ce alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36wherein the molecular massis at least 3,000 Da.

11. The compound of claim 10, wherein12. The compound of claim 10 or 11, wherein R2is -COOH, R3is H, R4is hydroxy, R5is -NHC(O)R5awherein R5ais substituted or unsubstituted Ci-Cg alkyl, and R7is hydroxy.

13. The compound of any one of claims 10-12, wherein Q and Q1are each independently selected from:

14. The compound of any one of claims 10-13, wherein the BAS is a protein (such as an enzyme or an antibody) or a nanoparticle.Atty Dkt No.: ADTH-007WO015. The compound of any one of claims 10-14, wherein the molecular mass of0-D2l l-D- -M- b j b - jJk is from 3,000 Da to 50,000 Da.

16. The compound of any 1 - o Nne of claims 10-15, wherein the molecular mass ofQ— D20 Q— D20Q1— D1- D3-M Q r1-D1— D3-M- J b - 0kor U. — -,Jk is from 5,000 Da to 45,000 Da,1 — —,00from 5,000 Da to 30,000 Da, from 5,000 Da to “ 1..15,000 Da, from 5,000 Da to 10,000 Da, 10,000 Da to 45,000 Da, from 10,000 Da to 30,000 Da, from 10,000 Da to 15,000 Da, from 7,500 Da to 12,500 Da, and from 12,500 Da to 25,000 Da.

17. The compound of any one of claims 10-16, whereinwhen E1is substituted or unsubstituted Ci-Cg alkyleneoxy, g is 24 or less;when X2is substituted or unsubstituted Ci-Cg alkyleneoxy, m is 24 or less; andwhen E2is substit 1uted or unsubstituted Ci-Ce alkyleneoxy, h is 24 or less.S Q -1J 1O Q18. The co 1 _ 1 _ 1mpound of any one of claims 10-17, whereineach X1is independently absent, O, S, triazole, -CH(OH)-, -CH?-, -CHF-, -NH-, or -CF2-; each E1is independently absent, -(CH2CH2O)g-, -(CH2)g-, -(CH2CH2O)g(CH2)q-, -(OCH2CH2)g(CH2)q-, -(CH2)gO-, -(CH2CH2O)g(CH2)qO-, -(OCH2CH2)g(CH2)qO-, -(CH2)q(OCH2CH2)gO-, - (CH2CH2O)g(CH2)qO(CH2)q-, -(OCH2CH2)g(CH2)qO(CH2)q-, -(CH2)q(OCH2CH2)gO(CH2)q-, - (CH2)gO(CH2)q-, benzyl, -(CH2CH2O)gbenzyl-, -(OCH2CH2)gbenzyl-, benzyloxy, - (CH2CH2O)gbenzyloxy, -(OCH2CH2)gbenzyloxy, or cycloalkyl, wherein g is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and q is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36;each Y is independently absent, alkylene, phenylene, substituted phenylene, -O-, -NH-, -S-, - C=C-, -CH2C=C-, -C(O)-, -OP(O)O-, -NH-(cyclobut-3-ene-l,2-dione)-NH-, -NHC(O)-, triazole, - (alkylene)triazole- such as -(methylene)triazole-, -(al kylene)triazole(a Ikylene)- such as - (methylene)triazole(alkylene)- or -(methylene)triazole(methylene)-, -(CH2CH2O)n-, -(CH2)n-, wherein n is an integer ranging from 1 to 10;Atty Dkt No.: ADTH-007WO each X2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)m-, -(CH2)m-, - (CH2CH2O)m(CH2)w-, -(OCH2CH2)m(CH2)w-, -(CH2)mO-, -(CH2CH2O)m(CH2)wO-, - (OCH2CH2)m(CH2)wO-, -(CH2)w(OCH2CH2)mO-, -(CH2CH2O)m(CH2)wO(CH2)w-, - (OCH2CH2)m(CH2)wO(CH2)w-, -(CH2)w(OCH2CH2)mO(CH2)w-, -(CH2)mO(CH2)w-, -(CH2)mNHC(O)-, - (OCH2CH2)mNHC(O)-, -(CH2CH2O)m(CH2)wNHC(O)-, -(OCH2CH2)m(CH2)wNHC(O)-, - (CH2)w(OCH2CH2)mNHC(O)-, -(CH2)mNHC(O)(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)(CH2)w-, -(CH2CH2O)mC(O)NH-, - (OCH2CH2)mC(O)NH-, -(CH2)mC(O)NH-, -(CH2CH2O)m(CH2)wC(O)NH-, - (OCH2CH2)m(CH2)wC(O)NH-, -(CH2)w(OCH2CH2)mC(O)NH-, -(CH2CH2O)mC(O)NH(CH2)w-, - (OCH2CH2)mC(O)NH(CH2)w-, -(CH2)mC(O)NH(CH2)w-, -(CH2CH2O)m(CH2)wC(O)NH(CH2)w-, - (OCH2CH2)m(CH2)wC(O)NH(CH2)w-, -(CH2)w(OCH2CH2)mC(O)NH(CH2)w-, -(CH2CH2O)mC(O)-, - (CH2)mC(O)-, -(CH2CH2O)m(CH2)wC(O)-, -(OCH2CH2)m(CH2)wC(O)-, -(CH2)w(OCH2CH2)mC(O)-, - (CH2CH2O)mC(O)O-, -(CH2)mC(O)(CH2)w-, -(CH2CH2O)m(CH2)wC(O)(CH2)w-, - (OCH2CH2)m(CH2)wC(O)(CH2)w-, -(CH2)w(OCH2CH2)mC(O)(CH2)w-, -(CH2CH2O)mC(O)O(CH2)w-, - (CH2)mC(O)O-, -(CH2CH2O)m(CH2)wC(O)O-, -(OCH2CH2)m(CH2)wC(O)O-, - (CH2)w(OCH2CH2)mC(O)O-, -(CH2)mOC(O)-, -(CH2CH2O)m(CH2)wOC(O)-, - (OCH2CH2)m(CH2)wOC(O)-, -(CH2)w(OCH2CH2)mOC(O)-, -(OCH2CH2)mNHC(O)O-, - (CH2)mNHC(O)O-, -(CH2CH2O)m(CH2)wNHC(O)O-, -(OCH2CH2)m(CH2)wNHC(O)O-, - (CH2)m(OCH2CH2)wNHC(O)O-, -(CH2)mNHC(O)O(CH2)w-, -(CH2CH2O)m(CH2)wNHC(O)O(CH2)w-, - (OCH2CH2)m(CH2)wNHC(O)O(CH2)w-, -(CH2)w(OCH2CH2)mNHC(O)O(CH2)w-, - (OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH-, -(CH2CH2O)m(CH2)wOC(O)NH-, - (OCH2CH2)m(CH2)wOC(O)NH-, -(CH2)w(OCH2CH2)mOC(O)NH-, -(CH2)mOC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wOC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wOC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mOC(O)NH(CH2)w-, -(OCH2CH2)mNHC(O)NH-, -(CH2)mNHC(O)NH-, - (CH2CH2O)m(CH2)wNHC(O)NH-, -(OCH2CH2)m(CH2)wNHC(O)NH-, - (CH2)w(OCH2CH2)mNHC(O)NH-, -(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2)mNHC(O)NH(CH2)w-, - (CH2CH2O)m(CH2)wNHC(O)NH(CH2)w-, -(OCH2CH2)m(CH2)wNHC(O)NH(CH2)w-, - (CH2)w(OCH2CH2)mNHC(O)NH(CH2)w-, -(CH2CH2O)mtriazole-, -(CH2CH2O)m(CH2)wtriazole-, - (OCH2CH2)m(CH2)wtriazole, -(CH2)w(OCH2CH2)mtriazole-, -(CH2CH2O)m(CH2)wO-triazole-, - (CH2)mO(CH2)w-triazole, -(CH2)m-triazole, -(CH2)mOtriazole-, triazole, -(methylene)triazole-, or -(methylene)triazole(methylene)-, wherein m is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and w is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36;Atty Dkt No.: ADTH-007WO each E2is independently absent, O, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -NH-, -C(O)NH-, - NHC(O)-, -NHC(O)O-, -OP(O)(OH)O-, -NHC(O)NH-, -(CH2CH2O)h-, -(CH2)h-, -(CH2CH2O)h(CH2)x-, -(OCH2CH2)h(CH2)x-, -(CH2)hO-, -(CH2CH2O)h(CH2)xO-, -(OCH2CH2)h(CH2)xO-, - (CH2)x(OCH2CH2)hO-, -(CH2CH2O)h(CH2)xO(CH2)x-, -(OCH2CH2)h(CH2)xO(CH2)x-, - (CH2)x(OCH2CH2)hO(CH2)x-, -(CH2)hO(CH2)x-, -(CH2)hNHC(O)-, -(OCH2CH2)hNHC(O)-, - (CH2CH2O)h(CH2)xNHC(O)-, -(OCH2CH2)h(CH2)xNHC(O)-, -(CH2)x(OCH2CH2)hNHC(O)-, - (CH2)hNHC(O)(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)(CH2)x-, - (CH2)x(OCH2CH2)hNHC(O)(CH2)x-, -(CH2CH2O)hC(O)NH-, -(OCH2CH2)hC(O)NH-, -(CH2)hC(O)NH-, -(CH2CH2O)h(CH2)xC(O)NH-, -(OCH2CH2)h(CH2)xC(O)NH-, -(CH2)x(OCH2CH2)hC(O)NH-, - (CH2CH2O)hC(O)NH(CH2)x-, -(OCH2CH2)hC(O)NH(CH2)x-, -(CH2)hC(O)NH(CH2)x-, - (CH2CH2O)h(CH2)xC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xC(O)NH(CH2)x-, - (CH2)x(OCH2CH2)hC(O)NH(CH2)x-, -(CH2CH2O)hC(O)-, (CH2)hC(O)-, -(CH2CH2O)h(CH2)xC(O)-, - (OCH2CH2)h(CH2)xC(O)-, -(CH2)x(OCH2CH2)hC(O)-, -(CH2CH2O)hC(O)O-, -(CH2)hC(O)(CH2)x-, - (CH2CH2O)h(CH2)xC(O)(CH2)x-, -(OCH2CH2)h(CH2)xC(O)(CH2)x-, -(CH2)x(OCH2CH2)hC(O)(CH2)x-, - (CH2CH2O)hC(O)O(CH2)x-,-(CH2)hC(O)O-, -(CH2CH2O)h(CH2)xC(O)O-, -(OCH2CH2)h(CH2)xC(O)O-, -(CH2)x(OCH2CH2)hC(O)O-, -(CH2)hOC(O)-, -(CH2CH2O)h(CH2)xOC(O)-, -(OCH2CH2)h(CH2)xOC(O)-, -(CH2)x(OCH2CH2)hOC(O)-, -(OCH2CH2)hNHC(O)O-, -(CH2)hNHC(O)O-, - (CH2CH2O)h(CH2)xNHC(O)O-, -(OCH2CH2)h(CH2)xNHC(O)O-, -(CH2)x(OCH2CH2)hNHC(O)O-, - (CH2)hNHC(O)O(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)O(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)O(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)O(CH2)x-, -(OCH2CH2)hOC(O)NH-, -(CH2)hOC(O)NH-, - (CH2CH2O)h(CH2)xOC(O)NH-, -(OCH2CH2)h(CH2)xOC(O)NH-, -(CH2)x(OCH2CH2)hOC(O)NH-, - (CH2)hOC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xOC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xOC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hOC(O)NH(CH2)x-, -(OCH2CH2)hNHC(O)NH-, -(CH2)hNHC(O)NH-, - (CH2CH2O)h(CH2)xNHC(O)NH-, -(OCH2CH2)h(CH2)xNHC(O)NH-, -(CH2)x(OCH2CH2)hNHC(O)NH-, - (OCH2CH2)hNHC(O)NH(CH2)x-, -(CH2)hNHC(O)NH(CH2)x-, -(CH2CH2O)h(CH2)xNHC(O)NH(CH2)x-, -(OCH2CH2)h(CH2)xNHC(O)NH(CH2)x-, -(CH2)x(OCH2CH2)hNHC(O)NH(CH2)x-, or - (alkylene)C(O)N(substituted alkylene)2-, wherein h is an integer ranging from 1 to 36, or from 1 to 25, or from 6 to 36 and x is an integer ranging 1 to 36, or from 1 to 25, or from 6 to 36; or a pharmaceutically acceptable salt thereof.

19. The compound of claim 18, whereinwhen E1is CH2CH2O, g is 24 or less;when X2is CH2CH2O, m is 24 or less; andAtty Dkt No.: ADTH-007WO when E2is CH2CH2O, h is 24 or less.

20. A pharmaceutical composition comprising a compound of any one of claims 10-19 and a pharmaceutically acceptable carrier.

21. A method of treating a subject in need thereof for a disorder / disease, the method comprising administering to the subject the compound of any one of claims 10-19, or the pharmaceutical composition of claim 20.

22. The method of claim 21, wherein the disorder / disease is selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, phenylketonuria, juvenile idiopathic arthritis, leukemia, colorectal cancer, a non-small cell lung cancer, a head and neck cancer, multiple sclerosis, or Type 2 Diabetes, gout, immune thrombocytopenia, organ transplantation (e.g., kidney), NMOSD / neuromyelitis optica, anti-phospholipid syndrome, membrane nephritis, myasthenia gravis, and pemphigus vulgaris.